{
    "clinical": {
        "clinical_0": {
            "question": "Does the compound ADA improve cognitive function in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38185066"
        },
        "clinical_1": {
            "question": "Did the patient experience symptoms resembling delirium after receiving low-dose cyclophosphamide chemotherapy?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38552085"
        },
        "clinical_2": {
            "question": "Does pNaktide have potential therapeutic effects for Alzheimer's disease by mitigating neuroinflammation and oxidative stress?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36689848"
        },
        "clinical_3": {
            "question": "Does the regulation of PSMC5 expression have potential therapeutic implications for Alzheimer's disease-associated cognitive deficits?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38001534"
        },
        "clinical_4": {
            "question": "Does low-intensity pulsed ultrasound (LIPUS) reduce memory impairment in a model simulating Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30873554"
        },
        "clinical_5": {
            "question": "Does loading quercetin into nanoparticles improve its efficacy in preventing neuroinflammation associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24802026"
        },
        "clinical_6": {
            "question": "Does apigenin treatment restore cognitive function in a model of MTX-induced neurotoxicity similar to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36943623"
        },
        "clinical_7": {
            "question": "Does antithrombotic therapy show significant cognitive benefits in people with small vessel disease without Alzheimer's?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid35833913"
        },
        "clinical_8": {
            "question": "Does the combination of osthole and notopterol exhibit a synergistic anti-Alzheimer's effect in the zebrafish model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39053867"
        },
        "clinical_9": {
            "question": "Does Ashwagandha have neuroprotective effects in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32305638"
        },
        "clinical_10": {
            "question": "Does activation of alpha7nAChR by GTS-21 improve cognitive deficits in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35533773"
        },
        "clinical_11": {
            "question": "Does alogliptin treatment alleviate cognitive impairment in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33125461"
        },
        "clinical_12": {
            "question": "Does Memantine improve cognitive performance in Alzheimer's disease by regulating NGF signaling?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24846616"
        },
        "clinical_13": {
            "question": "Does Berula erecta improve cognitive functioning in a model of Parkinson's disease, which is related to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39546440"
        },
        "clinical_14": {
            "question": "Is pimavanserin approved for the treatment of psychosis in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid32695312"
        },
        "clinical_15": {
            "question": "Does the combination therapy with TSA and LEV improve outcomes in delirium post-TBI?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37762352"
        },
        "clinical_17": {
            "question": "Does gossypitrin have potential therapeutic applications for Alzheimer's disease by mitigating iron-induced oxidative stress and mitochondrial damage?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34199597"
        },
        "clinical_18": {
            "question": "Does dexmedetomidine reduce neuronal hyperactivity and overactive behaviors caused by esketamine, which could be relevant to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34712126"
        },
        "clinical_19": {
            "question": "Does NXP031 reduce Abeta accumulation and improve memory function in Alzheimer's disease models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39521153"
        },
        "clinical_20": {
            "question": "Does meloxicam improve memory loss in Alzheimer's disease by inhibiting neuronal apoptosis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36279100"
        },
        "clinical_21": {
            "question": "Does Cudraflavone B have potential therapeutic effects for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25061726"
        },
        "clinical_22": {
            "question": "Does carbenoxolone supplementation improve cognitive decline associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33412218"
        },
        "clinical_23": {
            "question": "Do antipsychotics like haloperidol and risperidone, which are used to treat delirium in cancer patients, enhance the effectiveness of doxorubicin in resistant uterine sarcoma cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26122223"
        },
        "clinical_24": {
            "question": "Does dexmedetomidine reduce the risk of delirium by inhibiting proinflammatory factors through the beta2 adrenergic receptor pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38411331"
        },
        "clinical_25": {
            "question": "Does remimazolam reduce the incidence of delirium in clinical reports?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39322063"
        },
        "clinical_26": {
            "question": "Does the CDK4/6 inhibitor abemaciclib mesylate improve cognitive function in Alzheimer's disease models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36907286"
        },
        "clinical_27": {
            "question": "Does kinetin show protective effects against cognitive impairment in an Alzheimer's disease model induced by aluminum chloride and D-galactose?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28867383"
        },
        "clinical_28": {
            "question": "Does Torin2 have potential therapeutic implications for Alzheimer's disease based on its anti-inflammatory effects in macrophages?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35874059"
        },
        "clinical_29": {
            "question": "In a mouse model of sepsis, BML-111 treatment has been shown to reduce cognitive impairment and neuroinflammation through activation of SIRT1 and inhibition of the NF-κB signaling pathway. Considering the pathophysiology of delirium associated with sepsis, which of the following statements is most accurate?",
            "options": "A. BML-111 enhances NF-κB signaling to promote immune activation and improve delirium symptoms.; B. Inhibition of SIRT1 with EX527 reduces inflammation and protects against delirium-related neuronal damage.; C. Delirium is primarily caused by cerebral ischemia and is not associated with glial activation.; D. SIRT1 activation reduces glial activation and inflammation via NF-κB suppression, which may protect against sepsis-induced delirium.",
            "correct_option": "D",
            "pmid": "pmid30186119"
        },
        "clinical_30": {
            "question": "Does overexpression of CX3CL1 improve cognitive function in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31822518"
        },
        "clinical_31": {
            "question": "Does the anti-inflammatory effect of Erinacine C, as described, suggest potential benefits for Alzheimer's disease, given its role in neuroinflammation?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31547327"
        },
        "clinical_32": {
            "question": "Does the NOX1/4 inhibitor GKT136901 have potential applications in the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23848532"
        },
        "clinical_33": {
            "question": "Does the modulation of 5'-nucleotidases (5'NTs) have therapeutic implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23992313"
        },
        "clinical_34": {
            "question": "Does the combination of Ocimum sanctum extract and Levetiracetam improve memory impairment in Alzheimer's disease?",
            "options": "A. No; B. Yes",
            "correct_option": "B",
            "pmid": "pmid34973350"
        },
        "clinical_35": {
            "question": "Does activating AhR improve cognitive deficits in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34522212"
        },
        "clinical_36": {
            "question": "Does T-817MA show potential as a therapeutic agent for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21439944"
        },
        "clinical_37": {
            "question": "Does narciclasine from Lycoris radiata have a potential therapeutic role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30738987"
        },
        "clinical_38": {
            "question": "Is Derrubone a potential therapeutic agent for Alzheimer's disease based on its binding to Hsp90alpha CTD?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24785461"
        },
        "clinical_39": {
            "question": "Does beetroot supplementation improve cognitive function in a model simulating Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33054666"
        },
        "clinical_40": {
            "question": "Does SAP removal by CPHPC treatment address Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26842068"
        },
        "clinical_41": {
            "question": "Does the use of subcutaneous oxycodone in opioid rotation for cancer patients improve delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid10423053"
        },
        "clinical_42": {
            "question": "Does cotinine (COT) and 6-hydroxy-L-nicotine (6HLN) improve memory and reduce anxiety in the scopolamine-induced zebrafish model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33535660"
        },
        "clinical_43": {
            "question": "Does the sulfated polysaccharide from pearl oyster nacre improve memory impairment, which could be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33804892"
        },
        "clinical_44": {
            "question": "Does ononin treatment improve cognitive impairment in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34354404"
        },
        "clinical_45": {
            "question": "Does muscone improve memory impairment in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32538849"
        },
        "clinical_46": {
            "question": "Does guanabenz treatment protect against Alzheimer's disease-related behavioral and pathological indicators?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35195784"
        },
        "clinical_47": {
            "question": "Does chronic exposure to galantamine decrease cellular responses to nicotinic receptor activation in neuroblastoma cells, which is relevant to Alzheimer's disease treatment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid15937519"
        },
        "clinical_48": {
            "question": "Can levofloxacin therapy lead to delirium with psychotic features?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid18585545"
        },
        "clinical_49": {
            "question": "Does Houttuynia cordata improve cognitive deficits in Alzheimer's disease-like models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25009697"
        },
        "clinical_50": {
            "question": "Does Linderae Radix improve cognitive dysfunction in Alzheimer's disease models by inhibiting neuroinflammation and synaptic damage?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37542650"
        },
        "clinical_51": {
            "question": "Is NK-4 currently approved for the treatment of Alzheimer's disease or delirium in Japan?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid36901839"
        },
        "clinical_52": {
            "question": "Does prone positioning reduce the risk of delirium in patients undergoing mechanical ventilation?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36405620"
        },
        "clinical_53": {
            "question": "Does N-stearoylethanolamine have a therapeutic potential for the prevention of cognitive dysfunction caused by neuroinflammation or autoimmune reaction, as it relates to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28963942"
        },
        "clinical_54": {
            "question": "Does alpha-chymotrypsin improve neuroinflammation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22464639"
        },
        "clinical_55": {
            "question": "Does Akebia saponin D (ASD) improve cognitive impairment in Alzheimer's disease by reducing corticosterone levels?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30092401"
        },
        "clinical_56": {
            "question": "Does the use of DMARDs reduce the likelihood of Alzheimer's disease and/or dementia in patients with autoimmune disorders?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38288824"
        },
        "clinical_57": {
            "question": "Does galantamine treatment improve cognitive function in patients with Alzheimer's disease or mixed dementia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid12860497"
        },
        "clinical_58": {
            "question": "Can primidone, which inhibits RIPK1 kinase, potentially be repurposed for the treatment of delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38086800"
        },
        "clinical_59": {
            "question": "Does 5,19-cyclo-9beta,10xi-androstane-3,17-dione (CAD) have potential therapeutic effects for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid17980863"
        },
        "clinical_60": {
            "question": "Does Souvenaid improve cognitive function in individuals with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid33320335"
        },
        "clinical_61": {
            "question": "Does temsirolimus have potential therapeutic benefits for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24880087"
        },
        "clinical_62": {
            "question": "Does intermittent theta burst stimulation (iTBS) improve cognitive deficits in an Alzheimer's-like disease model caused by trimethyltin (TMT)?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35656538"
        },
        "clinical_63": {
            "question": "Does (R)-ketamine have a potential role as a prophylactic drug for delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34313805"
        },
        "clinical_64": {
            "question": "Does N2L, a novel lipoic acid-niacin dimer, show potential as a therapeutic agent for Alzheimer's disease by attenuating ferroptosis and lipid peroxidation in HT22 cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34171402"
        },
        "clinical_65": {
            "question": "Does the inhibition of JNK activation improve cognitive deficits in Alzheimer's disease models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25611954"
        },
        "clinical_66": {
            "question": "Does the use of memantine as an initial antidementia medication increase in individuals with Alzheimer's disease who also have asthma or COPD?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31929157"
        },
        "clinical_67": {
            "question": "Does cinnarizine improve haloperidol-induced memory impairment, which could be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27540345"
        },
        "clinical_68": {
            "question": "Is propofol recommended for patients with refractory delirium tremens?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26893017"
        },
        "clinical_69": {
            "question": "Does melatonin treatment improve the chemotaxis index in C. elegans exposed to isoflurane, which could be relevant to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35388108"
        },
        "clinical_70": {
            "question": "Does COP-22 have potential anti-aging activity that could be used in the therapy of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38347285"
        },
        "clinical_71": {
            "question": "Does the Huangqi-Gegen drug pair have a potential role in treating Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38815405"
        },
        "clinical_72": {
            "question": "Does zinc supplementation reduce the risk or slow cognitive decline in individuals with Alzheimer's disease or mild cognitive impairment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33597269"
        },
        "clinical_73": {
            "question": "Does Aquilaria crassna Leaf Extract (ACH) improve lifespan in Caenorhabditis elegans exposed to high glucose, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36079924"
        },
        "clinical_74": {
            "question": "Is delirium associated with increased odds of non-emergency control intervention use in older psychiatric inpatients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34616324"
        },
        "clinical_75": {
            "question": "Does Marsilea quadrifolia Linn exhibit potential neuroprotective effects that could be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37781695"
        },
        "clinical_76": {
            "question": "Does the chloroform extract of Vanda roxburghii exhibit potential in the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26100408"
        },
        "clinical_77": {
            "question": "Does Angelica purpurascens essential oil improve memory impairments through mechanisms relevant to Alzheimer's disease, such as cholinergic modulation and antioxidant effects?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35448824"
        },
        "clinical_78": {
            "question": "Does tocilizumab treatment reduce cognitive deficits in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27443846"
        },
        "clinical_79": {
            "question": "Does the cyclic (aza)peptide tracer effectively cross the blood-brain barrier (BBB) to target Abeta oligomers in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36442093"
        },
        "clinical_80": {
            "question": "Does the ethanolic extract of Aster glehni (AG-D) improve cognitive function in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31225769"
        },
        "clinical_81": {
            "question": "Does MLKL deficiency improve motor symptoms and reduce neuroinflammation in a Parkinson's disease model, which is analogous to changes seen in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38041169"
        },
        "clinical_82": {
            "question": "Does music therapy significantly reduce anxiety in patients with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19250995"
        },
        "clinical_83": {
            "question": "Does thiopurine exposure reduce the risk of Alzheimer's disease in patients with inflammatory bowel disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31788536"
        },
        "clinical_84": {
            "question": "Does add-on therapy with a low-dose carbamylating inhibitor enhance the clinical efficacy of donepezil in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24217282"
        },
        "clinical_85": {
            "question": "Does taraxerol have potential therapeutic value in alleviating memory impairments observed in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29355563"
        },
        "clinical_86": {
            "question": "Is donepezil approved for the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid11830754"
        },
        "clinical_87": {
            "question": "Does donepezil, which is used in Alzheimer's disease, show protective effects against alcohol-induced toxicity in cell culture by inhibiting caspase-3?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29804239"
        },
        "clinical_88": {
            "question": "Does the combination of lycopene and human amniotic epithelial cells improve cognitive deficits in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33249184"
        },
        "clinical_89": {
            "question": "Did the patient develop Alzheimer's disease or delirium during the course of her treatment with trimethoprim-sulfamethoxazole?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid36607874"
        },
        "clinical_90": {
            "question": "Does stigmasterol treatment alleviate cognitive deficits in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35772378"
        },
        "clinical_91": {
            "question": "Does betulinic acid improve microvascular responsivity and reduce cytokine levels in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30178892"
        },
        "clinical_92": {
            "question": "Does switching from ziprasidone to duloxetine improve neuropsychiatric behavior in a patient with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19752843"
        },
        "clinical_93": {
            "question": "Are pyramidal cell volumes in the dorsolateral prefrontal cortex reduced in Alzheimer's disease compared to post-stroke patients with no dementia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24974383"
        },
        "clinical_94": {
            "question": "Does amentoflavone improve memory deficits in a model of Alzheimer's disease by influencing autophagy and mTOR signaling?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33492604"
        },
        "clinical_95": {
            "question": "Are flavonoids from Millettia brandisiana studied for their effects against Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38106662"
        },
        "clinical_96": {
            "question": "Does the compound PADK exhibit a positive effect on CatB that correlates with improved memory in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29805718"
        },
        "clinical_97": {
            "question": "Does menadione sodium bisulfite (MSB) show potential as a therapeutic agent for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30036601"
        },
        "clinical_98": {
            "question": "Does pre-infusion of hypertonic saline reduce the incidence of delirium in geriatric patients after shoulder arthroscopy?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38082215"
        },
        "clinical_99": {
            "question": "Does methylpenicinoline from Penicillium sp. (SF-5995) have potential therapeutic effects for Alzheimer's disease or delirium based on its anti-inflammatory properties?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25379644"
        },
        "clinical_100": {
            "question": "Does the compound LM-021 exhibit antiaggregative, antioxidative, and neuroprotective effects in models of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34812274"
        },
        "clinical_101": {
            "question": "Does the triazole grandisin analogue (TGA) exhibit neuroprotective effects against amyloid-beta oligomer-induced cognitive impairment in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38048522"
        },
        "clinical_102": {
            "question": "Does TKM01 reduce acetylcholinesterase (AChE) activity in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39552492"
        },
        "clinical_103": {
            "question": "Is Aniracetam used in the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid12070527"
        },
        "clinical_104": {
            "question": "Does 5-heptadecylresorcinol (AR-C17) have a protective effect against cognitive impairments in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32385942"
        },
        "clinical_105": {
            "question": "Does intermittent fasting improve cognitive function in a model of sepsis, suggesting potential benefits for delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24886300"
        },
        "clinical_106": {
            "question": "Does donepezil reduce proinflammatory cytokines in Alzheimer's disease patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29420357"
        },
        "clinical_107": {
            "question": "Does octadecaneuropeptide (ODN) have potential therapeutic implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31514417"
        },
        "clinical_108": {
            "question": "Does the use of low-dose atypical antipsychotic risperidone improve the 5-year outcome in Alzheimer's disease patients with sleep disturbances?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26279176"
        },
        "clinical_109": {
            "question": "Are fullerene derivatives with amino acids or peptides being investigated for the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35051749"
        },
        "clinical_110": {
            "question": "Is lithium more cost-effective than aducanumab for treating cognitive decline in patients with mild cognitive impairment or Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35961514"
        },
        "clinical_111": {
            "question": "Does nabilone show anti-inflammatory effects in agitated patients with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31547752"
        },
        "clinical_112": {
            "question": "Does Captopril show greater effectiveness than Perindopril in preventing Alzheimer's disease-like pathology induced by aluminium chloride?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35243060"
        },
        "clinical_113": {
            "question": "Does apicidin improve learning and memory impairments in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36708130"
        },
        "clinical_114": {
            "question": "Does the inhibition of tau aggregation by the three Aspergillus nidulans secondary metabolites have potential therapeutic implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24414310"
        },
        "clinical_115": {
            "question": "Does donepezil improve cognitive deficits in a patient with neurosyphilis, similar to its use in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26166240"
        },
        "clinical_116": {
            "question": "Does donepezil, a medication used for Alzheimer's disease, increase collagen 1 expression in mesenchymal stroma cells in an ovine osteoporosis model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30179213"
        },
        "clinical_117": {
            "question": "Do Spiroisoxazoline (SIO) alkaloids represent a potential new structural manifold for lead-discovery of new therapeutics for treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36095307"
        },
        "clinical_118": {
            "question": "Does xanthoceraside have potential therapeutic effects for Alzheimer's disease based on its protective effects in SH-SY5Y cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23909924"
        },
        "clinical_119": {
            "question": "Does (m)RVD-hemopressin have a potential therapeutic application in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32241604"
        },
        "clinical_120": {
            "question": "Does L-serine improve cognitive dysfunction in an ALS/PDC model that presents symptoms analogous to Alzheimer's-like dementia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30476904"
        },
        "clinical_121": {
            "question": "Does cytokine signaling in CAR-T cell therapy have a known relationship with delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37591521"
        },
        "clinical_122": {
            "question": "Does the UCNPs-LMB/VQIVYK nanosystem inhibit Tau aggregation to reduce neurotoxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37103297"
        },
        "clinical_123": {
            "question": "Does the aqueous extract of Ziziphus jujuba exhibit antiamnesic effects comparable to donepezil, a standard drug for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34422074"
        },
        "clinical_124": {
            "question": "Does memantine, a drug used for Alzheimer's disease, have a protective effect against cartilage destruction in osteoarthritis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28545202"
        },
        "clinical_125": {
            "question": "Does the extract POEE from Marapuama reduce cognitive impairment in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20739160"
        },
        "clinical_126": {
            "question": "Does xanthoceraside improve cognitive impairment in Alzheimer's disease by promoting neurogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28744803"
        },
        "clinical_127": {
            "question": "Does remifentanil reduce the occurrence of delirium in mechanically ventilated patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28910303"
        },
        "clinical_128": {
            "question": "Does Deacetyl Ganoderic Acid F (DeGA F) have potential therapeutic effects for conditions associated with neural inflammation, such as Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31892211"
        },
        "clinical_129": {
            "question": "Does nervonic acid have the potential to be developed as an antioxidant drug for the prevention and early therapy of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37823115"
        },
        "clinical_130": {
            "question": "Does Lonicera japonica polysaccharide (LJP) improve learning and memory impairments associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32954750"
        },
        "clinical_131": {
            "question": "Does the behavioral variant of Alzheimer's disease show reduced attention to salient facial features compared to typical Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36268579"
        },
        "clinical_132": {
            "question": "Does cabergoline's neuroprotective effect against oxidative stress suggest a potential role in treating Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24914776"
        },
        "clinical_133": {
            "question": "Does the use of amlodipine in Alzheimer's dementia patients reduce the risk of ischaemic stroke compared to other calcium channel blockers?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32854138"
        },
        "clinical_134": {
            "question": "Does the core sequence of PIF compete for insulin/amyloid beta in insulin degrading enzyme, potentially offering a treatment for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30338033"
        },
        "clinical_135": {
            "question": "Does trametinib, a MEK1/2 inhibitor, reduce amyloid beta (Abeta) deposition in a model of Alzheimer's Disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35948663"
        },
        "clinical_136": {
            "question": "Does the ethanolic extract of D. moldavica leaves (EEDM) show potential for treating Alzheimer's disease based on its effects in scopolamine-induced cognitive impairment studies?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32035879"
        },
        "clinical_137": {
            "question": "Does prazosin improve behavioral symptoms in patients with Alzheimer disease experiencing agitation and aggression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19700947"
        },
        "clinical_138": {
            "question": "Does the pro-drug peptide (PDp) exhibit neuroprotective effects against Alzheimer's disease in vitro?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28714389"
        },
        "clinical_139": {
            "question": "Does donepezil treatment affect cholesterol levels in Alzheimer's disease patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28861608"
        },
        "clinical_140": {
            "question": "Does the compound ZLWH-23 show potential as a drug lead for Alzheimer's disease treatment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34995924"
        },
        "clinical_141": {
            "question": "Does the presence of cerebral amyloid angiopathy (CAA) correlate with reduced NEP activity in Alzheimer's disease patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21382117"
        },
        "clinical_142": {
            "question": "Does the combined treatment of MC5523 and LiCl improve neuroprotection and reduce side effects in the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30513908"
        },
        "clinical_143": {
            "question": "Does TRPC3 suppression improve memory deficits in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39345364"
        },
        "clinical_144": {
            "question": "Does the use of angiotensin II-inhibiting antihypertensive medications increase the risk of Alzheimer's disease in patients with colorectal cancer compared to angiotensin II-stimulating medications?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37215552"
        },
        "clinical_145": {
            "question": "Is QS-21 used in therapeutic vaccines for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31182297"
        },
        "clinical_146": {
            "question": "Is donepezil, an acetylcholinesterase inhibitor, also found to inhibit BACE-1 and thus potentially beneficial for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid17541560"
        },
        "clinical_147": {
            "question": "Does the hydroxylated form of docosahexaenoic acid (DHA-H) improve survival and motor function in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28284721"
        },
        "clinical_148": {
            "question": "Does Piper wallichii's petroleum ether fraction (PPF) exhibit anti-Alzheimer's disease effects in Caenorhabditis elegans?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37327643"
        },
        "clinical_149": {
            "question": "Does Triticum aestivum L. (TAL) have neuroprotective effects against beta-amyloid-induced cell death and memory impairments in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19441012"
        },
        "clinical_150": {
            "question": "Does early initiation of donepezil treatment improve outcomes for patients with geriatric depression and Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25919986"
        },
        "clinical_151": {
            "question": "Does Callicarpa kwangtungensis Chun (CK) improve cognitive function in Alzheimer's disease (AD) models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39586557"
        },
        "clinical_152": {
            "question": "Does flufenamic acid inhibit the activation of the NLRP3 inflammasome in microglia, thereby offering a potential treatment for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35474599"
        },
        "clinical_153": {
            "question": "Can the disruption of gut microbiota caused by treatments like Acyclovir contribute to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32760124"
        },
        "clinical_154": {
            "question": "Is hypophosphatemia associated with neurotoxicity symptoms resembling delirium in CD19-targeted CAR T-cell therapy?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36259217"
        },
        "clinical_155": {
            "question": "Does imatinib methanesulfonate reduce hippocampal amyloid-beta and restore cognitive function in a model of Alzheimer's disease following repeated endotoxin exposure?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23665252"
        },
        "clinical_156": {
            "question": "Does Armillaria mellea polysaccharides (AMPS) improve cognitive function in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29081887"
        },
        "clinical_157": {
            "question": "Does donepezil treatment protect against doxorubicin-induced chemobrain by reducing Alzheimer's disease-associated lesions?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34312765"
        },
        "clinical_158": {
            "question": "Does the compound 4v inhibit Abeta42-induced cytotoxicity and show potential for Alzheimer's disease treatment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31402645"
        },
        "clinical_159": {
            "question": "What was the outcome of the patient's treatment regarding delirium and Behcet's disease symptoms?",
            "options": "A. Delirium worsened, and Behcets symptoms persisted., B. Delirium resolved, and Behcets symptoms persisted., C. Delirium and Behcets symptoms both resolve, D. Delirium persisted, and Behcets symptoms worsened.",
            "correct_option": "C",
            "pmid": "pmid16840933"
        },
        "clinical_160": {
            "question": "What was the primary outcome measure in the AMARANTH and DAYBREAK-ALZ trials for assessing lanabecestat's efficacy in Alzheimer's disease?",
            "options": "A. Mini-Mental State Examination, B. Alzheimer Disease Assessment Scale-cognitive subscale, C. Clinical Dementia Rating, D. Functional Activities Questionnaire",
            "correct_option": "B",
            "pmid": "pmid31764959"
        },
        "clinical_161": {
            "question": "What is the relationship between cholinergic drugs used for treating neuroleptic-induced tardive dyskinesia and Alzheimer's disease?",
            "options": "A. Cholinergic drugs are effective in treating both conditions.; B. Cholinergic drugs have been primarily developed for Alzheimers disease., C. Cholinergic drugs used for tardive dyskinesia are the same as those used for Alzheimers disease., D. There is potential for new cholinergic agents used for Alzheimers disease to be investigated for treating tardive dyskinesia.",
            "correct_option": "D",
            "pmid": "pmid12137608"
        },
        "clinical_162": {
            "question": "What is the effect of ethyl pyruvate on the neurotoxicity induced by aluminum chloride in an in vitro model of Alzheimer's disease?",
            "options": "A. It increases neuronal cell death.; B. It ameliorates neuronal cell death.; C. It has no effect on neuronal cell death.; D. It enhances oxidative stress in neurons.",
            "correct_option": "B",
            "pmid": "pmid32030557"
        },
        "clinical_163": {
            "question": "How does the BQCA-SA-P80-NP conjugate improve therapeutic outcomes in Alzheimer's disease?",
            "options": "A. By selectively activating peripheral M1 receptors, B. By enhancing the brain bioavailability of BQCA, C. By reducing the elimination rate of AChE inhibitors, D. By increasing the peripheral side effects of BQCA",
            "correct_option": "B",
            "pmid": "pmid35423107"
        },
        "clinical_164": {
            "question": "How does the use of QU-SA-5HTM-PA-PLGA nanoparticles contribute to the management of Alzheimer's disease?",
            "options": "A. By enhancing the aggregation of phosphatidic acid in the formulation, B. By suppressing caspase-3 expression and reducing neuronal apoptosis, C. By increasing the production of amyloid-beta fibrils in the brain, D. By decreasing the permeability of the blood-brain barrier",
            "correct_option": "B",
            "pmid": "pmid33405649"
        },
        "clinical_165": {
            "question": "What was the effect of nicergoline on the ADAS-Cog score in Alzheimer's disease patients?",
            "options": "A. Significant improvement, B. No significant benefit, C. Worsening of symptoms, D. Inconsistent results",
            "correct_option": "B",
            "pmid": "pmid11687175"
        },
        "clinical_166": {
            "question": "How does the combined formulation of Ramipril and Black Seed Oil (BSO) address the therapeutic management of Alzheimer's disease?",
            "options": "A. By enhancing the solubility and bioavailability of Ramipril and THQ, potentially improving cognitive outcomes.; B. By directly targeting amyloid-beta plaques in the brain.; C. By reducing inflammation in the brain, specifically targeting microglial cells.; D. By increasing the production of acetylcholine in the brain.",
            "correct_option": "A",
            "pmid": "pmid36145341"
        },
        "clinical_167": {
            "question": "What is the potential benefit of combining low doses of lupeol and metformin in the management of dementia, particularly in Alzheimer's disease (AD) type?",
            "options": "A. They increase the production of acetylcholinesterase (AChE) in the brain.; B. They reduce the need for STZ administration in inducing dementia models.; C. They produce a more pronounced effect than high doses of either agent alone.; D. They enhance the activity of thiobarbituric acid reactive species (TBARS).",
            "correct_option": "C",
            "pmid": "pmid38842663"
        },
        "clinical_168": {
            "question": "What effect does pranlukast have on cognitive deficits associated with Alzheimer's disease?",
            "options": "A. It worsens spatial learning impairments, B. It reverses memory deficits, C. It increases amyloid-beta deposition, D. It enhances neuroinflammation",
            "correct_option": "B",
            "pmid": "pmid24229499"
        },
        "clinical_169": {
            "question": "How might the inclusion of evodiamine in hydroxypropyl-beta-cyclodextrin (HP-beta-CD) affect Alzheimer's disease treatment?",
            "options": "A. By enhancing the solubility and bioavailability of evodiamine, potentially improving its efficacy.; B. By directly targeting beta-amyloid plaques in the brain.; C. By inhibiting acetylcholinesterase activity, thus increasing neurotransmitter levels.; D. By reducing inflammation in the brain, independent of evodiamines effects.",
            "correct_option": "A",
            "pmid": "pmid27458481"
        },
        "clinical_170": {
            "question": "How does breviscapine combined with BMSCs treatment affect Abeta deposition in Alzheimer's disease?",
            "options": "A. It increases Abeta deposition by upregulating APP and BAEC1.; B. It decreases Abeta deposition by promoting the degradation of APP and BAEC1.; C. It has no effect on Abeta deposition but reduces neuroinflammation.; D. It increases Abeta deposition by inhibiting NF-kB signaling.",
            "correct_option": "B",
            "pmid": "pmid35048805"
        },
        "clinical_171": {
            "question": "What effect did donepezil treatment have on the gray matter volume in the hippocampus of Alzheimer's disease patients?",
            "options": "A. No significant change, B. Significant increase, C. Significant decrease, D. Only temporary increase",
            "correct_option": "B",
            "pmid": "pmid27131829"
        },
        "clinical_172": {
            "question": "What is the effect of ETA receptor antagonists on cognitive impairment caused by amyloid-beta in a model of Alzheimer's disease?",
            "options": "A. They worsen cognitive impairment.; B. They significantly reduce cognitive impairment.; C. They have no effect on cognitive impairment.; D. They improve cognitive impairment only in the brain stem.",
            "correct_option": "B",
            "pmid": "pmid21116051"
        },
        "clinical_173": {
            "question": "What effect does vanillin have on memory deficits in a scopolamine-induced model of Alzheimer's disease?",
            "options": "A. It worsens memory deficits.; B. It reverses memory deficits.; C. It has no effect on memory deficits.; D. It temporarily improves memory deficits.",
            "correct_option": "B",
            "pmid": "pmid36408377"
        },
        "clinical_174": {
            "question": "What was the primary symptom observed in the patient following pembrolizumab therapy that was associated with delirium?",
            "options": "A. Acute renal insufficiency, B. Fever, C. Cardiac insufficiency, D. Hepatic failure",
            "correct_option": "B",
            "pmid": "pmid36626467"
        },
        "clinical_175": {
            "question": "What effect does vinpocetine have on memory and learning impairment in an Alzheimer's disease model induced by Abeta peptide?",
            "options": "A. Worsens memory deficits, B. Ameliorates memory deficits, C. No effect on memory deficits, D. Initially improves, then worsens memory deficits",
            "correct_option": "B",
            "pmid": "pmid31991177"
        },
        "clinical_176": {
            "question": "What effect does IRL-1620, an endothelin receptor type B agonist, have on Alzheimer's disease (AD) in experimental models?",
            "options": "A. It worsens cognitive impairment by increasing oxidative stress.; B. It improves cognitive function by reducing oxidative stress.; C. It has no effect on oxidative stress or cognitive impairment.; D. It blocks the beneficial effects of ETB receptor stimulation.",
            "correct_option": "B",
            "pmid": "pmid24561065"
        },
        "clinical_177": {
            "question": "What effect does SS31 have on Alzheimer's disease progression in early-stage AD?",
            "options": "A. It increases beta-amyloid plaque formation.; B. It delays the progression of behavioral deficits.; C. It worsens mitochondrial dysfunction.; D. It reduces synaptic integrity.",
            "correct_option": "B",
            "pmid": "pmid37018887"
        },
        "clinical_178": {
            "question": "What is a potential benefit of using B6-RES-OPC-HA nanoparticles in the treatment of Alzheimer's disease?",
            "options": "A. They can increase ROS production in the brain.; B. They can scavenge ROS, reduce brain inflammation, and improve learning and memory ability.; C. They can prevent the formation of the blood-brain barrier.; D. They can enhance the degradation of polyphenols in the body.",
            "correct_option": "B",
            "pmid": "pmid37206236"
        },
        "clinical_179": {
            "question": "How does mindfulness-based stress reduction (MBSR) therapy impact outcomes in cirrhosis patients and their caregivers, particularly in relation to Alzheimer's disease or delirium?",
            "options": "A. MBSR improves mood, sleep, and HRQOL in patients and reduces caregiver burden.; B. MBSR increases anxiety and caregiver burden.; C. MBSR has no impact on HRQOL or caregiver burden.; D. MBSR worsens patient-reported outcomes.",
            "correct_option": "A",
            "pmid": "pmid28749453"
        },
        "clinical_180": {
            "question": "What therapeutic approach does MRZ-99030 represent for Alzheimer's disease?",
            "options": "A. Inhibiting Abeta1-42 oligomer formation, B. Preventing Abeta1-42 monomer interactions, C. Promoting large, non-toxic Abeta aggregates, D. Reducing Abeta1-42 concentration in the retina",
            "correct_option": "C",
            "pmid": "pmid25634238"
        },
        "clinical_181": {
            "question": "What is the primary outcome measure used to assess the effectiveness of premedication in preventing emergence delirium in children undergoing strabismus surgery?",
            "options": "A. Paediatric Anaesthesia Emergence Delirium scale, B. Postoperative pain intensity, C. Length of stay in the postanaesthesia care unit, D. Incidence of postoperative nausea or vomiting (PONV)",
            "correct_option": "A",
            "pmid": "pmid32976205"
        },
        "clinical_182": {
            "question": "What is a key factor that makes ANAVEX 2-73 (blarcamesine) an intriguing candidate for Rett syndrome treatment, based on its profile in Alzheimer's disease?",
            "options": "A. Its role in calcium homeostasis and mitochondrial function, B. Its ability to target the IGF-1 pathway, C. Its effectiveness in improving motor coordination in mice, D. Its strong safety record and preliminary efficacy in Alzheimers disease",
            "correct_option": "D",
            "pmid": "pmid31704481"
        },
        "clinical_183": {
            "question": "What effect does reducing the levels of KIF5B have on memory impairment in Alzheimer's disease models?",
            "options": "A. Worsens memory impairment, B. Reduces memory impairment, C. No effect on memory impairment, D. Temporarily improves memory impairment",
            "correct_option": "B",
            "pmid": "pmid36387285"
        },
        "clinical_184": {
            "question": "What is the effect of donepezil on homocysteine (Hcy) levels and dyssomnia in Alzheimer's disease patients?",
            "options": "A. Donepezil increases Hcy levels and worsens dyssomnia.; B. Donepezil decreases Hcy levels and improves dyssomnia.; C. Donepezil has no effect on Hcy levels but improves dyssomnia.; D. Donepezil has no effect on dyssomnia but decreases Hcy levels.",
            "correct_option": "B",
            "pmid": "pmid30680019"
        },
        "clinical_185": {
            "question": "What effect did methylene blue have on neurotoxicity in a zebrafish model for tauopathies, specifically in relation to Alzheimer's disease?",
            "options": "A. It reduced abnormal phosphorylation of Tau.; B. It prevented neuronal cell loss.; C. It was ineffective in rescuing neurotoxicity.; D. It improved swimming behavior in larvae.",
            "correct_option": "C",
            "pmid": "pmid20381619"
        },
        "clinical_186": {
            "question": "What is the protective effect of Housefly (Musca domestica) Larvae powder (HL) against Alzheimer's disease?",
            "options": "A. It increases oxidative stress.; B. It enhances memory ability and prevents oxidative stress injury.; C. It decreases the expression of UCP4 and CyclinD1.; D. It inhibits the phosphorylation of JNK and P38 MAPK.",
            "correct_option": "B",
            "pmid": "pmid30540319"
        },
        "clinical_187": {
            "question": "In Alzheimer's disease, where was aluminum consistently detected?",
            "options": "A. Throughout the entire brain tissue of Alzheimer's patients.; B. In the blood vessels surrounding the brain in Alzheimer's disease cases.; C. Within the tangle-bearing neurons in the hippocampus of Alzheimer's disease cases.; D. Primarily in the cerebellum of individuals with Alzheimer's.",
            "correct_option": "C",
            "pmid": "pmid17004365"
        },
        "clinical_188": {
            "question": "What category size affects verbal fluency in Alzheimer's patients?",
            "options": "A. Small semantic categories; B. The concreteness of semantic categories; C. Large semantic categories; D. Abstract semantic categories",
            "correct_option": "C",
            "pmid": "pmid15010242"
        },
        "clinical_189": {
            "question": "What brain changes are described as examples of aging and Alzheimer's disease?",
            "options": "A. Increased levels of dopamine and serotonin.; B. Choline acetyltransferase, somatostatin-containing neurons, and dendrites.; C. Proliferation of glial cells and increased neurogenesis.; D. Enhanced synaptic plasticity and long-term potentiation.",
            "correct_option": "B",
            "pmid": "pmid2893306"
        },
        "clinical_190": {
            "question": "What changes occur in cortical mean diffusivity (MD) in early Alzheimer's disease?",
            "options": "A. Cortical MD increases compared to healthy controls.; B. Cortical MD shows no significant change compared to healthy controls.; C. Cortical MD decreases compared to healthy controls.; D. Cortical MD initially increases, then decreases over time compared to healthy controls.",
            "correct_option": "C",
            "pmid": "pmid29080407"
        },
        "clinical_191": {
            "question": "Which brain region correlates with ideomotor and dressing apraxia in Alzheimer's disease?",
            "options": "A. Hippocampus; B. Parietal lobe; C. Anterior cingulate cortex; D. Cerebellum",
            "correct_option": "C",
            "pmid": "pmid9605726"
        },
        "clinical_192": {
            "question": "Which animals are proposed as natural, non-transgenic models for Alzheimer's disease research?",
            "options": "A. Mice and Rats; B. Monkeys and Chimpanzees; C. The chick embryo and the dog; D. Zebrafish and Fruit flies",
            "correct_option": "C",
            "pmid": "pmid19355852"
        },
        "clinical_193": {
            "question": "What differences in outcome were observed between men and women with Alzheimer's disease?",
            "options": "A. Men experienced more disability and longer survival, while women had greater comorbid conditions and higher mortality.; B. There were no significant differences in outcome between men and women with Alzheimer's disease.; C. Men with Alzheimer's disease had greater comorbid conditions and higher mortality, while women recorded more disability and longer survival.; D. Women with Alzheimer's disease had greater comorbid conditions and higher mortality, while men recorded more disability and longer survival.",
            "correct_option": "C",
            "pmid": "pmid20733307"
        },
        "clinical_194": {
            "question": "How does chronic kidney disease affect cognitive impairment in Alzheimer's disease mice?",
            "options": "A. Chronic kidney disease slows down cognitive impairment in 5XFAD mice.; B. Chronic kidney disease has no effect on cognitive impairment in 5XFAD mice.; C. Chronic kidney disease accelerates cognitive impairment in 5XFAD mice, potentially through angiotensin II.; D. Chronic kidney disease reverses cognitive impairment in 5XFAD mice, likely due to amyloid plaque removal.",
            "correct_option": "C",
            "pmid": "pmid27916702"
        },
        "clinical_195": {
            "question": "How does dual tasking affect postural sway in preclinical Alzheimer's disease?",
            "options": "A. Individuals with preclinical Alzheimer's disease exhibit significantly less postural sway during dual tasking compared to healthy controls.; B. Dual tasking has no impact on postural sway in individuals with preclinical Alzheimer's disease.; C. Participants with preclinical Alzheimer's disease demonstrated significantly greater dual task cost in postural sway compared to those without preclinical AD.; D. Dual tasking only affects postural sway in individuals with advanced Alzheimer's disease, not in the preclinical stage.",
            "correct_option": "C",
            "pmid": "pmid38554257"
        },
        "clinical_196": {
            "question": "What two main factors affect support for Iranian older spousal caregivers of people with Alzheimer's disease?",
            "options": "A. Patient's age and caregiver's financial status.; B. Caregiver's education level and availability of respite care.; C. Caregiver's support-seeking and capacities of support resources.; D. Patient's disease severity and caregiver's religious beliefs.",
            "correct_option": "C",
            "pmid": "pmid39097934"
        },
        "clinical_197": {
            "question": "What condition can share cognitive decline and a positive Amyloid-PET scan with Alzheimer's disease?",
            "options": "A. Vascular dementia; B. Frontotemporal dementia; C. Cerebral amyloid angiopathy; D. Lewy body dementia",
            "correct_option": "C",
            "pmid": "pmid38405347"
        },
        "clinical_198": {
            "question": "Which brain area shows decreased diffusivity potentially indicating early Alzheimer's disease?",
            "options": "A. Amygdala; B. Hippocampus; C. Posterior cingulate/precuneus; D. Visual cortex",
            "correct_option": "C",
            "pmid": "pmid22651939"
        },
        "clinical_199": {
            "question": "Which delirium subtypes are associated with shorter survival periods in terminally ill patients?",
            "options": "A. Hyperactive and hyperkinetic subtypes; B. Absence and presence subtypes; C. Hypoactive and mixed subtypes; D. Reactive and proactive subtypes",
            "correct_option": "C",
            "pmid": "pmid26397939"
        },
        "clinical_200": {
            "question": "Which cognitive tests correlate with functional decline in both Parkinson's and Alzheimer's disease?",
            "options": "A. Wisconsin Card Sorting Test (WCST), Trail Making Test (TMT), and Stroop Test; B. Rey Auditory Verbal Learning Test (AVLT), Controlled Oral Word Association (COWA), and Animal Fluency; C. Mini-Mental State Examination (MMSE), Clock Drawing Test, and Geriatric Depression Scale (GDS); D. Visual Object and Space Perception Battery (VOSP), Benton Judgement of Line Orientation, and Facial Recognition Test",
            "correct_option": "B",
            "pmid": "pmid17851237"
        },
        "clinical_201": {
            "question": "What pathology is linked to iatrogenic Alzheimer's disease in growth hormone recipients?",
            "options": "A. Lewy body formation and alpha-synuclein aggregation.; B. Prion protein accumulation and spongiform encephalopathy.; C. Abeta deposition in brain parenchyma and blood vessels (cerebral amyloid angiopathy) and neurofibrillary tangles of hyperphosphorylated tau.; D. Selective neuronal loss in the substantia nigra and locus coeruleus.",
            "correct_option": "C",
            "pmid": "pmid38287166"
        },
        "clinical_202": {
            "question": "What functional domains were identified as highly relevant for assessment in early Alzheimer's disease?",
            "options": "A. Motor skills, language fluency, and social interaction.; B. Difficulties at work, spatial navigation and memory, and planning skills and memory required for task completion.; C. Sensory perception, emotional regulation, and artistic expression.; D. Financial management, cooking abilities, and driving skills.",
            "correct_option": "B",
            "pmid": "pmid33250792"
        },
        "clinical_203": {
            "question": "What role do home healthcare nurses play in delirium?",
            "options": "A. They primarily focus on medication administration for patients experiencing delirium.; B. They are mainly responsible for providing respite care to family caregivers of patients with delirium.; C. They play a key role in the assessment, early identification, and management of delirium, and in the support and education of patients and their family caregivers.; D. They only consult with specialists regarding delirium management.",
            "correct_option": "C",
            "pmid": "pmid19114784"
        },
        "clinical_204": {
            "question": "What data types were used to identify conversion from normal cognition to Alzheimer's disease?",
            "options": "A. Genetic sequencing and cerebrospinal fluid analysis.; B. Neuropsychological assessments and electroencephalography.; C. Magnetic resonance imaging and positron emission tomography data.; D. Clinical interviews and family history.",
            "correct_option": "C",
            "pmid": "pmid26401783"
        },
        "clinical_205": {
            "question": "Which brain volumes at baseline predict cognitive outcomes in early-onset Alzheimer's disease?",
            "options": "A. Hippocampal volume and ventricular volume.; B. Hippocampal volume and hemispheric cortical thickness.; C. Hemispheric cortical thickness, ventricular volume, and amygdalar volume.; D. Only hippocampal volume.",
            "correct_option": "C",
            "pmid": "pmid34665329"
        },
        "clinical_206": {
            "question": "Which factors significantly increase the risk of delirium in trauma ICU patients?",
            "options": "A. Administration of opioid analgesics and benzodiazepines.; B. Hypoactive delirium and sleep disturbances.; C. Physical restraints and active infection or sepsis.; D. Pre-existing dementia and advanced age only.",
            "correct_option": "C",
            "pmid": "pmid28335673"
        },
        "clinical_207": {
            "question": "Does combining MAOI with tricyclic antidepressants increase the risk of delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid6376486"
        },
        "clinical_208": {
            "question": "What mechanisms are associated with levofloxacin-induced delirium?",
            "options": "A. Direct neurotoxicity and disruption of the gut microbiome leading to increased inflammatory cytokine production.; B. Increased dopamine levels in the brain and decreased serotonin levels in the gut.; C. Liver enzyme induction resulting in altered metabolism of other medications.; D. The cases reflect an under-recognition of drug-induced delirium, particularly for levofloxacin, suggesting that this severe adverse effect is more common than previously reported.",
            "correct_option": "D",
            "pmid": "pmid31178301"
        },
        "clinical_209": {
            "question": "Are there cases of delirium related to intrathecal baclofen?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19079356"
        },
        "clinical_210": {
            "question": "What are the perceived benefits of early out-of-bed mobilisation in reducing delirium risk among patients with severe acquired brain injury?",
            "options": "A. It is perceived to increase delirium risk by causing overstimulation.; B. It is perceived to have no effect on delirium risk.; C. It is perceived by clinicians as beneficial for reducing the risk of delirium.; D. It is perceived to be beneficial for reducing falls, but increases delirium risk.",
            "correct_option": "C",
            "pmid": "pmid39788872"
        },
        "clinical_211": {
            "question": "Does concomitant use of hydroxyzine with haloperidol worsen delirium in patients with cancer?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid38409802"
        },
        "clinical_212": {
            "question": "Does perioperative delirium increase the risk of Alzheimer’s disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35525395"
        },
        "clinical_213": {
            "question": "What non-motor symptoms of Parkinson’s disease are associated with postoperative delirium in elderly patients undergoing spinal surgery?",
            "options": "A. Restless legs syndrome and excessive daytime sleepiness; B. Decreased olfactory function (hyposmia) and REM sleep behavior disorder; C. Constipation and urinary urgency; D. Orthostatic hypotension and seborrheic dermatitis",
            "correct_option": "B",
            "pmid": "pmid29630637"
        },
        "clinical_214": {
            "question": "What is the effect of dexmedetomidine infusion on postoperative delirium in elderly patients undergoing oral and maxillofacial surgery?",
            "options": "A. It significantly increased the incidence of postoperative delirium.; B. It significantly decreased the incidence of postoperative delirium.; C. It had no significant effect on postoperative delirium.; D. It always eliminated postoperative delirium completely.",
            "correct_option": "C",
            "pmid": "pmid35846796"
        },
        "clinical_215": {
            "question": "What is the effect of the Haga Brain Care Strategy on postoperative delirium rates?",
            "options": "A. It leads to an increase in the incidence of postoperative delirium.; B. It has no effect on the incidence of postoperative delirium.; C. It leads to a reduction in the incidence of postoperative delirium.; D. It increases the severity of postoperative delirium without changing incidence.",
            "correct_option": "C",
            "pmid": "pmid22778141"
        },
        "clinical_216": {
            "question": "What factors are associated with an increased risk of delirium episodes in elderly patients with asthma during hospitalization?",
            "options": "A. Well-controlled asthma and a history of regular exercise.; B. Young age, no prior cognitive impairment, and non-smoking status.; C. Use of short-acting beta-agonists only, without inhaled corticosteroids.; D. Advanced age, dementia, smoking, and uncontrolled or partially controlled asthma.",
            "correct_option": "D",
            "pmid": "pmid34250429"
        },
        "clinical_217": {
            "question": "Do esketamine and dexmedetomidine help in preventing postoperative delirium in elderly patients undergoing thoracic surgery?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37917895"
        },
        "clinical_218": {
            "question": "Do melatonin receptor agonists reduce the risk of postoperative delirium compared to zolpidem and temazepam in older adults?",
            "options": "A.Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid38979845"
        },
        "clinical_219": {
            "question": "Does delirium occur after alcohol withdrawal seizures in patients treated with oxazepam?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid7573789"
        },
        "clinical_220": {
            "question": "What types of delirium are associated with increased one-year mortality in critically ill patients with cancer?",
            "options": "A. Hyperactive delirium types; B. Absence of delirium; C. Hypoactive and mixed delirium types; D. Isolated periods of lucidity",
            "correct_option": "C",
            "pmid": "pmid37610551"
        },
        "clinical_221": {
            "question": "What are the complications associated with delirium in men with spinal cord injury following lower extremity fractures?",
            "options": "A. Increased risk of developing pneumonia.; B. Delirium is one of several complications observed within the first month post-fracture, alongside respiratory infections, pressure ulcers, urinary tract infections, thromboembolic events, and depression.; C. Accelerated bone healing at the fracture site.; D. Decreased risk of urinary tract infections.",
            "correct_option": "B",
            "pmid": "pmid23392311"
        },
        "clinical_222": {
            "question": "Does delirium in neurocritically ill patients predict relevant clinical outcomes such as functional independence and cognition?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30142098"
        },
        "clinical_223": {
            "question": "Does the presence of Confusion Assessment Method (CAM) core symptoms at baseline predict incident delirium in older long-term care residents?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23448799"
        },
        "clinical_224": {
            "question": "Does hypercapnia in patients with chronic obstructive pulmonary disease (COPD) lead to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27736515"
        },
        "clinical_225": {
            "question": "Does Five-Element music therapy reduce the incidence of delirium in ICU patients with difficult weaning?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39586722"
        },
        "clinical_226": {
            "question": "What is the effect of perioperative dexmedetomidine administration on delirium incidence in patients after cardiac surgery?",
            "options": "A. Perioperative dexmedetomidine administration significantly increases the incidence of postoperative delirium.; B. Perioperative dexmedetomidine administration has no effect on the incidence of postoperative delirium.; C. Perioperative dexmedetomidine administration significantly decreases the incidence of postoperative delirium.; D. Perioperative dexmedetomidine administration can increase or decrease the incidence of postoperative delirium depending on the dosage.",
            "correct_option": "C",
            "pmid": "pmid29958125"
        },
        "clinical_227": {
            "question": "Does initiating pharmacologic delirium treatment within 24 hours reduce physical restraint use in ICU patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24259659"
        },
        "clinical_228": {
            "question": "What is the presentation of delirium caused by chloromethcathinone and cannabis ingestion?",
            "options": "A. Delirium tremens with severe hallucinations and tremors.; B. Mild confusion and disorientation resolving within a few hours.; C. Prolonged excited delirium syndrome with severe agitation lasting over 24 hours.; D. Catatonic state with minimal responsiveness to stimuli.",
            "correct_option": "C",
            "pmid": "pmid33093258"
        },
        "clinical_229": {
            "question": "Does normal pressure hydrocephalus (NTH) have an association with delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid1949310"
        },
        "clinical_230": {
            "question": "What is the effect of remimazolam administration at the end of tonsillectomy and adenoidectomy under sevoflurane anesthesia on the incidence of emergence delirium in children?",
            "options": "A. It significantly increases the incidence of emergence delirium.; B. It has no effect on the incidence of emergence delirium.; C. It significantly reduces the incidence of emergence delirium.; D. It initially reduces, then significantly increases the incidence of emergence delirium.",
            "correct_option": "C",
            "pmid": "pmid36203819"
        },
        "clinical_231": {
            "question": "What factors predict ICU admission among Parkinson's disease patients with delirium?",
            "options": "A. Presence of hallucinations, bradykinesia, and tremor.; B. Age >65 years, history of previous admission within the last 12 months, delirium, and hypoalbuminemia.; C. Use of levodopa, family history of Parkinson's, and constipation.; D. Disease duration less than 5 years, normal cognitive function, and hypertension.",
            "correct_option": "B",
            "pmid": "pmid30692764"
        },
        "clinical_232": {
            "question": "An elderly patient is scheduled for primary total joint arthroplasty. Which of the following combinations of factors is most strongly associated with an increased risk of developing postoperative delirium?",
            "options": "A. Low pain tolerance, intraoperative hypotension, and epidural anesthesia; B. Advanced age, dementia, psychiatric history, general anesthesia, and intraoperative blood transfusion; C. Obesity, short operative time, and preoperative anemia treated with iron supplementation; D. Family history of delirium, female sex, and postoperative fever without infection.",
            "correct_option": "B",
            "pmid": "pmid39259060"
        },
        "clinical_233": {
            "question": "Which of the following best describes the relationship between BDNF levels and delirium tremens (DT) in alcohol withdrawal?",
            "options": "A. BDNF levels rise early in withdrawal and predict the onset of DT.; B. Patients with DT show higher BDNF levels than those without DT.; C. BDNF levels are unrelated to DT risk.; D. Lower baseline BDNF levels are associated with increased risk of DT and improve after detoxification.",
            "correct_option": "D",
            "pmid": "pmid21039634"
        }
    },
    "cell": {
        "cell_0": {
            "question": "Does Platycodin D inhibit beta-amyloid-induced inflammation and oxidative stress in BV-2 cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33394221"
        },
        "cell_1": {
            "question": "Do activated astrocytes contribute to Abeta production, implicated in Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22047170"
        },
        "cell_2": {
            "question": "Does beta-patchoulene alleviate delirium by inhibiting microglia activation through the Sirt1/Nrf2 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36608000"
        },
        "cell_3": {
            "question": "Do atypical antipsychotic drugs (APDs) reduce beta-amyloid peptide(25-35)-induced PC12 cell death, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid15948179"
        },
        "cell_4": {
            "question": "Does TUDCA reduce p53-induced apoptosis in Alzheimer's disease mutant neuroblastoma cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid16923170"
        },
        "cell_5": {
            "question": "Does oligomeric amyloid-beta (Abeta) stimulate NFAT activation in astrocyte cultures, potentially contributing to Alzheimer's disease progression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19828810"
        },
        "cell_6": {
            "question": "Does dihydroactinidiolide (DHAc) protect SH-SY5Y cells from oxidative stress-induced neuronal apoptosis in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33617922"
        },
        "cell_7": {
            "question": "Do viral infections contribute to Alzheimer's disease by reducing neprilysin levels in astrocytes?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36321194"
        },
        "cell_8": {
            "question": "Does disruption of the Sigma-2 receptor complex-TMEM97, PGRMC1, and LDLR affect Abeta42 uptake in primary neurons, potentially relevant to Alzheimer's disease progression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32572762"
        },
        "cell_9": {
            "question": "Does AT2R activation contribute to neuroprotection in Alzheimer's disease by inhibiting microglia pro-inflammatory activation?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30076526"
        },
        "cell_10": {
            "question": "Does TRPV4-induced oxidative stress contribute to neurotoxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27799895"
        },
        "cell_11": {
            "question": "Does GPR120 signaling in astrocytes negatively regulate amyloid-beta degradation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34099509"
        },
        "cell_12": {
            "question": "Does PQQ protect primary cortical neurons against microglia-mediated neurotoxicity, potentially relevant in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25314304"
        },
        "cell_13": {
            "question": "Does SIRT2 play a significant role in astrocytic GABA production in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39815261"
        },
        "cell_14": {
            "question": "Could an MMP-8 inhibitor be therapeutic for Alzheimer's disease by reducing astrocyte reactivity?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30470240"
        },
        "cell_15": {
            "question": "Does hBD3 inhibit Pg LPS-induced oxidative and inflammatory responses in microglia, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36499428"
        },
        "cell_16": {
            "question": "Does Phillyrin prevent BBB damage by inhibiting microglial neuroinflammation through the PPARgamma/NF-kappaB pathway, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34744713"
        },
        "cell_17": {
            "question": "Could inhibiting pro-inflammatory DAM (Disease-Associated Microglia) be beneficial in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29784049"
        },
        "cell_18": {
            "question": "Does hepcidin-mediated neuronal iron deposition and oxidative stress contribute to Alzheimer's-like cognitive impairment in mice exposed to chronic intermittent hypoxia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34394834"
        },
        "cell_19": {
            "question": "Does withanolide A reduce 7-ketocholesterol's effects on pro-inflammatory genes in brain endothelial cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35159267"
        },
        "cell_20": {
            "question": "Does dexamethasone inhibit Nox-dependent ROS production in activated microglia, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21615929"
        },
        "cell_21": {
            "question": "Does DHEA exacerbate nigericin-induced pyroptosis in LPS-primed macrophages, potentially relevant to delirium mechanisms?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35440074"
        },
        "cell_23": {
            "question": "Does arundic acid affect astrocytic EAAT1 expression, implicated in Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28812276"
        },
        "cell_24": {
            "question": "Does thonningianin A enhance microglial cell autophagy to alleviate Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35918778"
        },
        "cell_25": {
            "question": "Does Ferulago angulata extract protect against beta-amyloid-induced toxicity in PC12 cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38050568"
        },
        "cell_26": {
            "question": "Does Sirt1 regulation of microglial activation via the Shh/Gli-1 pathway have implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36725745"
        },
        "cell_27": {
            "question": "Does overexpression of presenilin2 and its Alzheimer's-disease-linked variants influence TRPC6-mediated calcium entry in HEK293 cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid15601622"
        },
        "cell_28": {
            "question": "Does Miltefosine improve Alzheimer's-like pathology by alleviating tauopathy via microglia/neuron crosstalk in mice?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36388134"
        },
        "cell_29": {
            "question": "Does IRAK-M influence microglial NLRP3 inflammasome activation and GSDMD-mediated pyroptosis, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36765034"
        },
        "cell_30": {
            "question": "Does Ponesimod increase microglial Abeta42 phagocytosis relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37480622"
        },
        "cell_31": {
            "question": "Do simvastatin and atorvastatin increase neprilysin secretion from astrocytes, facilitating amyloid beta-protein degradation relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26875818"
        },
        "cell_33": {
            "question": "Does inhibiting microglial activation by 2-Cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride offer potential therapeutic benefits for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24752390"
        },
        "cell_34": {
            "question": "Does cancer history affect long-term lymphocyte cell death susceptibility in individuals who later develop Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29472838"
        },
        "cell_35": {
            "question": "Can Berberine-treated BMSCs rescue neurons from oxidative stress damage relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32108297"
        },
        "cell_36": {
            "question": "Does beta-amyloid exacerbate inflammation in FAAH-lacking astrocytes through PPAR-alpha, PPAR-gamma, and TRPV1, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22321194"
        },
        "cell_37": {
            "question": "Does the DSPE-PEG-TPP/MoS2 QD blend reduce oxidative stress and inflammation in Abeta-activated microglial cells in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37606394"
        },
        "cell_38": {
            "question": "Does Erjingpill exhibit anti-neuroinflammatory effects by influencing microglial cell glycolysis relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38824976"
        },
        "cell_39": {
            "question": "Can metformin, rapamycin, or nicotinamide mononucleotide inhibit microglial phagocytosis in a manner relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35769369"
        },
        "cell_40": {
            "question": "Does BG45 reduce inflammation in the entorhinal cortex of young APP/PS1 mice, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36902234"
        },
        "cell_41": {
            "question": "Which of the following statements best describes the role of DHA in THP-1 monocytes exposed to Aβ25-35 in the context of Alzheimer's disease (AD)?",
            "options": "A. DHA enhanced NF-κB/p65 signaling activation and promoted necroptosis in THP-1 monocytes.; B. DHA alone activated RIPK1 and MLKL, resulting in increased production of pro-inflammatory cytokines.; C. DHA blocked the differentiation of THP-1 monocytes by upregulating p38 signaling.; D. DHA suppressed Aβ-induced necroptosis and ERK1/2 signaling, reducing RIPK1/RIPK3 expression and restoring cell migration.",
            "correct_option": "D",
            "pmid": "pmid32199223"
        },
        "cell_42": {
            "question": "Does chlorogenic acid alleviate inflammatory stress in BV2 cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35633920"
        },
        "cell_43": {
            "question": "Does inhibiting RXRalpha nuclear export reduce neuronal apoptosis relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28627642"
        },
        "cell_44": {
            "question": "Is the Sur1-Trpm4 channel implicated in regulating NOS2 expression in microglia, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27246103"
        },
        "cell_45": {
            "question": "Does glimepiride protect neurons against amyloid-beta-induced synapse damage in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26432105"
        },
        "cell_46": {
            "question": "Does CD45RB cross-linking inhibit Abeta-induced microglial activation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid18478117"
        },
        "cell_47": {
            "question": "Does donepezil, commonly used for Alzheimer's disease, inhibit MPP+-induced M1 polarization in microglia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26114860"
        },
        "cell_48": {
            "question": "Does Spns2 promote pro-inflammatory activation of microglia in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30484906"
        },
        "cell_49": {
            "question": "Does neoechinulin A inhibit amyloid-beta-induced microglia activation, a process relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23261590"
        },
        "cell_50": {
            "question": "Can antioxidants like thymoquinone or EGCG reduce amyloid beta oxidation in neuroblastoma cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25405415"
        },
        "cell_51": {
            "question": "Does the small molecule MFM 4 inhibit Abeta-induced neuronal toxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31140779"
        },
        "cell_52": {
            "question": "Does quetiapine inhibit microglial activation, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26732345"
        },
        "cell_53": {
            "question": "Does 2-methoxyestradiol (2ME) protect against neuronal cell death and tau hyperphosphorylation relevant to Alzheimer's Disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36208660"
        },
        "cell_54": {
            "question": "Does Schisandrin treatment restore cell viability in the SH-SY5Y cell model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31739764"
        },
        "cell_55": {
            "question": "Does strontium treatment in high-fat diet-induced NAFLD mice reduce neuroinflammation and improve synaptic plasticity, processes also implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37373395"
        },
        "cell_56": {
            "question": "Can mesenchymal stem cells prevent pyroptosis in macrophages exposed to ITO nanoparticles, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27194621"
        },
        "cell_57": {
            "question": "Does Amanita muscaria extract affect proinflammatory cytokines in a manner relevant to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37124206"
        },
        "cell_58": {
            "question": "Does 9-Methylfascaplysin (9-MF) reduce neuroinflammation and synaptic damage in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39563011"
        },
        "cell_59": {
            "question": "Can esculetin and fucoidan help prevent Alzheimer's disease by modulating reactive astrocytes and proinflammatory cytokines?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35448455"
        },
        "cell_60": {
            "question": "Does guanosine show neuroprotective effects in an Alzheimer's disease model by reducing neuronal death and reactive oxygen species?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20846477"
        },
        "cell_61": {
            "question": "Does microglial activation by silica-coated magnetic nanoparticles contribute to Alzheimer's disease pathogenesis through D-serine secretion?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34384435"
        },
        "cell_62": {
            "question": "Does MAC1 receptor activation in microglia contribute to beta-amyloid peptide-induced neurotoxicity associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21232086"
        },
        "cell_63": {
            "question": "Does CD45 deficiency contribute to increased neurotoxic Abeta oligomer levels in Alzheimer's disease mice?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21273420"
        },
        "cell_64": {
            "question": "Does astroglial connexin43 deletion in APP/PS1 mice improve cognitive dysfunction in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30031059"
        },
        "cell_65": {
            "question": "Does aging enhance exosomal cytokine mRNA release by Abeta1-42-stimulated macrophages relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24014820"
        },
        "cell_66": {
            "question": "Does inhibiting tissue transglutaminase (tTG) promote beta-amyloid (Abeta)-induced apoptosis in SH-SY5Y cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27665848"
        },
        "cell_67": {
            "question": "Does Gamma-interferon-inducible lysosomal thiol reductase (GILT) expression in microglia correlate with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30560017"
        },
        "cell_68": {
            "question": "Does Abeta-induced TRPC6 up-regulation in BV-2 microglia contribute to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28458019"
        },
        "cell_69": {
            "question": "Does biliverdin regulate macrophage C5aR expression via the mTOR pathway, potentially relevant to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24814708"
        },
        "cell_70": {
            "question": "Does Cu(II) disrupt autophagy-mediated lysosomal degradation of oligomeric Abeta in microglia, contributing to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32512069"
        },
        "cell_71": {
            "question": "Does Physalin B reduce cell apoptosis in HEK293/Tau cells, an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37489791"
        },
        "cell_72": {
            "question": "Does blocking TGF-beta-Smad2/3 signaling in peripheral macrophages improve Alzheimer's-like pathology in mice?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid18516051"
        },
        "cell_73": {
            "question": "Does All-trans retinoic acid (ATRA) increase Transglutaminase 2 (TG2) expression in BV-2 cells and astrocytes involved in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37916634"
        },
        "cell_74": {
            "question": "Does curcumin inhibit appoptosin-induced apoptosis in SH-SY5Y cells, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25891083"
        },
        "cell_75": {
            "question": "Are glial hypo- and hyperactivation observed in predementia Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38093257"
        },
        "cell_76": {
            "question": "Does a diabetic phenotype reduce microglial numbers around beta-amyloid plaques in Alzheimer's disease (mice and humans)?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33168021"
        },
        "cell_77": {
            "question": "Does USP19 knockdown reduce ferroptosis in SH-SY5Y cells, alleviating mitochondrial damage in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38943386"
        },
        "cell_78": {
            "question": "Does Bazi Bushen capsule improve cognitive deficits by inhibiting microglia activation and cellular senescence, similarly to Alzheimer's disease treatments?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36263579"
        },
        "cell_79": {
            "question": "Do activated microglia promote GDNF production by BMSCs to protect neurons against oxygen-glucose deprivation, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28018176"
        },
        "cell_80": {
            "question": "Does GRP78 play a role in disrupting neuron-microglia communication, similar to its involvement in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37365565"
        },
        "cell_81": {
            "question": "Does increased HO-1 activity in astrocytes contribute to iron-mediated cytotoxicity in Alzheimer's-affected neural tissues?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22881289"
        },
        "cell_82": {
            "question": "Which of the following best reflects the proposed cellular mechanism contributing to the development of delirium according to the gliocentric perspective?",
            "options": "A. Neuronal apoptosis due to direct oxidative damage.; B. Synaptic pruning by overactive microglia in the prefrontal cortex.; C. Disruption of mitochondrial metabolism in cortical neurons.; D. Astrocyte dysfunction impairing the cholinergic anti-inflammatory response, leading to neuroinflammation.",
            "correct_option": "D",
            "pmid": "pmid26029046"
        },
        "cell_83": {
            "question": "Does CIRP overexpression in astrocytes contribute to Alzheimer's disease development by inhibiting uPA expression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39741909"
        },
        "cell_84": {
            "question": "Do CD11c-positive microglia have a suppressive influence on the inflammatory response in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27425031"
        },
        "cell_85": {
            "question": "Does amyloid-beta induce Smac release via AP-1/Bim activation in cerebral endothelial cells relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid12427831"
        },
        "cell_86": {
            "question": "Does luteolin induce apoptosis and autophagy in macrophages, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30246034"
        },
        "cell_87": {
            "question": "Does acute hypoxia affect M1/M2 microglial activation in Alzheimer's disease mice and wild-type littermates?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28890695"
        },
        "cell_88": {
            "question": "Does MKP-1 regulate microglia phenotype and inflammatory factor release in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37602891"
        },
        "cell_89": {
            "question": "Does galantamine inhibit beta-amyloid-induced cytostatic autophagy in PC12 cells by decreasing ROS production, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29292543"
        },
        "cell_90": {
            "question": "Does adoptive transfer of ex vivo expanded human regulatory T cells reduce amyloid burden in an Alzheimer's disease preclinical model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36180898"
        },
        "cell_91": {
            "question": "Which of the following best explains how systemic inflammation contributes to delirium through neuroinflammatory processes at the cellular level?",
            "options": "A. Astrocytes directly release acetylcholine, which neutralizes systemic cytokines and prevents delirium onset.; B. Endothelial cells in the blood-brain barrier become hyperpermeable, allowing neurotransmitter leakage into peripheral tissues.; C. Microglia exhibit an exaggerated inflammatory response due to age-related priming, amplifying central cytokine signaling.; D. Peripheral immune cells migrate into the hippocampus and displace local neurons, leading to acute cognitive deficits.",
            "correct_option": "C",
            "pmid": "pmid20309566"
        },
        "cell_92": {
            "question": "Does passion fruit seed extract protect against beta-amyloid-induced neuronal cell death in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35592293"
        },
        "cell_93": {
            "question": "Does FUT8-catalyzed core fucosylation play a role in microglial activation during Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36692036"
        },
        "cell_94": {
            "question": "Does TGF-beta1 protect against Alzheimer's disease by inhibiting microglial FPR2 expression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid15240683"
        },
        "cell_95": {
            "question": "Does alpha-boswellic acid affect astrocytic Reelin expression, related to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27567921"
        },
        "cell_96": {
            "question": "Does Sig1R downregulation contribute to neuroinflammation-induced microglial dysfunction in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32653342"
        },
        "cell_97": {
            "question": "Does Ca2+-binding protein upregulation in VTA dopamine neurons contribute to their survival in early-stage Alzheimer's disease in Tg2576 mice?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36434727"
        },
        "cell_98": {
            "question": "Does demyelination-derived lysophosphatidylserine (LysoPS) contribute to microglial dysfunction and neuropathology in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39741193"
        },
        "cell_99": {
            "question": "Does VAP regulate apoptosis in an Alzheimer's disease cell model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33361033"
        },
        "cell_100": {
            "question": "Does microglial QUIN elevation in the basolateral amygdala contribute to cognitive dysfunction in delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36160165"
        },
        "cell_101": {
            "question": "Does 3,5,4'-Trihydroxy-6,7,3'-trimethoxyflavone (TTF) protect astrocytes against oxidative stress involved in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25217804"
        },
        "cell_102": {
            "question": "Does microglial CD2AP deficiency protect against amyloidosis in an Alzheimer's disease model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39695808"
        },
        "cell_103": {
            "question": "Does Aster tataricus have potential anti-neuroinflammatory effects relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28344491"
        },
        "cell_104": {
            "question": "Does DHCR24 overexpression modulate microglia polarization and inflammatory response in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32950573"
        },
        "cell_105": {
            "question": "Does compound 4c2 exhibit anti-inflammatory effects by reducing pro-inflammatory cytokines like NO, IL-6, and TNF-alpha relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35987018"
        },
        "cell_106": {
            "question": "Does inhibiting microglial activation by PS/PC liposomes suggest a potential Alzheimer's disease treatment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid17349923"
        },
        "cell_107": {
            "question": "Do T1AM and SG-2 induce autophagy in human glioblastoma cell lines, potentially offering therapeutic benefits for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29311919"
        },
        "cell_108": {
            "question": "Does BACE-1 inhibition prevent gamma-secretase inhibitor-evoked Abeta rise in human neuroblastoma SH-SY5Y cells, a model relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22018341"
        },
        "cell_109": {
            "question": "Does Ganoderic Acid D protect human amniotic mesenchymal stem cells against oxidative stress-induced senescence, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32774686"
        },
        "cell_110": {
            "question": "Does stearidonic acid (SDA) have a neuroprotective effect against Amyloid-beta-induced neurotoxicity relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36552565"
        },
        "cell_111": {
            "question": "Does GMFG regulate Abeta42 phagocytosis in macrophages, implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39243388"
        },
        "cell_112": {
            "question": "Does amyloid beta protein's inhibition of MTT reduction in astrocytes relate to its role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid9809588"
        },
        "cell_113": {
            "question": "Do astrocytes produce amyloid beta when stimulated with certain cytokine combinations relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid11114266"
        },
        "cell_114": {
            "question": "Does nimodipine inhibit microglial IL-1beta release in response to amyloid beta, implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22831460"
        },
        "cell_115": {
            "question": "Does astrocytic alpha7 nAChR activation inhibit beta-amyloid aggregation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30345917"
        },
        "cell_116": {
            "question": "Does S-equol's attenuation of astrocytic NO production have potential implications for mitigating neuroinflammation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29692883"
        },
        "cell_117": {
            "question": "Does peroxisome deficiency in neural cells contribute to Alzheimer's disease development by activating the innate immune system and causing CNS axonal loss?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22458306"
        },
        "cell_118": {
            "question": "Does biatractylolide protect against glutamate-induced cell damage relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29075302"
        },
        "cell_119": {
            "question": "Does erythrosine B (ER) reduce Abeta-associated impaired neuronal cell function in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21998691"
        },
        "cell_120": {
            "question": "Can Liensinine, Isoliensinine, and Neferine reduce apoptosis in PC12 cells injured by amyloid-beta, potentially offering therapeutic potential for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35762411"
        },
        "cell_121": {
            "question": "Does 25-hydroxyvitamin D3 inhibit nitric oxide production in activated microglia, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25352759"
        },
        "cell_122": {
            "question": "Does NPS 2143 suppress excess endogenous Abeta42 secretion in human cortical astrocytes and neurons relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23628734"
        },
        "cell_123": {
            "question": "Do Dendrobium polysaccharides improve cognitive impairment in Alzheimer's disease by modulating microglial activation?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30253123"
        },
        "cell_124": {
            "question": "Do murine Abeta oligomers disrupt endothelial barrier integrity through astrocyte-derived factors relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35163801"
        },
        "cell_125": {
            "question": "Does inhibiting endothelial cell YAP improve BBB integrity and reduce brain damage in ischemia-reperfusion injury, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34899341"
        },
        "cell_126": {
            "question": "Is microglia-induced neuroinflammation predominant in the white matter of aging mice and humans, as well as in early-onset Alzheimer's disease (EOAD) brains?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28713239"
        },
        "cell_127": {
            "question": "Does SRCL presence in astrocytes and microglia suggest a role in amyloid-beta clearance in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid16868960"
        },
        "cell_128": {
            "question": "Does S-Adenosylhomocysteine (SAH) increase microglial cell DNA damage, potentially contributing to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22064374"
        },
        "cell_129": {
            "question": "Does microglial DNase II deficiency contribute to Alzheimer's disease pathology?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39833906"
        },
        "cell_130": {
            "question": "Does leptin decrease neprilysin expression in primary cultured astrocytes, potentially contributing to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24508800"
        },
        "cell_131": {
            "question": "Does chlorogenic acid enhance autophagy to protect SH-SY5Y cells against H2O2-induced injury, relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33747165"
        },
        "cell_132": {
            "question": "Does curcumin's Nrf2 activation via PKCdelta-mediated p62 phosphorylation at S351 have a protective role in neurons relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33875681"
        },
        "cell_133": {
            "question": "Does PAR2 activation in glial cells contribute to neuroinflammation and neuronal death in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid17911636"
        },
        "cell_134": {
            "question": "Is PKC alpha immunoreactivity enhanced in reactive astrocytes associated with senile plaques in Alzheimer's disease brains?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid1990207"
        },
        "cell_135": {
            "question": "Do women with Alzheimer's disease exhibit weaker cytokine production in response to viral infection compared to men with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35708851"
        },
        "cell_136": {
            "question": "Does microglial heme oxygenase-1 (HO-1) deletion reduce tauopathy-induced neuroinflammation in the retina of old mice, an Alzheimer's-relevant model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36358522"
        },
        "cell_137": {
            "question": "Is defective TNFalpha-dependent control of astrocyte glutamate release associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid16253995"
        },
        "cell_138": {
            "question": "Does Abeta binding to phosphatidylserine on neuronal cells contribute to neurotoxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19324459"
        },
        "cell_139": {
            "question": "Can ultrasound-mediated exosome release from astrocytes alleviate amyloid-beta-induced neurotoxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33754065"
        },
        "cell_140": {
            "question": "How does PTPA knockdown affect cell viability and apoptosis relevant to Alzheimer's disease?",
            "options": "A. It increases cell viability by activating PP2A.; B. It induces apoptosis through the mitochondrial pathway.; C. It prevents apoptosis by hyperphosphorylating tau.; D. It enhances cell survival by upregulating Bcl-xl and Bcl-2.",
            "correct_option": "B",
            "pmid": "pmid24821282"
        },
        "cell_141": {
            "question": "How does SRPK2 expression affect microglia activation in Alzheimer's disease?",
            "options": "A. SRPK2 decreases proinflammatory cytokine production.; B. SRPK2 increases the expression of anti-inflammatory cytokines.; C. SRPK2 promotes the proinflammatory activation of microglia.; D. SRPK2 reduces microglia proliferation.",
            "correct_option": "C",
            "pmid": "pmid35153686"
        },
        "cell_142": {
            "question": "Which compound inhibits Abeta aggregation and promotes neurite outgrowth in Alzheimer's disease cell models?",
            "options": "A. VB-030; B. VB-037; C. LPS; D. IFN-gamma",
            "correct_option": "B",
            "pmid": "pmid30707915"
        },
        "cell_143": {
            "question": "Which of the following best describes the cellular effect of Pon1 deficiency in relation to Alzheimer's disease pathology?",
            "options": "A. It enhances the production of pro-inflammatory cytokines through upregulation of ERK signaling in microglia.; B. It suppresses Trem2 expression, leading to impaired clearance of amyloid beta by microglia.; C. It directly increases neuronal apoptosis through increased oxidative stress in hippocampal neurons.; D. It promotes Trem2-mediated microglial phagocytosis and reduces pro-inflammatory cytokine release.",
            "correct_option": "D",
            "pmid": "pmid35589918"
        },
        "cell_144": {
            "question": "What effect does dipeptidyl vinyl sulfone (VS) have on Abeta-mediated microglial inflammation relevant to Alzheimer's disease?",
            "options": "A. It increases pro-inflammatory mediator production.; B. It reduces HMGB1 and NLRP3-inflammasome expression.; C. It enhances microglial phagocytosis of Abeta aggregates.; D. It promotes inflamma-miR activation in microglia.",
            "correct_option": "B",
            "pmid": "pmid27797173"
        },
        "cell_145": {
            "question": "What effect does water-soluble chitosan (WSC) have on pro-inflammatory cytokine production in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta, relevant to Alzheimer's disease?",
            "options": "A. WSC increases pro-inflammatory cytokine production.; B. WSC decreases pro-inflammatory cytokine production.; C. WSC has no effect on pro-inflammatory cytokine production.; D. WSC only affects interleukin-6 (IL-6) production.",
            "correct_option": "B",
            "pmid": "pmid11872267"
        },
        "cell_146": {
            "question": "Which olive biophenol extract showed the highest neuroprotection against H2O2-induced oxidative stress and Cu-induced toxicity in SH-SY5Y cells, suggesting potential Alzheimer's disease benefits?",
            "options": "A. Olive leaf extract (OLE); B. Olive fruit extract (OFE); C. Hydroxytyrosol Extreme (HTE); D. Olivenol plus (OLP)",
            "correct_option": "C",
            "pmid": "pmid29109370"
        },
        "cell_147": {
            "question": "Which of the following best explains how hypoxia contributes to microglial dysfunction in the context of Alzheimer’s disease pathology?",
            "options": "A. Hypoxia stimulates beta-amyloid clearance by promoting microglial proliferation through HIF1 activation.; B. Hypoxia overactivates HIF1, which suppresses mitochondrial respiration and proliferation in microglia, reducing their clustering around amyloid plaques.; C. Hypoxia induces reactive oxygen species production that enhances microglial phagocytic activity and reduces neuropathology.; D. Hypoxia downregulates HIF1 signaling, leading to increased microglial migration and enhanced plaque surveillance.",
            "correct_option": "B",
            "pmid": "pmid37117599"
        },
        "cell_148": {
            "question": "Epiisopiloturine (EPI), a Pilocarpus microphyllus alkaloid, reduces microglial inflammation. How might this compound potentially influence Alzheimer's disease progression?",
            "options": "A. By promoting neuroinflammation through TLR4 activation; B. By inhibiting the TLR4/NF-κB-MAPK signaling pathway in microglia; C. By increasing pro-inflammatory cytokines like IL-6 and TNF-α; D. By enhancing anti-inflammatory IL-10 production",
            "correct_option": "B",
            "pmid": "pmid37151606"
        },
        "cell_149": {
            "question": "How does PKC activation affect gliosis in NPC1 patient-derived iPSC glial cells, and what is its implication for Alzheimer's disease?",
            "options": "A. PKC activation worsens gliosis and increases cholesterol accumulation; worsening Alzheimers symptoms.; B. PKC activation reduces gliosis and restores cholesterol levels; suggesting a potential therapeutic avenue for Alzheimers.; C. PKC activation has no effect on gliosis but increases delirium symptoms in Alzheimers patients.; D. PKC activation triggers delirium by altering intermediate filaments; unrelated to Alzheimers progression.",
            "correct_option": "B",
            "pmid": "pmid28841900"
        },
        "cell_150": {
            "question": "Which of these is enriched in extracellular vesicles from NEP-enhanced hUC-MSCs and contributed to therapeutic effects in an Alzheimer's disease model?",
            "options": "A. BACE-1; B. GFAP; C. NEP; D. Iba-1",
            "correct_option": "C",
            "pmid": "pmid34899919"
        },
        "cell_151": {
            "question": "Which cytokine is inhibited by TREM2 in response to Abeta42 in HMC3 cells relevant to Alzheimer's disease?",
            "options": "A. IL-8; B. MIP-1a; C. FGF-2; D. IP-10",
            "correct_option": "C",
            "pmid": "pmid33461764"
        },
        "cell_152": {
            "question": "Which molecule protects human microglial cells (HMC3) against apoptosis and DNA damage induced by LPS and Abeta1-42 aggregates in vitro, offering potential Alzheimer's disease therapeutic benefits?",
            "options": "A. Dopamine; B. Serotonin; C. Noradrenaline; D. Acetylcholine",
            "correct_option": "C",
            "pmid": "pmid39518952"
        },
        "cell_153": {
            "question": "Which microglial type reduces Abeta plaque deposition in Alzheimer's disease during IL-1beta-dependent neuroinflammation?",
            "options": "A. iNOS+ microglia; B. Arg1+ microglia; C. Neutrophils; D. Eosinophils",
            "correct_option": "B",
            "pmid": "pmid26538310"
        },
        "cell_154": {
            "question": "How does soluble epoxide hydrolase (sEH) affect astrocytic immune responses in an Alzheimer's disease model?",
            "options": "A. sEH enhances pro-inflammatory marker expression in activated astrocytes.; B. sEH suppresses pro-inflammatory marker expression in activated astrocytes.; C. sEH has no significant effect on astrocytic immune responses.; D. sEH increases STAT3 phosphorylation in activated astrocytes.",
            "correct_option": "B",
            "pmid": "pmid31176371"
        },
        "cell_155": {
            "question": "What is a potential implication of A20 deficiency for neuroinflammatory diseases like Alzheimer's?",
            "options": "A. Reduced oxidative stress in brain endothelium; B. Increased susceptibility to axonal injury; C. Decreased cytokine production in astrocytes; D. Lower levels of pro-inflammatory molecules like TNF and IL-6",
            "correct_option": "B",
            "pmid": "pmid25026958"
        },
        "cell_156": {
            "question": "Beta-Amyrin reduces microglial inflammation. How might this mechanism be beneficial for Alzheimer's disease?",
            "options": "A. By increasing pro-inflammatory cytokine production; B. By promoting M1 pro-inflammatory microglial differentiation; C. By enhancing microglial activations neurotoxic effects; D. By modulating M1/M2 microglial phenotype balance to reduce neuroinflammation",
            "correct_option": "D",
            "pmid": "pmid29501766"
        },
        "cell_157": {
            "question": "Which of these is associated with increased Kir6.2 expression in reactive astrocytes in Alzheimer's disease?",
            "options": "A. Decreased GFAP-IR; B. Increased Kir6.1 in neurons; C. Increased Kir6.2 in astrocytes; D. Decreased Kir6.2 in neurons",
            "correct_option": "C",
            "pmid": "pmid27586053"
        },
        "cell_158": {
            "question": "Which compound inhibits pro-inflammatory mediator production in microglial cells stimulated with Abeta25-35 and IFN-gamma, suggesting a potential Alzheimer's disease therapeutic approach?",
            "options": "A. Amyloid beta peptide (Abeta); B. Tetramethylpyrazine (TMP); C. Interferon (IFN)-gamma; D. Tumor necrosis factor (TNF)-alpha",
            "correct_option": "B",
            "pmid": "pmid24975095"
        },
        "cell_159": {
            "question": "Which neurosteroid inhibits TLR4 activation in both male and female human macrophages, potentially contributing to anti-inflammatory effects relevant to Alzheimer's disease?",
            "options": "A. Allopregnanolone; B. 3alpha;5alpha-THDOC; C. SGE-516; D. Pregnanolone",
            "correct_option": "A",
            "pmid": "pmid35967446"
        },
        "cell_160": {
            "question": "How does astrocytic hepcidin overexpression affect Alzheimer's disease symptoms in APP/PS1 mice?",
            "options": "A. Worsens cognitive decline; B. Improves cognitive decline; C. No effect on cognitive decline; D. Increases amyloid-beta plaque formation",
            "correct_option": "B",
            "pmid": "pmid32707154"
        },
        "cell_161": {
            "question": "Which molecule, released by astrocytes upon tau oligomer exposure, contributes to cellular senescence and neuropathology in Alzheimer's disease and frontotemporal dementia?",
            "options": "A. HMGB1; B. TauO; C. EP; D. GA",
            "correct_option": "A",
            "pmid": "pmid34289368"
        },
        "cell_162": {
            "question": "How does glypican 4 (Gpc4) contribute to Alzheimer's disease pathophysiology in neural stem cells?",
            "options": "A. By reducing Abeta internalization via LRP1; B. By increasing Abeta internalization via LRP1; C. By decreasing mitochondrial membrane potential; D. By promoting cell apoptosis independently of Abeta",
            "correct_option": "B",
            "pmid": "pmid34552470"
        },
        "cell_163": {
            "question": "In Alzheimer's disease, which protein is associated with a stronger neuroinflammatory response compared to Abeta42?",
            "options": "A. Hyperphosphorylated tau protein; B. Synuclein; C. Amyloid-beta precursor protein; D. Glial fibrillary acidic protein",
            "correct_option": "A",
            "pmid": "pmid38105410"
        },
        "cell_164": {
            "question": "Which Algerian mint extract showed the highest cytoprotective effect on 7-ketocholesterol-treated RAW 264.7 macrophages, potentially relevant to Alzheimer's disease or delirium?",
            "options": "A. Mentha spicata L. (MS); B. Mentha pulegium L. (MP); C. Mentha rotundifolia (L.) Huds (MR); D. None of the above",
            "correct_option": "A",
            "pmid": "pmid30563252"
        },
        "cell_165": {
            "question": "Which microglial type significantly increased in mice receiving HUMSC-NC transplantation, contributing to amyloid-beta deposition reduction in an Alzheimer's disease model?",
            "options": "A. M1-like microglia; B. M2-like microglia; C. Synapsin I; D. Insulin-degrading enzyme",
            "correct_option": "B",
            "pmid": "pmid23826983"
        },
        "cell_166": {
            "question": "How does inhibiting microglial choline transport affect M1/M2 polarization, potentially influencing conditions like Alzheimer's disease?",
            "options": "A. It promotes M1 polarization; exacerbating inflammation.; B. It suppresses M1 polarization; reducing inflammatory cytokines.; C. It enhances M2 polarization; promoting anti-inflammatory responses.; D. It has no significant effect on M1/M2 polarization.",
            "correct_option": "C",
            "pmid": "pmid36012189"
        },
        "cell_167": {
            "question": "Which metal sulfate combination synergistically up-regulates miRNA-125b and miRNA-146a in human astroglial cells, potentially contributing to Alzheimer's disease pathogenesis?",
            "options": "A. Magnesium and iron; B. Iron and aluminum; C. Gallium and aluminum; D. Magnesium and aluminum",
            "correct_option": "B",
            "pmid": "pmid22099153"
        },
        "cell_168": {
            "question": "Which cell type produces significantly less apoE than pericytes and is less involved in Abeta clearance near vasculature in Alzheimer's disease?",
            "options": "A. Astrocytes; B. Neurons; C. Microglia; D. Endothelial cells",
            "correct_option": "A",
            "pmid": "pmid20034483"
        },
        "cell_169": {
            "question": "How does repeated glucose deprivation/reperfusion affect neuronal cells, potentially contributing to Alzheimer's disease?",
            "options": "A. It increases cell viability and survival signaling pathways.; B. It decreases cell viability and activates apoptosis pathways.; C. It enhances phosphorylated Akt and Bcl-2 expression.; D. It inhibits FOXO3 localization in the cell nucleus.",
            "correct_option": "B",
            "pmid": "pmid27766247"
        },
        "cell_170": {
            "question": "How does PIEZO1 channel activation affect microglial function relevant to Alzheimer's disease?",
            "options": "A. Decreases amyloid beta phagocytosis; B. Enhances lysosomal activity and phagocytosis; C. Reduces cellular metabolism; D. Inhibits calcium transients",
            "correct_option": "B",
            "pmid": "pmid35706029"
        },
        "cell_171": {
            "question": "Which intracellular protein binds amyloid-beta in Alzheimer's disease?",
            "options": "A. Tau; B. Presenilin 1; C. ERAB; D. Amyloid Precursor Protein (APP)",
            "correct_option": "C",
            "pmid": "pmid9338779"
        },
        "cell_172": {
            "question": "In which Alzheimer's disease stages do initial cytoskeletal changes occur in the basal nucleus of Meynert?",
            "options": "A. Stages III and IV; B. Stages V and VI; C. Stages I and II; D. Stages VII and VIII",
            "correct_option": "C",
            "pmid": "pmid10965795"
        },
        "cell_173": {
            "question": "How do microglia-derived microvesicles contribute to Alzheimer's disease degeneration?",
            "options": "A. They promote the clearance of amyloid plaques, preventing neurotoxicity.; B. They inhibit the aggregation of tau protein, reducing tangle formation.; C. They promote formation of soluble Aβ species from insoluble aggregates and traffic neurotoxic Aβ forms after internalization.; D. They enhance neuronal survival by releasing neurotrophic factors.",
            "correct_option": "C",
            "pmid": "pmid24336048"
        },
        "cell_174": {
            "question": "What correlates with reduced dendritic arborization in the subiculum of Alzheimer's disease?",
            "options": "A. Increased levels of amyloid plaques; B. Decreased levels of acetylcholine; C. Neurofibrillary tangle (NFT) densities; D. Increased levels of synaptic proteins",
            "correct_option": "C",
            "pmid": "pmid14507668"
        },
        "cell_175": {
            "question": "What cells do Alzheimer's disease CSF antibodies selectively recognize?",
            "options": "A. Neurons and astrocytes; B. Oligodendrocytes and ependymal cells; C. Amoeboid microglial cells and activated microglia/neural macrophages; D. T cells and B cells",
            "correct_option": "C",
            "pmid": "pmid8871946"
        },
        "cell_176": {
            "question": "What characteristics define Alzheimer's disease plaques formed by human macrophages?",
            "options": "A. They are primarily composed of tau protein tangles and lack a distinct structure.; B. They consist of aggregated Abeta-peptide, reveal a typical ''Maltese cross'' structure, and are associated with glycosaminoglycanes, apolipoprotein E, cholesterol, and sphingomyelins.; C. They are characterized by an absence of Abeta-peptide and are solely composed of inflammatory cytokines.; D. They are made up of misfolded prions and do not interact with apolipoprotein E.",
            "correct_option": "B",
            "pmid": "pmid16765377"
        },
        "cell_177": {
            "question": "What is a key observed link between pro-inflammatory cellular responses and altered brain electrophysiology in the context of inflammation-associated delirium, and what type of signaling is implicated?",
            "options": "A. Pro-inflammatory cells trigger a widespread decrease in cortical slow wave activity (SWA) and enhanced brain connectivity, mediated by direct cholinergic disruption. B. Systemic inflammation leads to reduced cortical cytokine production and associated slow wave activity, suggesting a neuroprotective mechanism via GABAergic pathways. C. Elevated cortical pro-inflammatory cytokines correlate with increased slow wave activity (SWA), a phenomenon potentially linked to delirium and influenced by prostaglandin-adenosine signaling. D. The main electrophysiological sign of inflammation-induced delirium is reduced pro-inflammatory cytokine release and decreased slow wave activity, exacerbated by adenosine receptor antagonists.",
            "correct_option": "C",
            "pmid": "pmid33648701"
        },
        "cell_178": {
            "question": "What pathological features of alpha-synuclein are associated with postoperative delirium in patients undergoing gastrectomy?",
            "options": "A. Lewy body formation in the dorsal motor nucleus of the vagus nerve.; B. Increased levels of soluble alpha-synuclein in cerebrospinal fluid.; C. Both normal and phosphorylated alpha-synuclein pathologies were found in the myenteric plexus of the stomach.; D. Decreased alpha-synuclein mRNA expression in the substantia nigra.",
            "correct_option": "C",
            "pmid": "pmid23365056"
        },
        "cell_179": {
            "question": "What is the role of glia in the pathophysiology of delirium?",
            "options": "A. Glia primarily protect neurons from damage, thus playing a protective role against delirium.; B. Glial cells contribute to delirium through impaired energy metabolism, glymphatic dysfunction, neuroinflammation, blood-brain barrier disruption, and immune reactivity to glial proteins.; C. Glia are only involved in the later stages of delirium, after significant neuronal damage has occurred.; D. Glial cells play a minimal role in delirium, with the primary pathology stemming from neuronal dysfunction.",
            "correct_option": "B",
            "pmid": "pmid39463449"
        },
        "cell_180": {
            "question": "What cellular mechanisms underlie the effect of electroacupuncture in reducing delirium-like behavior associated with surgical pain?",
            "options": "A. Electroacupuncture reduces delirium by increasing pro-inflammatory cytokine production and promoting neuronal apoptosis.; B. Electroacupuncture alleviates delirium-like behavior by restoring gut microbiota balance, preventing microglia activation, and reversing dendritic spine elimination.; C. Electroacupuncture exacerbates delirium by disrupting the blood-brain barrier and increasing neuroinflammation.; D. Electroacupuncture has no significant effect on delirium-like behavior associated with surgical pain.",
            "correct_option": "B",
            "pmid": "pmid36003380"
        },
        "cell_181": {
            "question": "What cellular mechanisms contribute to delirium as a complication of chimeric antigen receptor T-cell therapy?",
            "options": "A. Direct CAR-T cell infiltration and destruction of neurons within the cerebral cortex.; B. Inhibition of microglial activation leading to impaired synaptic pruning and neuronal dysfunction.; C. Immune effector cell-associated neurotoxicity syndrome (ICANS) causing cytokine release, BBB dysfunction, and neuroinflammation.; D. Reduced cytokine production causing impaired neurotransmitter synthesis and neuronal signaling.",
            "correct_option": "C",
            "pmid": "pmid28049548"
        },
        "cell_182": {
            "question": "What cellular changes in reactive astrocytes are associated with delirium caused by systemic inflammation or acute liver failure?",
            "options": "A. Decreased expression of glial fibrillary acidic protein (GFAP) and vimentin.; B. Increased accumulation and redistribution of multivesicular bodies (MVBs), particularly to perivascular endfeet.; C. Reduced glutamate uptake and decreased expression of glutamate transporters.; D. Fragmentation of the Golgi apparatus and impaired protein synthesis.",
            "correct_option": "B",
            "pmid": "pmid33172595"
        },
        "cell_183": {
            "question": "What immune-related mechanisms are implicated in delirium associated with cytomegalovirus colitis in elderly patients?",
            "options": "A. Decreased pro-inflammatory cytokines and enhanced cholinergic regulation of microglia.; B. Age-related immune enhancement and reduced neuroinflammation.; C. Increased anti-inflammatory cytokines and preserved cholinergic function.; D. Age-related immune dysfunction, increased pro-inflammatory cytokines (such as IL-6, IL-8), and impaired cholinergic regulation of microglia, contributing to systemic and neuroinflammation.",
            "correct_option": "D",
            "pmid": "pmid17467406"
        },
        "cell_184": {
            "question": "What immune-related factors are associated with delirium in Morvan's syndrome?",
            "options": "A. IgE antibodies targeting mast cell receptors; B. Autoantibodies against aquaporin-4 (AQP4); C. Autoantibodies against voltage-gated potassium channel (VGKC)-complex proteins, particularly anti-CASPR2 antibodies; D. Complement C3 deficiency",
            "correct_option": "C",
            "pmid": "pmid30090985"
        },
        "cell_185": {
            "question": "What effects do antipsychotic medications have on astrocytes in the context of delirium?",
            "options": "A. They invariably lead to gliotoxicity, exacerbating delirium symptoms.; B. They have no discernible impact on astrocyte function or delirium pathology.; C. They exclusively offer glioprotection, mitigating the effects of delirium.; D. They can modulate neuroinflammation, oxidative stress, and gliotransmission, potentially leading to either gliotoxicity or glioprotection, thereby impacting delirium pathophysiology.",
            "correct_option": "D",
            "pmid": "pmid26029046"
        },
        "cell_186": {
            "question": "What cellular mechanisms underlie delirium-like behaviors induced by sedation in an inflamed developing brain?",
            "options": "A. Neuronal apoptosis and subsequent cytokine release, leading to widespread neurodegeneration.; B. Direct suppression of neuronal activity by sedatives, independent of inflammation.; C. Microglial (Iba1) and astrocyte (GFAP) activation under inflammation and sedation, indicating glia-mediated neuroinflammatory responses despite unchanged cytokine levels.; D. Disruption of blood-brain barrier integrity, allowing peripheral immune cells to infiltrate the brain.",
            "correct_option": "C",
            "pmid": "pmid37302746"
        },
        "cell_187": {
            "question": "What cellular mechanisms underlie delirium induced by lithium therapy?",
            "options": "A. Primarily increased dopamine production in the prefrontal cortex.; B. Direct neurotoxicity caused by lithium accumulation in neurons.; C. Disruption of signal transduction pathways, particularly through inhibition of GSK-3β and inositol signaling.; D. Selective degradation of myelin sheaths in white matter tracts.",
            "correct_option": "C",
            "pmid": "pmid10664610"
        },
        "cell_188": {
            "question": "What role does complement-dependent synaptic pruning by microglia play in delirium associated with sepsis-associated encephalopathy?",
            "options": "A. It primarily promotes neuronal survival by removing damaged cells.; B. It plays a critical role by leading to synaptic loss, neuronal damage, and cognitive dysfunction.; C. It reduces inflammation and protects synapses from damage.; D. It enhances synaptic plasticity and improves cognitive function.",
            "correct_option": "B",
            "pmid": "pmid37235660"
        },
        "cell_189": {
            "question": "What cellular mechanisms are associated with delirium in Wernicke-Korsakoff syndrome?",
            "options": "A. Increased alpha-ketoglutarate dehydrogenase activity in neurons, leading to enhanced energy production.; B. Decreased microglial activation, resulting in reduced neuroinflammation.; C. Reduced cerebrospinal fluid (CSF) lactate and norepinephrine metabolite (MHPG) levels, indicating improved cellular function.; D. Reduced alpha-ketoglutarate dehydrogenase activity in astrocytes, leading to impaired energy metabolism and increased microglial activation.",
            "correct_option": "D",
            "pmid": "pmid23790077"
        },
        "cell_190": {
            "question": "How does systemic bacterial infection induce microglial activation leading to delirium?",
            "options": "A. By directly invading the brain parenchyma and causing neuronal cell death, which then triggers microglial response.; B. By releasing bacterial toxins that directly stimulate neuronal pathways responsible for cognition, indirectly activating microglia.; C. Through immune signaling that activates microglia, resulting in neuroinflammation, which contributes to delirium.; D. By suppressing the peripheral immune response, creating an imbalance that causes microglia to become overactive.",
            "correct_option": "C",
            "pmid": "pmid29755322"
        },
        "cell_191": {
            "question": "How does MANF inhibit inflammation and microglia activation in post-operative delirium?",
            "options": "A. MANF promotes the release of pro-inflammatory cytokines, exacerbating the inflammatory response.; B. MANF stimulates microglial M1 polarization, increasing neuroinflammation.; C. MANF suppresses inflammation and microglial M1 polarization, reducing neuroinflammatory responses.; D. MANF has no effect on inflammation or microglia activation in post-operative delirium.",
            "correct_option": "C",
            "pmid": "pmid34234505"
        },
        "cell_192": {
            "question": "Does astrocyte reactivity influence the association between amyloid-beta and tau phosphorylation in preclinical Alzheimer's disease?",
            "options": "A. No, astrocyte reactivity has no impact on this association.; B. Yes, astrocyte reactivity influences this association.; C. Only microglia reactivity influences this association, not astrocytes.; D. The association between amyloid-beta and tau phosphorylation is independent of any glial cell activity.",
            "correct_option": "B",
            "pmid": "pmid37248300"
        },
        "cell_193": {
            "question": "What is the role of syntaxin-4 in the trafficking of ionotropic glutamate receptors in Alzheimer's Disease?",
            "options": "A. It inhibits the trafficking of all glutamate receptors, leading to excitotoxicity and neuronal death.; B. It plays no significant role in glutamate receptor trafficking or Alzheimer's Disease.; C. It is essential for the trafficking of ionotropic glutamate receptors, supporting basal neurotransmission and synaptic plasticity, and its dysfunction may contribute to synaptic failure.; D. It solely traffics NMDA receptors to extrasynaptic locations, exacerbating excitotoxicity.",
            "correct_option": "C",
            "pmid": "pmid30481567"
        },
        "cell_194": {
            "question": "What are intranuclear inclusion bodies in the context of Alzheimer's disease?",
            "options": "A. Spherical lipid deposits found exclusively in oligodendrocytes, contributing to myelin breakdown.; B. Amyloid plaques that have migrated into the nucleus of neurons, exacerbating DNA damage.; C. Filamentous protein aggregates found in neurons and glia, potentially representing a rare neuropathological substrate of dementia, with their reduction suggesting altered nuclear structure or stress-related mechanisms.; D. Collections of tau protein tangles that have been encapsulated within the nucleus, triggering apoptosis.",
            "correct_option": "C",
            "pmid": "pmid7606903"
        },
        "cell_195": {
            "question": "What role does cathepsin B play in microglial Abeta clearance in Alzheimer's disease?",
            "options": "A. Cathepsin B inhibits microglial migration and reduces Abeta phagocytosis by suppressing PI3K-Akt signaling.; B. Cathepsin B promotes microglial migration and phagocytosis of amyloid beta through PI3K-Akt signaling, enhancing Abeta clearance.; C. Cathepsin B increases Abeta production by neurons, leading to worsening Alzheimer's disease pathology.; D. Cathepsin B triggers apoptosis in microglia, impairing their ability to clear Abeta.",
            "correct_option": "B",
            "pmid": "pmid39304744"
        },
        "cell_196": {
            "question": "How does the repeat domain of tau interact with lipid surfaces in the context of Alzheimer's disease?",
            "options": "A. It forms disordered aggregates that disrupt lipid bilayer integrity.; B. It binds weakly and transiently, preventing tau aggregation.; C. It binds to lipid micelles and vesicles and folds into an ordered structure, facilitating tau’s structural transitions and aggregation.; D. It is repelled by lipid surfaces, leading to increased cytosolic tau concentration.",
            "correct_option": "C",
            "pmid": "pmid16908029"
        },
        "cell_197": {
            "question": "Does the aqueous extract from Toona sinensis leaves inhibit microglia-mediated neuroinflammation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24444536"
        },
        "cell_198": {
            "question": "Are amplicon vectors suitable for transducing antigen-presenting cells in the context of Alzheimer's disease vaccines?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid16787189"
        },
        "cell_199": {
            "question": "In the study of Alzheimer's disease pathology, what is a key characteristic of the interaction between cholesterol and amyloid beta (Aβ) that has been noted at the subcellular level?",
            "options": "A. Cholesterol primarily acts to accelerate the clearance of Aβ from the brain.; B. Amyloid beta formation is exclusively dependent on elevated systemic cholesterol levels, with no feedback from Aβ to cholesterol pathways.; C. A pattern of reciprocal regulation between cholesterol and Aβ has been identified, influencing their respective pathways.; D. The interaction is largely one-directional, with cholesterol metabolism being significantly altered by Aβ, but Aβ production remaining unaffected by cholesterol.",
            "correct_option": "C",
            "pmid": "pmid22626060"
        },
        "cell_200": {
            "question": "What is the role of cinnamate derivatives in targeting Alzheimer's disease?",
            "options": "A. They primarily act as acetylcholinesterase inhibitors, enhancing cholinergic neurotransmission.; B. They promote Abeta aggregation and increase oxidative stress, exacerbating AD pathology.; C. They exhibit neuroprotective and anti-amyloid effects by inhibiting Abeta aggregation, reducing oxidative stress and inflammation, and targeting multiple AD-related pathways including BuChE, GSK-3β, and PPARα.; D. They solely target PPARα receptors to modulate lipid metabolism and indirectly impact AD.",
            "correct_option": "C",
            "pmid": "pmid38203753"
        },
        "cell_201": {
            "question": "Does the infrared spectroscopic analysis of mononuclear leukocytes show differences in protein secondary structure between Alzheimer's disease patients and controls?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22271100"
        },
        "cell_202": {
            "question": "What is the role of tubulin acetylation in Alzheimer's disease?",
            "options": "A. Tubulin acetylation is decreased, promoting microtubule stability and reducing Tau aggregation.; B. Tubulin acetylation is unchanged and has no impact on the progression of Alzheimer's disease.; C. Tubulin acetylation is decreased, exacerbating microtubule instability and impairing axonal transport.; D. Tubulin acetylation is increased and may reflect a compensatory mechanism for impaired microtubule dynamics and Tau dysfunction, but also contributes to disrupted intracellular transport and autophagy.",
            "correct_option": "D",
            "pmid": "pmid36092705"
        },
        "cell_203": {
            "question": "Which subcellular organelles are involved in NLRP3 localization and inflammasome assembly in the context of Alzheimer's disease?",
            "options": "A. Nucleus, ribosomes, peroxisomes; B. Mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus, endosomes, and the centrosome; C. Cytoskeleton, plasma membrane, extracellular matrix; D. Nucleolus, vacuoles, transport vesicles",
            "correct_option": "B",
            "pmid": "pmid39816134"
        },
        "cell_204": {
            "question": "What is the role of PrPC in Alzheimer's disease?",
            "options": "A. It primarily functions to clear amyloid-beta plaques from the brain.; B. It solely promotes the formation of protective exosomes.; C. It has a dual role: promoting neurotoxicity as an amyloid-beta receptor and facilitating amyloid-beta detoxification on exosomes.; D. It acts as an enzyme to directly degrade tau proteins.",
            "correct_option": "C",
            "pmid": "pmid28413194"
        },
        "cell_205": {
            "question": "How does acute diesel exhaust particle exposure affect P-glycoprotein in the blood-brain barrier related to Alzheimer's disease?",
            "options": "A. Acute DEP exposure increases P-gp expression and function, enhancing BBB integrity and decreasing permeability.; B. Acute DEP exposure has no significant effect on P-gp expression or function in the BBB.; C. Acute DEP exposure decreases P-gp expression and function, impairing BBB integrity and increasing permeability.; D. Acute DEP exposure initially increases, then subsequently decreases, P-gp expression without affecting BBB permeability.",
            "correct_option": "C",
            "pmid": "pmid37332622"
        },
        "cell_206": {
            "question": "Does the model simulate microtubule changes in Alzheimer disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20713128"
        },
        "cell_207": {
            "question": "What is the role of NRBP1 in the degradation of BRI2 and BRI3 in Alzheimer's disease?",
            "options": "A. NRBP1 directly cleaves BRI2 and BRI3, breaking them down into smaller, inactive peptides.; B. NRBP1 inhibits the production of BRI2 and BRI3, preventing their synthesis.; C. NRBP1 acts as a chaperone, protecting BRI2 and BRI3 from degradation.; D. NRBP1 acts as a substrate receptor of a Cullin-RING ubiquitin ligase complex (CRL2/CRL4A) that targets BRI2 and BRI3 for degradation, thereby promoting amyloid-beta production.",
            "correct_option": "D",
            "pmid": "pmid32160551"
        },
        "cell_208": {
            "question": "What is the antigenic composition of aluminum-induced neurofibrillary degeneration compared to Alzheimer's disease?",
            "options": "A. Both show strong immunoreactivity for tau and MAP2.; B. Aluminum-induced neurofibrillary degeneration shows strong immunoreactivity for tau and MAP2, similar to Alzheimer's disease.; C. Aluminum-induced neurofibrillary degeneration lacks phosphorylated neurofilament proteins, unlike Alzheimer's disease.; D. Aluminum-induced neurofibrillary degeneration shows strong immunoreactivity for phosphorylated neurofilament proteins but lacks tau and MAP2 staining, which are typical in Alzheimer's disease.",
            "correct_option": "D",
            "pmid": "pmid2725861"
        },
        "cell_209": {
            "question": "How does Fli-1 contribute to pericyte loss in Alzheimer's disease?",
            "options": "A. Fli-1 down-regulation leads to pericyte apoptosis and subsequent clearance by microglia.; B. Fli-1 directly inhibits pericyte proliferation through disruption of PDGF signaling.; C. Fli-1 up-regulation promotes inflammation and Abeta accumulation, contributing to decreased pericyte number.; D. Fli-1 mutations cause structural defects in pericyte anchoring junctions, resulting in detachment.",
            "correct_option": "C",
            "pmid": "pmid35038582"
        },
        "cell_210": {
            "question": "What role does miR-155 play in Alzheimer's disease?",
            "options": "A. It is downregulated in early Alzheimer's disease and reduces neuroinflammation.; B. It is exclusively beneficial, promoting amyloid-beta clearance without any negative side effects.; C. It is upregulated early in Alzheimer's disease and promotes neuroinflammation by activating microglia and astrocytes.; D. It solely regulates T-cell function and has no impact on amyloid-beta clearance.",
            "correct_option": "C",
            "pmid": "pmid25983691"
        },
        "cell_211": {
            "question": "What is the role of human umbilical cord blood derived lineage negative stem cells in treating Alzheimer's disease?",
            "options": "A. They differentiate into neurons and replace damaged brain cells, directly reversing amyloid-beta accumulation.; B. They directly clear amyloid plaques, thus reducing the amyloid burden in the brain.; C. They improve cognitive deficits by releasing neuroprotective factors and inhibiting apoptosis, without directly clearing amyloid plaques or differentiating into neurons.; D. They primarily function by stimulating the immune system to attack and remove amyloid plaques.",
            "correct_option": "C",
            "pmid": "pmid30443207"
        },
        "cell_212": {
            "question": "What is the role of PIP2 phospholipids in the aggregation of tau filaments in Alzheimer's disease?",
            "options": "A. PIP2 phospholipids inhibit the aggregation of tau filaments, protecting neural membranes.; B. PIP2 phospholipids are not involved in the aggregation of tau filaments.; C. PIP2 phospholipids induce aggregation of tau filaments, which are implicated in deleterious mechanisms on neural membranes.; D. PIP2 phospholipids regulate the breakdown of tau filaments, preventing their accumulation.",
            "correct_option": "C",
            "pmid": "pmid30278104"
        },
        "cell_213": {
            "question": "What membrane proteins are found to be significantly higher in red blood cells of Alzheimer's disease patients compared to healthy subjects?",
            "options": "A. Aquaporin channels and sodium-potassium pumps.; B. Acetylcholine receptors and GABA transporters.; C. The GLUT1 transporter and the insulin receptor (INSR).; D. Voltage-gated calcium channels and NMDA receptors.",
            "correct_option": "C",
            "pmid": "pmid27239515"
        },
        "cell_214": {
            "question": "What mechanism does EphB2 use to prevent amyloid-beta-induced depletion of glutamate receptors in Alzheimer's disease?",
            "options": "A. EphB2 directly binds to amyloid-beta, neutralizing its toxic effects.; B.EphB2 prevents amyloid-beta-induced depletion of glutamate receptors by stabilizing AMPA-type receptors such as GluA2 through its PDZ-binding motif, which helps retain NMDA receptors at the neuronal surface.; C. EphB2 increases the rate of glutamate synthesis, compensating for receptor loss.; D. EphB2 activates microglia to phagocytose and remove amyloid-beta plaques.",
            "correct_option": "B",
            "pmid": "pmid26589795"
        }
    },
    "pathway": {
        "pathway_0": {
            "question": "What is the role of the DJ2/Hsp70 pathway in Alzheimer's disease?",
            "options": "A. It enhances the aggregation and phosphorylation of tau.; B. It decreases the aggregation and phosphorylation of tau.; C. It increases the activity of tau-kinases like GSK3alpha/beta.; D. It promotes the degradation of microtubule-associated proteins.",
            "correct_option": "B",
            "pmid": "pmid33972400"
        },
        "pathway_1": {
            "question": "How does the PPARalpha pathway contribute to the pathogenesis of Alzheimer's Disease?",
            "options": "A. It increases the production of amyloid-beta peptides.; B. It regulates synaptic plasticity and cognitive function.; C. It decreases the clearance of amyloid-beta peptides.; D. It promotes oxidative stress in neural tissues.",
            "correct_option": "B",
            "pmid": "pmid32422896"
        },
        "pathway_2": {
            "question": "What is the role of the ezrin/radixin/moesin family/phosphatidylinositol-3-kinase/protein kinase B pathway in Alzheimer's disease?",
            "options": "A. It promotes amyloid beta protein-induced apoptosis in PAJU cells.; B. It inhibits telencephalin expression in neural tumor cells.; C. It protects PAJU cells from amyloid beta protein-induced apoptosis.; D. It enhances oxidative stress in neuronal cells.",
            "correct_option": "C",
            "pmid": "pmid25538739"
        },
        "pathway_3": {
            "question": "How does the somatostatin pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting the accumulation of tau protein; B. By reducing the expression of somatostatin in the hippocampus; C. By increasing the production of amyloid-beta peptide; D. By enhancing the immune response in the brain",
            "correct_option": "B",
            "pmid": "pmid34445147"
        },
        "pathway_4": {
            "question": "What is the role of the IL-33/ST2 signaling pathway in Alzheimer's disease?",
            "options": "A. It promotes the recruitment and Abeta phagocytic activity of microglia.; B. It increases the expression of proinflammatory genes.; C. It enhances amyloid plaque deposition.; D. It decreases synaptic plasticity and memory function.",
            "correct_option": "A",
            "pmid": "pmid27091974"
        },
        "pathway_5": {
            "question": "How does the beta-secretase pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By cleaving APP to generate A beta peptides; which form plaques; B. By promoting the clearance of A beta peptides; C. By enhancing the synthesis of APP; D. By inhibiting the production of soluble APP fragments",
            "correct_option": "A",
            "pmid": "pmid11083922"
        },
        "pathway_6": {
            "question": "What is the role of the ZBTB16-mediated autophagy pathway in Alzheimer's disease?",
            "options": "A. It promotes the accumulation of Abeta oligomers and plaques.; B. It reduces Abeta oligomer and plaque load by activating autophagy.; C. It increases neurogliosis and inflammation.; D. It inhibits the mTOR-dependent pathway.",
            "correct_option": "B",
            "pmid": "pmid32296772"
        },
        "pathway_7": {
            "question": "How does the adenylyl cyclase pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Increased adenylyl cyclase activity is associated with reduced G-protein alpha-subunit levels.; B. Adenylyl cyclase I levels increase in the hippocampus with neurofibrillary staging.; C. Adenylyl cyclase II isoforms are the primary contributors to G-protein signaling in AD.; D. The pathway is inhibited by increased levels of G-protein alpha-subunits.",
            "correct_option": "B",
            "pmid": "pmid12960778"
        },
        "pathway_8": {
            "question": "How does the SP1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By reducing APP cleavage; B. By increasing Abeta production; C. By enhancing autophagy; D. By decreasing oxidative stress",
            "correct_option": "B",
            "pmid": "pmid18334759"
        },
        "pathway_9": {
            "question": "What is the role of the GDE2-RECK-ADAM10 pathway in Alzheimer's disease?",
            "options": "A. It promotes APP cleavage to generate neuroprotective sAPPalpha.; B. It increases Abeta production; contributing to AD pathogenesis.; C. It enhances oxidative stress pathways in neurons.; D. It stimulates autophagy to reduce protein aggregates.",
            "correct_option": "A",
            "pmid": "pmid33731436"
        },
        "pathway_10": {
            "question": "How does the mammalian target of rapamycin (mTOR) pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By activating autophagy; it reduces Abeta accumulation.; B. By inhibiting autophagy; it leads to Abeta accumulation.; C. By promoting lipid metabolism; it enhances brain function.; D. By increasing insulin sensitivity; it mitigates Alzheimers disease.",
            "correct_option": "B",
            "pmid": "pmid22829447"
        },
        "pathway_11": {
            "question": "What is the role of the enkephalin signaling pathway in Alzheimer's disease?",
            "options": "A. It compensates for cognitive impairments by enhancing memory function.; B. It contributes to neuronal and behavioral impairments by elevating enkephalin levels.; C. It reduces amyloid-beta peptide accumulation in the brain.; D. It activates autophagy pathways to clear neurotoxic aggregates.",
            "correct_option": "B",
            "pmid": "pmid18463254"
        },
        "pathway_12": {
            "question": "How does the orexin signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By activating BACE1 to increase amyloid-beta production; B. By shortening the period of the hippocampal clock and regulating clock-controlled genes; C. By promoting the degradation of amyloid-beta plaques; D. By enhancing synaptic plasticity in the hippocampus",
            "correct_option": "B",
            "pmid": "pmid27796320"
        },
        "pathway_13": {
            "question": "How does the ABCC1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. ABCC1 decreases glutathione release; worsening oxidative stress.; B. ABCC1 increases glutathione release; providing temporary protection from oxidative stress.; C. ABCC1 is unrelated to glutathione release in Alzheimers disease.; D. ABCC1 inhibits the release of glutamate; reducing neurotoxicity.",
            "correct_option": "B",
            "pmid": "pmid26200696"
        },
        "pathway_14": {
            "question": "How does the Grb2 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Grb2 shows subtle alterations in subcellular distribution; overlapping with cytoskeletal abnormalities.; B. Grb2 promotes neuronal differentiation.; C. Grb2 enhances synaptic plasticity.; D. Grb2 reduces inflammation in the brain.",
            "correct_option": "A",
            "pmid": "pmid9878757"
        },
        "pathway_15": {
            "question": "How does the ErbB2 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. ErbB2 promotes the degradation of APP-C99.; B. ErbB2 suppresses autophagic flux by dissociating Beclin-1 from the Vps34-Vps15 complex.; C. ErbB2 activates gamma-secretase to increase amyloid-beta production.; D. ErbB2 enhances the clearance of amyloid-beta plaques.",
            "correct_option": "B",
            "pmid": "pmid28351972"
        },
        "pathway_16": {
            "question": "How does the IL-7/IL-7R pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting neuroinflammation and hippocampal atrophy; B. By enhancing cognitive function and memory retention; C. By increasing anti-inflammatory cytokine production; D. By mitigating the effects of neurotoxic proteins",
            "correct_option": "A",
            "pmid": "pmid39129310"
        },
        "pathway_17": {
            "question": "How does the Reelin signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By increasing the production of amyloid-beta peptides; B. By reducing the number of Reelin-expressing pyramidal neurons in the entorhinal cortex; C. By enhancing the clearance of amyloid-beta plaques; D. By promoting the aggregation of tau proteins",
            "correct_option": "B",
            "pmid": "pmid17360894"
        },
        "pathway_18": {
            "question": "How does the ZBTB20/GSK-3beta/Tau pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Overexpression of ZBTB20 inhibits GSK-3beta expression and Tau phosphorylation.; B. Downregulation of ZBTB20 promotes GSK-3beta expression and Tau phosphorylation; contributing to disease progression.; C. Activation of the ZBTB20/GSK-3beta/Tau pathway enhances cell viability and reduces apoptosis.; D. The pathway modulates oxidative stress and lipid metabolism.",
            "correct_option": "B",
            "pmid": "pmid36502636"
        },
        "pathway_19": {
            "question": "Which downstream targets of the AdipoR1/AMPK/TFEB pathway are implicated in Alzheimer's disease development?",
            "options": "A. Lysosomal enzymes and autophagy-related proteins.; B. Beta-amyloid precursor protein and tau kinases.; C. Glucose transporters and insulin receptors.; D. Mitochondrial biogenesis factors.",
            "correct_option": "A",
            "pmid": "pmid36077318"
        },
        "pathway_20": {
            "question": "How does the VDAC1-AKT-GSK3beta signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting neuroinflammation and amyloid-beta overproduction; B. By reducing tau phosphorylation; C. By enhancing cognitive function; D. By decreasing amyloid-beta levels",
            "correct_option": "A",
            "pmid": "pmid33761858"
        },
        "pathway_21": {
            "question": "What is the impact of zinc on the Raf/MEK/ERK pathway in Alzheimer's disease?",
            "options": "A. Zinc inhibits the pathway; reducing tau phosphorylation; B. Zinc activates the pathway; leading to tau phosphorylation at serine 214; C. Zinc has no effect on the pathway; D. Zinc activates the pathway; leading to tau dephosphorylation",
            "correct_option": "B",
            "pmid": "pmid21934536"
        },
        "pathway_22": {
            "question": "How does the Th-9 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By producing IL-9; which is associated with increased neuroinflammation.; B. By decreasing the production of pro-inflammatory cytokines.; C. By enhancing the clearance of amyloid-beta through phagocytosis.; D. By promoting the differentiation of naive T cells into memory T cells.",
            "correct_option": "A",
            "pmid": "pmid21167930"
        },
        "pathway_23": {
            "question": "What is the role of the reelin pathway in Alzheimer's disease?",
            "options": "A. It promotes neurite outgrowth in hippocampal neurons.; B. It inhibits neurite outgrowth; which can be disrupted by the APP cytoplasmic domain.; C. It enhances synaptic plasticity by increasing APP cleavage.; D. It decreases the formation of amyloid-beta peptides.",
            "correct_option": "B",
            "pmid": "pmid17169463"
        },
        "pathway_24": {
            "question": "How does the NOD2/p-p38 MAPK/BACE1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By reducing oxidative stress in neurons.; B. By increasing the production of Abeta1-42 oligomers through activation of p-p38 MAPK and BACE1.; C. By promoting neurogenesis and synaptic repair.; D. By suppressing the immune response to amyloid-beta plaques.",
            "correct_option": "B",
            "pmid": "pmid33070520"
        },
        "pathway_25": {
            "question": "What is the role of the MAP2K3 pathway in Alzheimer's disease?",
            "options": "A. It is involved in beta-amyloid mediated apoptosis.; B. It enhances lipid metabolism in neurons.; C. It promotes oxidative stress in glial cells.; D. It regulates the blood-brain barrier integrity.",
            "correct_option": "A",
            "pmid": "pmid29896098"
        },
        "pathway_26": {
            "question": "How does the cGAS-STING pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It promotes the resolution of neuroinflammation and amyloid-beta clearance.; B. It induces chronic inflammation and contributes to neuronal dysfunction.; C. It downregulates oxidative stress and metal ion imbalance.; D. It enhances the phagocytic capacity of microglia to clear amyloid-beta.",
            "correct_option": "B",
            "pmid": "pmid39634577"
        },
        "pathway_27": {
            "question": "How does the AMPK signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting neurogenesis and synaptic plasticity.; B. By modulating inflammation and autophagy processes.; C. By enhancing glucose metabolism in neurons.; D. By activating antioxidant defense mechanisms.",
            "correct_option": "B",
            "pmid": "pmid34992508"
        },
        "pathway_28": {
            "question": "How does the farnesylation pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By downregulating amyloid-beta production.; B. By increasing the levels of farnesylated proteins like H-Ras; leading to hyperactivation of downstream effectors.; C. By promoting neuronal growth and synaptic plasticity.; D. By reducing oxidative stress in the brain.",
            "correct_option": "B",
            "pmid": "pmid34315531"
        },
        "pathway_29": {
            "question": "How does the RanBP9-cofilin pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting amyloid beta generation and disrupting focal adhesion; B. By enhancing mitochondrial calcium uniporter activity; C. By increasing synaptic mitochondrial activity; D. By reducing oxidative stress in neurons",
            "correct_option": "A",
            "pmid": "pmid23982146"
        },
        "pathway_30": {
            "question": "How does the homeostatic amyloid-reducing pathway contribute to the pathogenesis of Alzheimer's Disease?",
            "options": "A. By increasing the production of amyloid-beta.; B. By upregulating genes that reduce amyloid levels.; C. By promoting neurodegeneration.; D. By enhancing tau phosphorylation.",
            "correct_option": "B",
            "pmid": "pmid38167174"
        },
        "pathway_31": {
            "question": "What is the role of the Gcn2 pathway in modulating immune response in Alzheimer's disease?",
            "options": "A. It enhances neuroinflammation by activating microglia; B. It suppresses cytokine production in immune cells; C. It regulates amino acid starvation responses in immune cells; D. It promotes lipid metabolism in the brain",
            "correct_option": "C",
            "pmid": "pmid24256275"
        },
        "pathway_32": {
            "question": "What is the role of the visual pathway in [Alzheimer's disease]?",
            "options": "A. It is unaffected in the early stages of the disease.; B. It shows consistent involvement even in preclinical stages.; C. It is only involved in late-stage dementia.; D. It is used for postmortem diagnosis exclusively.",
            "correct_option": "B",
            "pmid": "pmid31809334"
        },
        "pathway_33": {
            "question": "How does the visual information transmission pathway (V-H pathway) contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It regulates the production of beta-amyloid plaques.; B. Dysregulation of hemoglobin expression in the V-H pathway leads to pathway dysfunction.; C. It enhances the clearance of tau proteins from the brain.; D. It increases the production of acetylcholine neurotransmitters.",
            "correct_option": "B",
            "pmid": "pmid38972885"
        },
        "pathway_34": {
            "question": "What is the role of the sphingosine kinase/sphingosine-1-phosphate (SphK/S1P) pathway in Alzheimer's disease?",
            "options": "A. It promotes amyloid-beta deposition and cognitive decline.; B. It enhances cognitive function and reduces amyloid-beta levels.; C. It increases neuroinflammation and synaptic damage.; D. It stimulates oxidative stress pathways leading to neuronal death.",
            "correct_option": "B",
            "pmid": "pmid33300254"
        },
        "pathway_35": {
            "question": "Which downstream targets of the circ-AXL pathway are implicated in Alzheimer's Disease development?",
            "options": "A. BACE1; B. Amyloid-beta; C. Neurite outgrowth; D. Apoptosis rate",
            "correct_option": "A",
            "pmid": "pmid35167942"
        },
        "pathway_36": {
            "question": "Is kynurenine pathway activation associated with poor prognosis in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24228074"
        },
        "pathway_37": {
            "question": "How does the Th17 cell differentiation pathway contribute to the pathogenesis of Late-Onset Alzheimer's Disease (LOAD)?",
            "options": "A. By increasing the production of anti-inflammatory cytokines.; B. By promoting the activation of microglia and neuroinflammation.; C. By reducing the infiltration of T cells into the brain.; D. By enhancing the blood-brain barrier integrity.",
            "correct_option": "B",
            "pmid": "pmid34864659"
        },
        "pathway_38": {
            "question": "What is the role of the hsa-miR-146a STAT1 MYC pathway in Alzheimer's disease?",
            "options": "A. It is a potential key pathway in AD progression; requiring further validation.; B. It contributes to oxidative stress in AD.; C. It regulates lipid metabolism in AD-affected tissues.; D. It mediates crosstalk with other signaling pathways in AD.",
            "correct_option": "A",
            "pmid": "pmid23990414"
        },
        "pathway_39": {
            "question": "What is the role of the Lfng/Notch1 signaling pathway in Alzheimer's disease?",
            "options": "A. It modulates immune response by increasing pro-inflammatory cytokines.; B. It regulates axon function and protein digestion and absorption.; C. It contributes to lipid metabolism and oxidative stress.; D. It mediates crosstalk with the Wnt/β-catenin signaling pathway.",
            "correct_option": "B",
            "pmid": "pmid36453506"
        },
        "pathway_40": {
            "question": "How does the IFNgamma pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By reducing neurofibrillary tangle formation.; B. By decreasing the expression of proinflammatory cytokines.; C. By infiltrating macrophages and natural killer cells that release IFNgamma; leading to glial activation.; D. By enhancing the clearance of amyloid-beta plaques.",
            "correct_option": "C",
            "pmid": "pmid23780663"
        },
        "pathway_41": {
            "question": "What is the role of the secretory pathway of APP in familial Alzheimer's disease with the Val717 to Ile mutation?",
            "options": "A. It leads to the generation of amyloidogenic full-length beta/A4 protein.; B. It does not alter the production of amyloidogenic full-length beta/A4 protein.; C. It increases the cleavage of APP into its amino-terminal fragments.; D. It decreases the secretion of beta/A4 protein into cerebrospinal fluid.",
            "correct_option": "B",
            "pmid": "pmid1436712"
        },
        "pathway_42": {
            "question": "How does the p21ras intracellular signal transduction pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By enhancing neuronal plasticity and repair mechanisms; B. By impairing differentiation control and promoting neuronal re-entry into the cell cycle; C. By increasing synaptic plasticity and memory formation; D. By reducing oxidative stress and inflammation",
            "correct_option": "B",
            "pmid": "pmid11193159"
        },
        "pathway_43": {
            "question": "Which downstream targets of the MIAT pathway are implicated in the development of Alzheimer's disease?",
            "options": "A. VEGF and miR-150-5p.; B. Insulin and glucose transporters.; C. Dopamine receptors and serotonin pathways.; D. Amyloid-beta and tau proteins.",
            "correct_option": "A",
            "pmid": "pmid27391072"
        },
        "pathway_44": {
            "question": "What is the role of the YAP/p73/Bax pathway in Alzheimer's disease?",
            "options": "A. It promotes apoptosis in response to Abeta(25-35).; B. It inhibits amyloid-beta peptide accumulation.; C. It prevents nuclear translocation of YAP.; D. It reduces Bax expression and activation.",
            "correct_option": "A",
            "pmid": "pmid21562856"
        },
        "pathway_45": {
            "question": "How does the RIPK1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting the degradation of amyloid beta (Abeta) in microglia; B. By reducing the levels of inflammatory cytokines in the brain; C. By mediating the induction of a disease-associated microglial (DAM) phenotype; D. By enhancing the phagocytic activity of microglia",
            "correct_option": "C",
            "pmid": "pmid28904096"
        },
        "pathway_46": {
            "question": "What is the role of signal transduction pathways in Alzheimer's disease?",
            "options": "A. They are unaffected by the disease progression.; B. They contribute to the pathogenesis through dysregulation of second messengers.; C. They enhance the clearance of amyloid plaques.; D. They prevent the formation of neurofibrillary tangles.",
            "correct_option": "B",
            "pmid": "pmid2391515"
        },
        "pathway_47": {
            "question": "How does the hexosamine biosynthesis pathway (HBP) contribute to the pathogenesis of Alzheimer disease?",
            "options": "A. It decreases UDP-N-acetylglucosamine (UDP-GlcNAc) levels; reducing O-GlcNAcylation.; B. It increases UDP-N-acetylglucosamine (UDP-GlcNAc) levels; enhancing O-GlcNAcylation.; C. It reduces mitochondrial reactive oxygen species (ROS) generation.; D. It promotes amyloid beta (Abeta) clearance from the brain.",
            "correct_option": "B",
            "pmid": "pmid25148700"
        },
        "pathway_48": {
            "question": "How does the BRCA1/BARD1 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It increases DNA double-strand breaks (DSBs) by enhancing amyloidogenic pathways.; B. It decreases DSB levels by activating a compensatory mechanism in the pathological situation.; C. It enhances the expression of Tip60 and Fe65; thereby promoting DSB repair.; D. It inhibits the amyloidogenic pathway by reducing Abeta 42 levels.",
            "correct_option": "B",
            "pmid": "pmid35237315"
        },
        "pathway_49": {
            "question": "How does the p53 pathway contribute to the pathogenesis of Alzheimer's disease in Down syndrome?",
            "options": "A. By reducing tau phosphorylation and preventing tangle formation.; B. By activating downstream targets like BAX and caspase-3; leading to apoptosis.; C. By increasing the expression of amyloid precursor protein.; D. By promoting the clearance of amyloid-beta plaques.",
            "correct_option": "B",
            "pmid": "pmid26967221"
        },
        "pathway_50": {
            "question": "How does the Akt pathway contribute to the pathogenesis of prostate cancer and Alzheimer's disease?",
            "options": "A. It contributes to the progression of both diseases by promoting cell survival and proliferation.; B. It only affects prostate cancer by mediating anti-androgen therapy resistance.; C. It solely contributes to Alzheimers disease by enhancing neurodegeneration.; D. It prevents the progression of both diseases by inducing apoptosis.",
            "correct_option": "A",
            "pmid": "pmid35985445"
        },
        "pathway_51": {
            "question": "How does the HGF/MET pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By promoting synaptic dysfunction and physical loss of synapses.; B. By enhancing amyloid-beta clearance from the brain.; C. By increasing neurogenesis and preventing neuronal loss.; D. By reducing oxidative stress and inflammation.",
            "correct_option": "A",
            "pmid": "pmid35903536"
        },
        "pathway_52": {
            "question": "What is the role of the betaPP binding pathway in Very Late Onset Dementia of the Alzheimer type?",
            "options": "A. It promotes the aggregation of beta amyloid peptides.; B. It facilitates the proteolytic cleavage of the Abeta precursor protein.; C. It attenuates the binding of FE65 with betaPP; contributing to resistance.; D. It enhances the signaling pathway leading to disease progression.",
            "correct_option": "C",
            "pmid": "pmid11854179"
        },
        "pathway_53": {
            "question": "How does the MLKL-USP7-UBA52 signaling pathway contribute to the pathogenesis of Alzheimer disease (AD)?",
            "options": "A. It enhances amyloid-beta production by increasing beta-secretase activity.; B. It maintains ubiquitin homeostasis; which is critical for autophagy and preventing neurodegeneration.; C. It inhibits autophagy by downregulating BECN1 and ULK1.; D. It promotes tau phosphorylation; leading to neurofibrillary tangles.",
            "correct_option": "B",
            "pmid": "pmid39193909"
        },
        "pathway_54": {
            "question": "How does the SNAI2 pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It facilitates the differentiation of BECs; enhancing BBB integrity.; B. It promotes the de-differentiation of BECs; leading to BBB dysfunction.; C. It suppresses angiogenesis and reduces vessel sprouting.; D. It decreases vascular amyloid-beta deposition and inflammation.",
            "correct_option": "B",
            "pmid": "pmid38016947"
        },
        "pathway_55": {
            "question": "How does the ERK/S6 signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It promotes somatodendritic accumulation of Tau through de novo protein synthesis.; B. It inhibits the phosphorylation of Tau.; C. It enhances the clearance of Amyloid-beta plaques.; D. It reduces the activation of Fyn kinase.",
            "correct_option": "A",
            "pmid": "pmid28864542"
        },
        "pathway_56": {
            "question": "How does the PUMA pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It promotes the clearance of amyloid-beta plaques.; B. It induces neuronal apoptosis through caspase-8 activation.; C. It enhances neuroprotective signaling in the hippocampus.; D. It inhibits the translocation of Bax to the mitochondria.",
            "correct_option": "B",
            "pmid": "pmid25457551"
        },
        "pathway_57": {
            "question": "How does the metabotropic glutamate receptor signaling pathway contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. By reducing synaptic C1q production.; B. By increasing synaptic C1q production and promoting microglial phagocytosis.; C. By suppressing microglial activity.; D. By enhancing glutamate transporter 1 (GLT1) expression.",
            "correct_option": "B",
            "pmid": "pmid32008166"
        },
        "pathway_58": {
            "question": "Does melatonin play a role in protecting against BBB disruption in Alzheimer's disease by inhibiting MMP-9 via the NOTCH3/NF-kappaB pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31811815"
        },
        "pathway_59": {
            "question": "Does dioscin alleviate Alzheimer's disease by regulating the RAGE/NOX4 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35691153"
        },
        "pathway_60": {
            "question": "Does rhANP treatment mitigate LPS-induced cognitive dysfunction by influencing pathways relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34949194"
        },
        "pathway_61": {
            "question": "Does the combination of panobinostat and ponatinib synergistically overcome imatinib-resistant CML cells by affecting pathways related to delirium or Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid27166836"
        },
        "pathway_62": {
            "question": "Does Yuk-Gunja-Tang (YG) exert neuroprotective effects by activating the ERK/CREB/BDNF signaling pathway in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36386241"
        },
        "pathway_63": {
            "question": "Does Huanglian Jiedu decoction (HLJDD) regulate the microbiota flora homeostasis to treat Alzheimer's disease through multiple targets and pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37009506"
        },
        "pathway_64": {
            "question": "Does ursolic acid inhibit the activation of transcription factors NF-kappaB, AP-1, and NF-AT, which are involved in inflammatory pathways, potentially relevant to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22363615"
        },
        "pathway_65": {
            "question": "Does ellagic acid inhibit the PI3K/Akt/FOXO3a signaling pathway, which may be relevant to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34373703"
        },
        "pathway_66": {
            "question": "Does linarin's activation of the PI3K/Akt pathway contribute to neuroprotection against Abeta-induced neurotoxicity, potentially offering therapeutic benefits for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21652214"
        },
        "pathway_67": {
            "question": "Does danshensu exhibit potential as a therapeutic agent for Alzheimer's disease by improving cognitive impairments through the PKA-CREB signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31425745"
        },
        "pathway_68": {
            "question": "Does engeletin attenuate oxidative stress and neuroinflammation in Alzheimer's disease by modulating the Keap1/Nrf2 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32445069"
        },
        "pathway_69": {
            "question": "Does 5-Hydroxymethylfurfural (5-HMF) have a potential therapeutic role in Alzheimer's disease by targeting inflammatory pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30642099"
        },
        "pathway_70": {
            "question": "Does the CEBPalpha/circAPLP2/miR-671-5p pathway play a role in regulating CNTN1/2 expression in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36734072"
        },
        "pathway_71": {
            "question": "Does gamma-Glutamylcysteine reduce neuroinflammation in Alzheimer's disease by inhibiting the NF-kappaB signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35714925"
        },
        "pathway_72": {
            "question": "Does Lancao decoction (LC) activate the PI3K/AKT pathway to enhance ERK activity in the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39528121"
        },
        "pathway_73": {
            "question": "Does the anti-inflammatory effect of taraxasterol involve the LXRalpha-ABCA1 signaling pathway, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29670526"
        },
        "pathway_74": {
            "question": "Does Pterostilbene regulate the PDE4A-CREB-BDNF pathway to protect against Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31737188"
        },
        "pathway_75": {
            "question": "Does the PD1/PD-L1 pathway play a role in the neuroinflammation of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21514692"
        },
        "pathway_76": {
            "question": "Does dysiarenone's inhibition of the 5-LOX/NF-kappaB/MAPK pathway have potential implications for treating Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33664584"
        },
        "pathway_77": {
            "question": "Does dexmedetomidine mitigate propofol-induced neurotoxicity by enhancing the PI3K/Akt pathway, which is relevant to delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30214209"
        },
        "pathway_78": {
            "question": "Are pathways related to Alzheimer's disease upregulated in NK cells of elderly patients with NSCLC compared to younger patients?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39244673"
        },
        "pathway_79": {
            "question": "Does neuronal cathepsin S increase neuroinflammation and cause cognitive decline in Alzheimer's disease through the CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39453382"
        },
        "pathway_80": {
            "question": "Does miR-330 targeting VAV1 through the MAPK signaling pathway reduce amyloid beta-protein production in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29369410"
        },
        "pathway_81": {
            "question": "Does the modulation of TLR4/NF-kappaB and Nrf2/HO-1 signaling pathways by naloxone have a known relationship with Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37661242"
        },
        "pathway_82": {
            "question": "Does miR-106b influence the TGF-beta signaling pathway, thereby contributing to the pathogenesis of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20709030"
        },
        "pathway_83": {
            "question": "Does meclizine's effect on neuroinflammation through the AKT/NF-kappabeta/ERK/JNK pathway have implications for the treatment of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37733253"
        },
        "pathway_84": {
            "question": "Does silibinin exert neuroprotective effects on sporadic Alzheimer's disease models by inhibiting the GluN2B pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36610115"
        },
        "pathway_85": {
            "question": "Do the lipid fractions from sandfish eggs inhibit pathways known to be involved in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32967264"
        },
        "pathway_86": {
            "question": "Does the activation of the IRE1alpha-XBP1 and ATF6 pathways differ between Alzheimer's disease and amyotrophic lateral sclerosis (ALS)?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29725981"
        },
        "pathway_87": {
            "question": "Does FTO activation contribute to Alzheimer's disease by affecting the TSC1-mTOR-Tau pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29501742"
        },
        "pathway_88": {
            "question": "Does the activation of the IRE1alpha/XBP1 pathway attenuate disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B, similar to potential therapeutic avenues in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38352425"
        },
        "pathway_89": {
            "question": "Does KMU-1170 inhibit the activation of NF-kappaB and NLRP3 inflammasome signaling pathways, which are relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33530480"
        },
        "pathway_90": {
            "question": "Does berberine (Ber) have a role in treating Alzheimer's disease (AD) by influencing the miR-188/NOS1 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32779043"
        },
        "pathway_91": {
            "question": "Does MLK3 activation via the AP-1 pathway contribute to inflammatory responses in macrophages, which could be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36142785"
        },
        "pathway_92": {
            "question": "Does the Bushen-Yizhi formula (BSYZ) target the endoplasmic reticulum (ER) stress pathway to improve cognitive deficits in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37586159"
        },
        "pathway_93": {
            "question": "Does FLZ enhance the BDNF/TrkB/CREB signaling pathway, which is implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20154710"
        },
        "pathway_94": {
            "question": "Does the inhibition of CSF1R via Ki20227 affect the NLRP3 pathway in a manner relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32908485"
        },
        "pathway_95": {
            "question": "Does hesperetin exert neuroprotective effects by targeting the SIRT6/NLRP3 pathway in a model of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37382831"
        },
        "pathway_96": {
            "question": "Does geranylgeranylacetone (GGA) suppress Alzheimer's disease-related phenotypes via the ERK/p38 MAPK signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29285052"
        },
        "pathway_97": {
            "question": "Does sevoflurane induce pyroptosis in Alzheimer's disease through the NLRP3/caspase-1/GSDMD pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35127716"
        },
        "pathway_98": {
            "question": "Does Ginsenoside Re inhibit the ROS/ASK-1 dependent mitochondrial apoptosis pathway in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31344860"
        },
        "pathway_99": {
            "question": "Does saikosaponin-D have potential therapeutic effects for Alzheimer's disease based on its antioxidant properties and Nrf2 pathway activation?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34994954"
        },
        "pathway_100": {
            "question": "Does TMEM43 play a role in pathways associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34766515"
        },
        "pathway_101": {
            "question": "Does Gypenoside IX alleviate Alzheimer's disease-like neuropathology by restoring the Akt/GSK-3beta pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38095632"
        },
        "pathway_102": {
            "question": "Does activation of the delta-opioid receptor (DOR) inhibit HMGB1 pathway in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39893485"
        },
        "pathway_103": {
            "question": "Is the iRhom2-TNF-alpha-BAFF signaling pathway associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38151421"
        },
        "pathway_104": {
            "question": "Does galectin-3 activation of the Tyro3 receptor tyrosine kinase pathway play a role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid32664510"
        },
        "pathway_105": {
            "question": "Does Dl-3-n-butylphthalide (NBP) improve cognitive impairment in Alzheimer's disease through the regulation of the STEP/ERK/CREB pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35350668"
        },
        "pathway_106": {
            "question": "Does nicergoline improve cognitive function in Alzheimer's disease by inhibiting the PI3K/AKT signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29568940"
        },
        "pathway_107": {
            "question": "Does moscatilin mitigate glycation-mediated damages relevant to Alzheimer's disease by activating AMPK and suppressing the RAGE/NF-kappaB pathway in SH-SY5Y cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33036367"
        },
        "pathway_108": {
            "question": "Does Artemether activate the AMPK/GSK3beta signaling pathway, which is associated with neuroprotection in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31871541"
        },
        "pathway_109": {
            "question": "Does Fuzhisan improve cognitive ability in Alzheimer's disease by affecting autophagy pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39736370"
        },
        "pathway_110": {
            "question": "Does ranuncoside show potential for managing Alzheimer's disease by modulating Nrf2 and NF-kB signaling pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37533493"
        },
        "pathway_111": {
            "question": "Do heparan sulfate proteoglycan (HSPG)-mediated pathways regulate the internalization of brain-derived tau oligomers (BDTOs) in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32366836"
        },
        "pathway_112": {
            "question": "Does 8-weeks of aerobic exercise improve cognitive function in Alzheimer's disease by upregulating the Xc-/GPx4 pathway in the prefrontal cortex?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39315073"
        },
        "pathway_113": {
            "question": "Does Ampelopsin improve cognitive impairment in Alzheimer's disease by inhibiting neuroinflammation and oxidative stress pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31797758"
        },
        "pathway_114": {
            "question": "Does donepezil improve cognitive function in a tree shrew model of Alzheimer's disease by activating the BDNF/TrkB signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30105614"
        },
        "pathway_115": {
            "question": "Does melatonin regulate the interplay of molecular signaling associated with the APP-BP1 pathway to prevent pathogenic mechanisms in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32579500"
        },
        "pathway_116": {
            "question": "Does copper exposure activate the PI3K/Akt pathway, which is implicated in metabolic disorders like Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid11795876"
        },
        "pathway_117": {
            "question": "Does miR-204 silencing reduce mitochondrial autophagy and ROS production in Alzheimer's disease via the TRPML1-activated STAT3 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34026326"
        },
        "pathway_118": {
            "question": "Does tetrahydroalstonine modulate the PI3K/AKT signaling pathway to reduce cell apoptosis in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38061471"
        },
        "pathway_119": {
            "question": "Does Ecliptae Herba exert its anti-Alzheimer's effect through multi-component, multi-target, and multi-pathway mechanisms?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37454776"
        },
        "pathway_120": {
            "question": "Does 1,7-diphenyl-4-hepten-3-one (C1) mitigate Alzheimer's disease by inhibiting pyroptosis through the Nrf2 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37878046"
        },
        "pathway_121": {
            "question": "Does Isoamericanin A improve memory impairment in Alzheimer's disease by suppressing the NADPH oxidase-dependent NF-kappaB signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37209001"
        },
        "pathway_122": {
            "question": "Does the ERK5/KLF4 signaling pathway play a role in protecting neurons against oxidative stress, which is implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25015774"
        },
        "pathway_123": {
            "question": "Does black mulberry fruit extract alleviate Alzheimer's disease-like symptoms in C. elegans through the DAF-16 insulin signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36076399"
        },
        "pathway_124": {
            "question": "Does sevoflurane exposure affect the AKT/GSK3β signaling pathway, which is implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24580743"
        },
        "pathway_125": {
            "question": "Does tripchlorolide inhibit the NF-kappaB and JNK signaling pathways to protect neuronal cells from beta-amyloid neurotoxicity in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19170180"
        },
        "pathway_126": {
            "question": "Does the FGF2/FGFR1 pathway play a role in mitigating astrocyte-mediated neuroinflammation after infrasound exposure, which could be relevant to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30210273"
        },
        "pathway_127": {
            "question": "Does ginkgetin's antiplatelet effect involve the cyclic AMP or cyclic GMP pathways, which are relevant in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid38334198"
        },
        "pathway_128": {
            "question": "Does Mori Cortex Radicis (MCR) help prevent neuronal damage associated with Alzheimer's disease by activating the IRS/Akt signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32575897"
        },
        "pathway_129": {
            "question": "Does Notoginsenoside R1 alleviate inflammation caused by amyloid-beta in Alzheimer's disease by inhibiting the SphK1/NF-kappaB pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38063180"
        },
        "pathway_130": {
            "question": "Does sodium houttuyfonate inhibit the NLRP3/GSDMD pathway to improve memory impairment in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34188608"
        },
        "pathway_131": {
            "question": "Does 11,12-Diacetyl-carnosol (NO.20) protect SH-SY5Y cells from hydrogen peroxide damage through the Nrf2/HO-1 pathway, which may be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35620405"
        },
        "pathway_132": {
            "question": "Does the up-regulation of the P38/HIF-1alpha pathway by intranasal deferoxamine have a role in mitigating Alzheimer's disease-related synapse loss?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26082716"
        },
        "pathway_133": {
            "question": "Does MGST3 regulate amyloidogenesis, a process associated with Alzheimer's disease, through the RGS4-mediated AKT signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38971310"
        },
        "pathway_134": {
            "question": "Does Raddeanin A (RDA) improve BRB function in Alzheimer's disease-related retinopathy by inhibiting NLRP3-mediated inflammation and Wnt/beta-catenin pathway-mediated apoptosis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38834846"
        },
        "pathway_135": {
            "question": "Does hyperforin affect Alzheimer's disease by regulating the Akt/GSK-3beta signaling pathway in PC12 cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28961505"
        },
        "pathway_136": {
            "question": "Does Icariside II mitigate myocardial ischemia and reperfusion injury by activating the PI3K/AKT signaling pathway, which could have implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid32945440"
        },
        "pathway_137": {
            "question": "Does the JAK2-STAT3-BACE1 pathway play a role in the neuroprotective effects of beta-caryophyllene against Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35296033"
        },
        "pathway_138": {
            "question": "Does the WNT signaling pathway have a protective association with colorectal cancer in a Saudi population, similar to its role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid31485167"
        },
        "pathway_139": {
            "question": "Does TGF-beta1 restore synaptic plasticity and memory in an Alzheimer's model through the PI3K/Akt/Wnt/beta-catenin pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30539409"
        },
        "pathway_140": {
            "question": "Does berberine activate the AMPK/mTOR/Ulk1 pathway to attenuate IL-1beta-induced damage in nucleus pulposus cells, which could have implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35915801"
        },
        "pathway_141": {
            "question": "Does donepezil suppress intracellular Ca2+ mobilization through the PI3K pathway in rodent microglia, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29273047"
        },
        "pathway_142": {
            "question": "Does baicalin inhibit the Ras-ERK signaling pathway in SH-SY5Y cells exposed to Abeta 1-42 to attenuate apoptosis, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35528169"
        },
        "pathway_143": {
            "question": "Does exercise training reduce cerebrovascular dysfunction in Alzheimer's disease by modulating the P2Y2 receptor and ER stress pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32383993"
        },
        "pathway_144": {
            "question": "Does vitegnoside mitigate neuronal injury and inflammation in an Alzheimer's disease cell model through the p38 MAPK/JNK pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31561371"
        },
        "pathway_145": {
            "question": "Does the acetylcholine-PKC-beta-PIX-Rac1-PAK pathway play a role in aversive learning, which is used to screen Alzheimer's disease drugs?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35665767"
        },
        "pathway_146": {
            "question": "Does protease nexin-1 (PN-1) protect against Alzheimer's disease by regulating the sonic hedgehog signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32449865"
        },
        "pathway_147": {
            "question": "Does methylnissolin-3-O-beta-d-glucopyranoside (MNG) from Astragalus membranaceus show cytoprotective effects relevant to Alzheimer's disease through the Nrf2/HO-1 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34202670"
        },
        "pathway_148": {
            "question": "Does the protective effect of PFTalpha on alcohol-induced osteonecrosis of the femoral head involve pathways related to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid29246013"
        },
        "pathway_149": {
            "question": "Does SAR1A influence the progression of delirium through the PI3K/AKT/mTOR pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid39595043"
        },
        "pathway_150": {
            "question": "Does Amarogentin (AMA) isolated from Gentiana rigescens Franch exhibit potential therapeutic effects for Alzheimer's disease by targeting the insulin receptor and activating downstream signaling pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34065446"
        },
        "pathway_151": {
            "question": "Does isoliquiritigenin alleviate Semen Strychni-induced neurotoxicity by restoring the neurotransmitter metabolic pathway, which could be relevant to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34867385"
        },
        "pathway_152": {
            "question": "Does metformin activate the ATF2/CREB-PGC-1alpha pathway to protect dopaminergic neurons, which could be relevant for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28611284"
        },
        "pathway_153": {
            "question": "Does Guhan Yangshengjing (GHYSJ) regulate the BACE1 expression pathway to treat Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38492794"
        },
        "pathway_154": {
            "question": "Does Armillariella tabescens-derived polysaccharides alleviate neuroinflammation and cognitive injury in Alzheimer's disease through the Keap-1/Nrf2 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38866276"
        },
        "pathway_155": {
            "question": "Does SKF83959 improve cognitive dysfunction in Alzheimer's disease by modulating the hippocampal BDNF signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29491219"
        },
        "pathway_156": {
            "question": "Does Rhodiola rosea, Withania somnifera, and Eleutherococcus senticosus inhibit the leukotriene signaling pathway, which is beneficial in Alzheimer disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30987861"
        },
        "pathway_157": {
            "question": "Does the A beta peptide activate complement pathways, contributing to inflammation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid10192224"
        },
        "pathway_158": {
            "question": "Does Chrysophanol exert neuroprotective effects by interfering with endoplasmic reticulum stress apoptotic pathways in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34791341"
        },
        "pathway_159": {
            "question": "Does the overexpression of BACE1 contribute to memory and cognitive deficits in Alzheimer's disease by regulating the cAMP/PKA/CREB pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22895721"
        },
        "pathway_160": {
            "question": "Does Anle138b affect pathways related to neuroinflammation in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36918909"
        },
        "pathway_161": {
            "question": "Does Astragaloside IV improve memory impairment related to Alzheimer's disease by promoting the PPARgamma/BDNF signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32739157"
        },
        "pathway_162": {
            "question": "** Does minocycline improve cognitive deficits in Alzheimer's-like pathology by inhibiting the Cdk5/p25 signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34856907"
        },
        "pathway_163": {
            "question": "Does formononetin target the tumor necrosis factor (TNF) receptor signaling pathway in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31175839"
        },
        "pathway_164": {
            "question": "Does l-theanine inhibit the NMDA receptor pathway to protect against Alzheimer's disease in a cell model?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20416364"
        },
        "pathway_165": {
            "question": "Does S6 kinase phosphorylation via the PI3K-PD1 pathway contribute to tau pathology and actin pathology in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26582459"
        },
        "pathway_166": {
            "question": "Does malnutrition exacerbate neuropsychiatric symptoms in Alzheimer's disease by suppressing the cAMP signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39868480"
        },
        "pathway_167": {
            "question": "Does pimozide reduce tau aggregates in an Alzheimer's disease model by activating autophagy through the AMPK-ULK1 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28632947"
        },
        "pathway_168": {
            "question": "Does Ginsenoside Compound K alleviate Amyloid beta42-induced neuroinflammation in Alzheimer's disease through the LRP1 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34968779"
        },
        "pathway_169": {
            "question": "Does beta-asarone show potential as a therapy for Alzheimer's disease by modulating the P13K/Akt/Nrf2 signaling pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34040526"
        },
        "pathway_170": {
            "question": "Does Kai-Xin-San improve cognitive dysfunction in Alzheimer's disease by regulating the SIRT3-mediated neuronal cell apoptosis pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36918872"
        },
        "pathway_171": {
            "question": "Does the chemokine SDF-1alpha suppress Abeta-induced neurotoxicity in Alzheimer's disease by activating specific signaling pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid21704645"
        },
        "pathway_172": {
            "question": "Do kuwanon T and sanggenon A exert anti-inflammatory effects relevant to Alzheimer's disease by regulating NF-kappaB and HO-1/Nrf2 pathways in BV2 and RAW264.7 cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34946724"
        },
        "pathway_173": {
            "question": "Does the Hippo/YAP pathway play a role in the effect of GDNF against Abeta-induced inflammation in microglial cells, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32255663"
        },
        "pathway_174": {
            "question": "Does Sagacious Confucius' Pillow Elixir (SCPE) improve cognitive function by regulating the PI3K/Akt/mTOR signaling pathway in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37517091"
        },
        "pathway_175": {
            "question": "How might EGCG influence pathways associated with Alzheimer's disease in early aged hypertension?",
            "options": "A. By increasing neural cell death through Fas-mediated pathways; B. By activating pro-survival pathways such as Sirt1/PI3K/AKT; C. By reducing the expression of Bcl-2 and Bcl-xL; D. By enhancing mitochondrial-mediated apoptosis",
            "correct_option": "B",
            "pmid": "pmid34456710"
        },
        "pathway_176": {
            "question": "Which pathway is associated with the protective effects of bavachin in LPS-induced AKI, potentially relevant to Alzheimer's disease or delirium?",
            "options": "A. The PKCbeta/MAPK/KLF5 axis; B. The NADPH oxidase (NOX) 4 pathway; C. The NF-kappaB signaling pathway; D. The MAPKs (P38; ERK; and JNK) pathway",
            "correct_option": "A",
            "pmid": "pmid36358467"
        },
        "pathway_177": {
            "question": "Which of the following pathways is identified as a significant shared pathway between delirium and Alzheimer's disease?",
            "options": "A. Dopamine signaling pathway; B. Neuroinflammation and glutamatergic signaling pathway; C. Insulin signaling pathway; D. Estrogen signaling pathway",
            "correct_option": "B",
            "pmid": "pmid39210294"
        },
        "pathway_178": {
            "question": "What signaling pathway was found to mediate the interaction between Abeta and IL-1beta, contributing to neuronal damage in Alzheimer's disease?",
            "options": "A. PI3K/AKT pathway; B. PLC-CN-NFAT1 signaling; C. Wnt/beta-catenin pathway; D. MAPK/ERK pathway",
            "correct_option": "B",
            "pmid": "pmid38749336"
        },
        "pathway_179": {
            "question": "Which pathway does bilberry anthocyanins regulate to improve cognitive dysfunction in Alzheimer's disease?",
            "options": "A. CD33/TREM2/TYROBP signaling pathway; B. Oxidative stress pathway; C. Lipid metabolism pathway; D. SCFA synthesis pathway",
            "correct_option": "A",
            "pmid": "pmid32003387"
        },
        "pathway_180": {
            "question": "Which pathway is activated by the MFH formula to prevent cognitive deficits in Alzheimer's disease?",
            "options": "A. The AEA-Trpv1-Nrf2 pathway; B. The AEA-Trpv1-Nrf2 pathway; C. The AEA-Trpv1-Nrf2 pathway; D. The AEA-Trpv1-Nrf2 pathway",
            "correct_option": "A",
            "pmid": "pmid39305407"
        },
        "pathway_181": {
            "question": "What pathway does PPSR inhibit to reduce microglial inflammation in Alzheimer's disease?",
            "options": "A. ROCK2 pathway; B. NLRP3/caspase 1 pathway; C. IL-1beta signaling; D. LPS-induced pathway",
            "correct_option": "B",
            "pmid": "pmid34874326"
        },
        "pathway_182": {
            "question": "Which signaling pathway is implicated in the protective effects of ITH91/IQM157 against neuronal cell death in an Alzheimer's disease model?",
            "options": "A. Wnt/β-catenin pathway; B. MAPK/ERK pathway; C. JAK-STAT pathway; D. NF-κB pathway",
            "correct_option": "B",
            "pmid": "pmid25393881"
        },
        "pathway_183": {
            "question": "In Alzheimer's disease, beta-amyloid-induced apoptosis is associated with up-regulation of which enzyme via the mitogen-activated protein kinase-NF-kappaB pathway?",
            "options": "A. Cyclooxygenase-1 (COX-1); B. Cyclooxygenase-2 (COX-2); C. Prostaglandin E(2) synthase (PGE(2)); D. Poly(ADP-ribose) polymerase (PARP)",
            "correct_option": "B",
            "pmid": "pmid15917189"
        },
        "pathway_184": {
            "question": "Which brain networks are dysfunctional in delirium?",
            "options": "A. The motor cortex and somatosensory cortex.; B. The visual cortex and auditory cortex.; C. The default-mode network, salience network, frontoparietal control network and dorsal attention network.; D. The cerebellum and basal ganglia.",
            "correct_option": "C",
            "pmid": "pmid28673598"
        },
        "pathway_185": {
            "question": "How does substrate translocation activity change with Alzheimer's disease progression?",
            "options": "A. Substrate translocation activity decreases due to impaired lysosomal function.; B. Substrate translocation activity remains constant, showing no correlation with disease progression.; C. Increased substrate translocation activity into lysosomes aligns with Alzheimer's disease progression.; D. Substrate translocation activity fluctuates randomly, showing no discernible pattern.",
            "correct_option": "C",
            "pmid": "pmid38787367"
        },
        "pathway_186": {
            "question": "Which brain region disconnection is associated with memory impairment in oldest-old Alzheimer's patients?",
            "options": "A. Disconnection between the left inferior frontal gyrus and the anterior cingulate cortex.; B. Disconnection between the hippocampus and the amygdala.; C. Disconnection between the right superior parietal lobule (SPL) and the precuneus.; D. Disconnection between the left temporal pole and the orbitofrontal cortex.",
            "correct_option": "C",
            "pmid": "pmid32728647"
        },
        "pathway_187": {
            "question": "What happens to I2(PP2A) levels in the neocortex in Alzheimer's disease?",
            "options": "A. They significantly decrease.; B. They remain unchanged compared to control cases.; C. They significantly increase.; D. They initially increase and then decrease over time.",
            "correct_option": "C",
            "pmid": "pmid15920161"
        },
        "pathway_188": {
            "question": "What brain region shows the highest proportion of cortical thickness outliers in Alzheimer's Disease?",
            "options": "A. Precentral gyrus; B. Superior temporal gyrus; C. Parahippocampal gyrus; D. Cingulate cortex",
            "correct_option": "C",
            "pmid": "pmid37127353"
        },
        "pathway_189": {
            "question": "What potential pathways are linked to delirium after cardiac surgery?",
            "options": "A. Primarily genetic predisposition and patient age.; B. Neurotransmitter interference, global cognitive disorder, and neuroinflammation.; C. Solely the length of the surgical procedure and anesthesia type.; D. Exclusively pre-existing heart conditions and medication interactions.",
            "correct_option": "B",
            "pmid": "pmid27119013"
        },
        "pathway_190": {
            "question": "What molecular pathways are alike between long COVID-19 and Alzheimer's disease?",
            "options": "A. Increased serotonin production and reduced amyloid plaque formation.; B. Enhanced mitochondrial function and increased neurogenesis.; C. Misregulations in folate-mediated one-carbon metabolism, a deficit of CoQ10, and disease-associated microglia.; D. Upregulation of antioxidant enzymes and improved cerebral blood flow.",
            "correct_option": "C",
            "pmid": "pmid38393535"
        },
        "pathway_191": {
            "question": "Which axis does tangeretin activate to prevent cognitive deficit in delirium?",
            "options": "A. BDNF/TrkB axis; B. NF-κB/IL-1β axis; C. RORalpha/gamma-E4BP4 axis; D. GABA-A receptor axis",
            "correct_option": "C",
            "pmid": "pmid36216079"
        },
        "pathway_192": {
            "question": "What is identified as a unifying mechanism present in all 30 Alzheimer's disease risk factors?",
            "options": "A. Amyloid plaque formation and tau protein tangles.; B. Genetic predisposition to early-onset Alzheimer's.; C. Dysfunction of the neuroimmune-neuroinflammation axis.; D. Reduced acetylcholine production in the brain.",
            "correct_option": "C",
            "pmid": "pmid38248256"
        },
        "pathway_193": {
            "question": "What is the mechanism by which concurrent lithium and electroconvulsive therapy leads to delirium?",
            "options": "A. The potentiation of lithium's antidepressant effects leads to over-stimulation and delirium.; B. Neuromuscular blockers used during ECT interact with lithium, causing increased central nervous system effects.; C. Repeated seizures and increased blood-brain barrier permeability (affected by ECT/age) can lead to lithium toxicity, particularly in those with preexisting brain damage.; D. ECT induces a rapid increase in lithium absorption from the gastrointestinal tract, leading to toxic levels.",
            "correct_option": "C",
            "pmid": "pmid3281716"
        },
        "pathway_194": {
            "question": "Does bacteremia contribute to the pathophysiology of delirium in elderly patients with community-acquired pneumonia?",
            "options": "A. No, delirium is solely caused by hypoxia in these patients.; B. No, delirium is only related to pre-existing cognitive impairment.; C. Yes, bacteremia can contribute to the pathophysiology of delirium.; D. Only viral infections, not bacterial infections, contribute to delirium.",
            "correct_option": "C",
            "pmid": "pmid27078731"
        },
        "pathway_195": {
            "question": "How does reduced opioid usage via regional analgesia influence delirium risk in geriatric trauma patients?",
            "options": "A. Regional analgesia increases the need for opioid medications, thereby increasing the risk of delirium.; B. Regional analgesia has no significant impact on delirium risk in geriatric trauma patients.; C. Regional analgesia decreases the need for opioid medications, which reduces the risk of delirium.; D. Regional analgesia always eliminates the risk of delirium completely in geriatric trauma patients.",
            "correct_option": "C",
            "pmid": "pmid30048325"
        },
        "pathway_196": {
            "question": "What neurotransmitter systems are implicated in delirium associated with Charles Bonnet Syndrome?",
            "options": "A. Serotonin and norepinephrine are suspected to be involved.; B. GABA and glutamate are suspected to be involved.; C. Acetylcholine and dopamine are suspected to be involved.; D. Endorphins and substance P are suspected to be involved.",
            "correct_option": "C",
            "pmid": "pmid36059364"
        },
        "pathway_197": {
            "question": "What neuroendocrine pathways are implicated in mediating delirium in pregnant women during COVID-19-related stress?",
            "options": "A. The sympathetic nervous system (SNS) and parasympathetic nervous system (PNS); B. The renin-angiotensin-aldosterone system (RAAS) and the atrial natriuretic peptide (ANP) system; C. The hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-thyroid (HPT) axis; D. The growth hormone (GH) axis and the prolactin (PRL) axis",
            "correct_option": "C",
            "pmid": "pmid36141770"
        },
        "pathway_198": {
            "question": "What signaling pathways are influenced by statins in the context of delirium?",
            "options": "A. Pathways primarily associated with bone density and calcium regulation.; B. Pathways exclusively involved in glucose metabolism and insulin sensitivity.; C. Pathways associated with neuroinflammation, neurotransmitter regulation, cerebral hypoperfusion, and microthrombosis.; D. Pathways that directly control hair follicle growth and skin pigmentation.",
            "correct_option": "C",
            "pmid": "pmid32691721"
        },
        "pathway_199": {
            "question": "What is the effect of switching from H2 receptor antagonists to proton pump inhibitors on delirium incidence in cancer patients?",
            "options": "A. Switching increases delirium incidence significantly.; B. Switching has no effect on delirium incidence.; C. Switching reduces delirium incidence.; D. Switching initially reduces, then increases, delirium incidence.",
            "correct_option": "C",
            "pmid": "pmid22949902"
        },
        "pathway_200": {
            "question": "What signaling pathways are influenced by co-ultraPEALut in relation to delirium?",
            "options": "A. Co-ultraPEALut increases inflammation and apoptosis while inhibiting antioxidant responses and depleting neurotrophins.; B. Co-ultraPEALut primarily influences neurotransmitter synthesis without affecting inflammation or cell survival pathways.; C. Co-ultraPEALut reduces inflammation, apoptosis, and stimulates an antioxidant response while preserving neurotrophins.; D. Co-ultraPEALut exclusively targets neurotrophin signaling, leading to increased neuronal growth and reduced inflammation.",
            "correct_option": "C",
            "pmid": "pmid31244434"
        },
        "pathway_201": {
            "question": "What changes in beta-endorphin signaling are associated with delirium?",
            "options": "A. Elevated beta-endorphin mRNA expression in the frontal cortex; B. Increased cerebrospinal fluid (CSF) beta-endorphin-like immunoreactivity levels; C. Lower cerebrospinal fluid (CSF) beta-endorphin-like immunoreactivity levels; D. Upregulation of mu-opioid receptors in the periaqueductal gray",
            "correct_option": "C",
            "pmid": "pmid2524220"
        },
        "pathway_202": {
            "question": "What role does the circadian rhythm protein Period 2 (PER2) play in the pathophysiology of delirium?",
            "options": "A. It inhibits the production of inflammatory cytokines, thus preventing delirium.; B. It directly causes neuronal death, leading to delirium symptoms.; C. It maintains cognitive function, and its disruption is linked to delirium-like phenotypes.; D. It regulates blood pressure, and its dysregulation indirectly contributes to delirium.",
            "correct_option": "C",
            "pmid": "pmid29489460"
        },
        "pathway_203": {
            "question": "What role do pro-inflammatory cytokines play in the development of delirium in Alzheimer’s disease patients?",
            "options": "A. They directly enhance neuronal activity, counteracting the effects of Alzheimer’s disease.; B. They promote the growth of amyloid plaques, leading to delirium.; C. They induce a reduced activity of the cholinergic system, contributing to delirium.; D. They increase the production of acetylcholine, preventing delirium.",
            "correct_option": "C",
            "pmid": "pmid12127594"
        },
        "pathway_204": {
            "question": "According to the neuroinflammatory hypothesis of delirium, what is a key sequence of pathway events linking peripheral inflammation to the development of this neuropsychiatric syndrome?",
            "options": "A. Acute peripheral inflammation triggers the activation of brain parenchymal cells and the expression of pro-inflammatory cytokines within the central nervous system, leading to neuronal dysfunction and delirium symptoms.; B. Peripheral inflammation directly suppresses microglial activity in the brain, leading to a failure of neuronal repair mechanisms and subsequent cognitive impairment.; C. Systemic inflammatory mediators primarily cause widespread neuronal apoptosis, which then triggers secondary neuroinflammatory changes leading to delirium.; D. The primary pathway involves a direct breach of the blood-brain barrier by peripheral pathogens, leading to immediate synaptic disruption without significant involvement of central nervous system inflammatory cells.",
            "correct_option": "A",
            "pmid": "pmid20309566"
        },
        "pathway_205": {
            "question": "What is the role of cytokine-acetylcholine interaction in the pathophysiology of delirium during septic encephalopathy?",
            "options": "A. It enhances neuronal excitability and increases acetylcholine release.; B. It leads to neuronal loss and alterations in cholinergic signaling.; C. It protects neurons from damage and stabilizes cholinergic function.; D. It reduces inflammation and promotes acetylcholine synthesis.",
            "correct_option": "B",
            "pmid": "pmid25722876"
        },
        "pathway_206": {
            "question": "What biological mechanisms are associated with opioid-induced delirium in critically ill adults?",
            "options": "A. Primarily, decreased blood flow to the frontal lobe and reduced neuron firing rates.; B. Exclusively, direct binding of opioids to dopamine receptors in the basal ganglia.; C. Opioid-induced delirium may involve disruptions in neurotransmitter systems and neuroinflammatory pathways.; D. Solely, increased levels of acetylcholine in the central nervous system.",
            "correct_option": "C",
            "pmid": "pmid33835902"
        },
        "pathway_207": {
            "question": "What antibodies are associated with delirium in cases of Hashimoto's encephalopathy?",
            "options": "A. Anti-smooth muscle antibodies (anti-SMA); B. Anti-parietal cell antibodies (anti-PCA); C. Anti-NH2-terminal of alpha-enolase (anti-NAE), Thyroid peroxidase antibody (anti-TPO), Anti-thyroglobulin (anti-TG), and Anti-thyroid antibodies; D. Anti-mitochondrial antibodies (AMA)",
            "correct_option": "C",
            "pmid": "pmid31494584"
        },
        "pathway_208": {
            "question": "What biological effect of olanzapine is linked to delirium development in elderly patients?",
            "options": "A. Its potentiation of dopamine reuptake.; B. Its direct neurotoxic effect on hippocampal neurons.; C. The intrinsic anticholinergic effects of the drug.; D. Its ability to selectively inhibit serotonin receptors.",
            "correct_option": "C",
            "pmid": "pmid16368923"
        },
        "pathway_209": {
            "question": "What inflammatory markers are associated with delirium in older adults?",
            "options": "A. Erythrocyte Sedimentation Rate (ESR), Hemoglobin, Albumin; B. Blood Urea Nitrogen (BUN), Creatinine, Sodium; C. C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-alpha), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Neutrophil-lymphocyte ratio (NLR); D. Prothrombin Time (PT), International Normalized Ratio (INR), Partial Thromboplastin Time (PTT)",
            "correct_option": "C",
            "pmid": "pmid37251808"
        },
        "pathway_210": {
            "question": "What signaling pathways are implicated in delirium development through sleep disruption by sedative-hypnotic agents?",
            "options": "A. Increased serotonin and dopamine signaling.; B. Upregulation of NMDA receptors and enhanced long-term potentiation.; C. Disruption of circadian rhythms, altered connectivity from the suprachiasmatic nucleus, deficiencies in melatonin, and effects on GABA-A, alpha(2) adrenoceptors, and orexin receptors.; D. Enhanced acetylcholine release in the hippocampus and cortex.",
            "correct_option": "C",
            "pmid": "pmid39541802"
        },
        "pathway_211": {
            "question": "In elderly patients undergoing surgery, pre-operative dysregulation within which of the following biological processes, marked by specific circulating mediators, has been identified as a significant risk factor for the development of post-operative delirium?",
            "options": "A. The coagulation cascade, indicated by abnormal prothrombin times.; B. The HPA axis stress response, indicated by elevated cortisol levels.; C. The inflammatory response, particularly evidenced by high pre-operative levels of Interleukin-6 (IL-6).; D. Neurotransmitter imbalance, specifically a deficit in cholinergic signaling.",
            "correct_option": "C",
            "pmid": "pmid25368603"
        },
        "pathway_212": {
            "question": "What signaling cascades are implicated in the development of delirium during sepsis?",
            "options": "A. Activation of the complement system and increased erythropoiesis.; B. Neuroinflammation, cytokine activation, blood-brain barrier breakdown, and neurotransmitter imbalances.; C. Increased bone density and decreased muscle mass.; D. Enhanced hepatic function and reduced renal filtration.",
            "correct_option": "B",
            "pmid": "pmid25567339"
        },
        "pathway_213": {
            "question": "What matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are associated with delirium?",
            "options": "A. Lower levels of MMP-2, MMP-3, MMP-10, TIMP-1, and TIMP-2, and higher levels of TIMP-4.; B. Higher levels of MMP-9 and MMP-12, and lower levels of TIMP-1 and TIMP-2.; C. Higher levels of MMP-2, MMP-3, MMP-10, TIMP-1, and TIMP-2, as well as lower levels of TIMP-4.; D. Lower levels of MMP-1, MMP-8, and TIMP-3, with no association to TIMP-1, TIMP-2, or TIMP-4.",
            "correct_option": "C",
            "pmid": "pmid38937571"
        },
        "pathway_214": {
            "question": "What are the potential signaling pathways disrupted by synthetic cannabinoid use in this case of delirium?",
            "options": "A. Primarily serotonergic and noradrenergic pathways.; B. GABAergic, glutamatergic, cholinergic, and dopaminergic pathways.; C. Only dopaminergic and serotonergic pathways, due to CB1R activation.; D. Solely the cholinergic pathway, leading to cognitive impairment.",
            "correct_option": "B",
            "pmid": "pmid26956672"
        },
        "pathway_215": {
            "question": "What role does beta-arrestin1 play in regulating mitochondrial fission through Drp1 during postoperative delirium?",
            "options": "A. Beta-arrestin1 inhibits Drp1 translocation to the nucleus, preventing DNA damage and delirium.; B. Beta-arrestin1 promotes Drp1 degradation, preventing excessive mitochondrial fission and protecting against delirium.; C. Beta-arrestin1 interacts with Drp1, and its deletion promotes Drp1 translocation to the mitochondrial membrane, causing mitochondrial fragmentation and dysfunction, contributing to cognitive dysfunctions in POD.; D. Beta-arrestin1 has no interaction with Drp1 and plays no role in regulating mitochondrial fission during postoperative delirium.",
            "correct_option": "C",
            "pmid": "pmid37170230"
        },
        "pathway_216": {
            "question": "What cytokine levels are associated with cognitive dysfunction following delirium in intensive care unit survivors?",
            "options": "A. Lower levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ); B. Higher levels of interleukin-10 (IL-10) and interleukin-6 (IL-6); C. Lower levels of interleukin-10 (IL-10) and interleukin-6 (IL-6); D. Higher levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ)",
            "correct_option": "B",
            "pmid": "pmid37712803"
        },
        "pathway_217": {
            "question": "What signaling pathway is implicated in the use of phenobarbital for managing delirium associated with gamma-hydroxybutyrate withdrawal?",
            "options": "A. Dopamine receptor signaling pathway.; B. NMDA receptor signaling pathway.; C. GABA-A receptor signaling pathway.; D. Serotonin receptor signaling pathway.",
            "correct_option": "C",
            "pmid": "pmid36269081"
        },
        "pathway_218": {
            "question": "What are the common pharmacological effects of oseltamivir and amantadine that may contribute to delirium?",
            "options": "A. Enhancing GABAergic neurotransmission and inhibiting serotonin reuptake.; B. Blocking nicotinic acetylcholine receptor channels and activation of the serotonergic system.; C. Enhancing cholinergic neurotransmission and inhibiting dopaminergic activity.; D. Blocking nicotinic acetylcholine receptor channels and activation of the dopaminergic system.",
            "correct_option": "D",
            "pmid": "pmid29925727"
        },
        "pathway_219": {
            "question": "What receptor oversaturation is associated with delirium/sedation syndrome caused by olanzapine?",
            "options": "A. D2 and 5-HT2A receptors; B. Alpha-1 and Beta-2 receptors; C. H1 and M1 receptors; D. GABA-A and NMDA receptors",
            "correct_option": "C",
            "pmid": "pmid37082516"
        },
        "pathway_220": {
            "question": "What signaling cascade involving cyclooxygenase-1 (COX-1) contributes to delirium during systemic inflammation?",
            "options": "A. Systemic inflammation decreases TNF-alpha, which reduces COX-1 expression in neurons, leading to decreased prostaglandin F2alpha production and subsequent cognitive dysfunction and delirium.; B. Systemic inflammation increases IL-1beta, which enhances COX-1 expression in astrocytes, leading to increased prostaglandin D2 production and subsequent cognitive dysfunction and delirium.; C. Systemic inflammation decreases IL-6, which inhibits COX-1 expression in endothelial cells, leading to decreased thromboxane A2 production and subsequent cognitive dysfunction and delirium.; D. Systemic inflammation increases IL-1beta, which enhances COX-1 expression in microglia, leading to increased prostaglandin E2 production and subsequent cognitive dysfunction and delirium.",
            "correct_option": "D",
            "pmid": "pmid24048854"
        },
        "pathway_221": {
            "question": "Investigations into the molecular underpinnings of postoperative delirium (POD) suggest that its development can be mediated by specific intracellular signaling cascades. According to findings implicating inflammatory processes, which pathway profile is consistent with a mediatory role in POD?",
            "options": "A. A deficiency in cholinergic neurotransmission leading to cognitive disruption.; B. Excessive dopaminergic activity in mesolimbic pathways.; C. Upregulation of the TLR4/NF-kappaB/MAGI-2 pathway, which is associated with increased pro-inflammatory cytokine activity.; D. Suppression of the NF-kappaB signaling pathway, thereby reducing neuroinflammation and protecting against delirium.",
            "correct_option": "C",
            "pmid": "pmid35294925"
        },
        "pathway_222": {
            "question": "What neurotransmitter receptor pathways are implicated in delirium caused by baclofen withdrawal?",
            "options": "A. The NMDA receptor signaling pathway.; B. The dopamine receptor signaling pathway.; C. The GABAB receptor signaling pathway.; D. The serotonin receptor signaling pathway.",
            "correct_option": "C",
            "pmid": "pmid34123673"
        },
        "pathway_223": {
            "question": "How does miR-219-5p affect tau phosphorylation via TTBK1 and GSK-3beta in the context of delirium associated with Alzheimer’s disease?",
            "options": "A. miR-219-5p overexpression increases TTBK1 and GSK-3beta protein levels, inhibiting tau phosphorylation and alleviating delirium.; B. miR-219-5p deletion has no effect on TTBK1 or GSK-3beta, and therefore does not influence tau phosphorylation or delirium.; C. miR-219-5p overexpression reduces TTBK1 and GSK-3beta protein levels, promoting tau phosphorylation at specific sites, contributing to Alzheimer's disease progression and delirium.; D. miR-219-5p overexpression increases TTBK1 and GSK-3beta protein levels, reducing tau phosphorylation and worsening Alzheimer's disease progression.",
            "correct_option": "C",
            "pmid": "pmid30556160"
        },
        "pathway_224": {
            "question": "What neuropeptides are involved in the brain's response during delirium caused by distant organ damage?",
            "options": "A. Cytokines, dopamine, and serotonin levels increase, triggering microglial activation.; B. Acetylcholine, GABA, and glutamate levels decrease, leading to neuronal hyper-excitability.; C. Beta-endorphin, orexin, and oxytocin levels increase in the brain without associated cytokine elevation.; D. Substance P, neurokinin A, and calcitonin gene-related peptide (CGRP) levels decrease, suppressing pain pathways.",
            "correct_option": "C",
            "pmid": "pmid26711566"
        },
        "pathway_225": {
            "question": "How does abrupt zolpidem withdrawal affect neurotransmitter systems in the development of delirium?",
            "options": "A. It enhances serotonin signaling, leading to neuronal excitation.; B. It primarily impairs dopamine signaling, causing cognitive deficits.; C. It disrupts neurotransmitter systems, specifically impairing gamma-aminobutyric acid (GABA) signaling.; D. It increases glutamate levels, promoting neuroprotective effects.",
            "correct_option": "C",
            "pmid": "pmid38024021"
        },
        "pathway_226": {
            "question": "What cytokine changes are associated with postoperative delirium after esophagectomy?",
            "options": "A. Decreased levels of IL-6 and increased levels of TNF-alpha.; B. Elevated levels of IL-1beta and decreased levels of IL-10.; C. Elevated levels of interleukin-8 (IL-8) and interleukin-10 (IL-10).; D. No significant changes in any cytokine levels.",
            "correct_option": "C",
            "pmid": "pmid33774004"
        },
        "pathway_227": {
            "question": "What are the mechanisms through which valproic acid modulates delirium?",
            "options": "A. Primarily through direct dopaminergic antagonism and GABA depletion.; B. Solely by reducing oxidative stress in the prefrontal cortex.; C. Through neurotransmitter modulation, neuroinflammation, oxidative stress, and transcriptional changes.; D. Exclusively by increasing cerebral blood flow and oxygen delivery.",
            "correct_option": "C",
            "pmid": "pmid26674479"
        },
        "pathway_228": {
            "question": "Which signaling pathway is regulated by miR-539-5p in Alzheimer's disease?",
            "options": "A. MAPK/ERK signaling pathway; B. Wnt/beta-catenin signaling pathway; C. PI3K/AKT/GSK-3beta signaling pathway; D. JAK-STAT signaling pathway",
            "correct_option": "C",
            "pmid": "pmid32415525"
        },
        "pathway_229": {
            "question": "What is the role of synaptosomal miRNAs in Alzheimer's disease?",
            "options": "A. They are downregulated during disease progression and primarily affect protein aggregation.; B. They are upregulated during disease progression and are involved in synapse function, nervous system development, and GABAergic synapse activity.; C. They remain unchanged during disease progression and serve as structural components of synapses.; D. They are only present in cytosolic regions and have no impact on synaptic activity.",
            "correct_option": "B",
            "pmid": "pmid35941185"
        }
    },
    "metabolism": {
        "metabolism_0": {
            "question": "Does isoforsythiaside (IFY) improve mitochondrial function to protect against Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32784451"
        },
        "metabolism_1": {
            "question": "Are alterations in purine metabolism observed in the frontal cortex at early stages of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29363833"
        },
        "metabolism_2": {
            "question": "Does TFR1 knockdown alleviate iron overload and mitochondrial dysfunction in neural cells differentiated from Alzheimer's disease-derived induced pluripotent stem cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38321571"
        },
        "metabolism_3": {
            "question": "Does ergothioneine (ET) have a protective effect against mitochondrial damage caused by 7-ketocholesterol in human brain endothelial cells, which could be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36982572"
        },
        "metabolism_4": {
            "question": "Does impaired vitamin B12 availability contribute to the development of Alzheimer's disease through ER stress pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23519122"
        },
        "metabolism_5": {
            "question": "Does Corchorus depressus (Cd) exhibit potential as an antioxidant and inhibitor of enzymes relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29200727"
        },
        "metabolism_6": {
            "question": "Does catalpol improve mitochondrial function in N2a/APP695swe cells, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35699892"
        },
        "metabolism_7": {
            "question": "Does impaired mitochondrial biogenesis contribute to mitochondrial dysfunction in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22077634"
        },
        "metabolism_8": {
            "question": "Is anosognosia independently associated with hypometabolism in specific brain regions in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29022655"
        },
        "metabolism_9": {
            "question": "Does the regulation of cholesterol metabolism by cis- and trans-palmitoleic acid isomers have any known association with delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid33363473"
        },
        "metabolism_10": {
            "question": "Does Apolipoprotein E4 (ApoE4) suppress mitochondrial function via the PGC-1alpha-Sirt3 pathway, contributing to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31808750"
        },
        "metabolism_11": {
            "question": "Does the d-enantiomeric decapeptide inhibit Cu2+-mediated amyloid beta-protein aggregation, a process linked to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30650306"
        },
        "metabolism_12": {
            "question": "Does di-O-demethylcurcumin protect against neuronal death in Alzheimer's disease by suppressing mitochondrial and ER stress pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25451798"
        },
        "metabolism_13": {
            "question": "Does the mitochondrial permeability transition pore contribute to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30199818"
        },
        "metabolism_14": {
            "question": "Does docosahexaenoic acid (DHA) modulation of the Nrf2/HO-1 pathway have potential implications for nutraceutical therapy in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31677009"
        },
        "metabolism_15": {
            "question": "Does the suppression of neuronal cholesterol biosynthesis contribute to the pathogenesis of Alzheimer's disease through impaired IGF-1-Akt signaling?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34671194"
        },
        "metabolism_16": {
            "question": "Does the silencing of LncRNA BDNF-AS reduce oxidative stress in PC12 cells modeling Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29902125"
        },
        "metabolism_17": {
            "question": "Does dietary lipophilic iron influence amyloidogenesis in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29424844"
        },
        "metabolism_18": {
            "question": "Is HMGA1 implicated in the regulation of glucose metabolism, which may have implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30034366"
        },
        "metabolism_19": {
            "question": "Does Sirtuin3-dependent mitochondrial redox homeostasis have a protective role against AGEs-induced intervertebral disc degeneration, potentially relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30216853"
        },
        "metabolism_20": {
            "question": "Does the methanolic extract of Teucrium stocksianum (METS) demonstrate potential benefits in managing oxidative stress, which is implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24893601"
        },
        "metabolism_21": {
            "question": "Does the oxidation of methionine 35 in the amyloid beta-peptide (1-42) reduce toxicity in neuroblastoma cells by enhancing the expression and function of methionine sulfoxide reductase A (MsrA), which has implications for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20060866"
        },
        "metabolism_22": {
            "question": "Does the fixed combination of citicoline, coenzyme Q10, and vitamin B3 have synergistic protective effects on neuronal cells relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35889920"
        },
        "metabolism_23": {
            "question": "Does tacrine treatment improve glucose metabolism in Alzheimer patients as shown by PET scans?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid1491741"
        },
        "metabolism_24": {
            "question": "Does thymoquinone (TQ) show potential for treating Alzheimer's disease by reducing oxidative stress and mitochondrial dysfunction in PC 12 cells exposed to Abeta(25-35)?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22752387"
        },
        "metabolism_25": {
            "question": "Can tyrosine modifications of the insulin-degrading enzyme (IDE) help in controlling the substrate specificity for Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39481143"
        },
        "metabolism_26": {
            "question": "Does mitochondrial dihydrolipoyl succinyltransferase (DLST) deficiency contribute to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19596066"
        },
        "metabolism_27": {
            "question": "Does PFKM play a role in enhancing oxidative phosphorylation and glycolysis, which might be relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35804014"
        },
        "metabolism_28": {
            "question": "Does donepezil reduce mitochondrial amyloid-beta accumulation in Alzheimer's disease models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25744714"
        },
        "metabolism_29": {
            "question": "Does miR-494-3p play a role in the degeneration of retinal pigment epithelial cells by influencing mitochondrial integrity, which could be relevant to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37163276"
        },
        "metabolism_30": {
            "question": "Does ATP interaction with amyloid-beta protein have potential significance to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24625803"
        },
        "metabolism_31": {
            "question": "Does Schisandrin B diet alleviate hepatotoxicity by inhibiting oxidative stress and ferroptosis, which could have implications for Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36060128"
        },
        "metabolism_32": {
            "question": "Does metformin alleviate lead-induced mitochondrial fragmentation via AMPK/Nrf2 activation in SH-SY5Y cells, which is relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32863218"
        },
        "metabolism_33": {
            "question": "Does the chloroform fraction of Stephania japonica inhibit acetylcholinesterase and oxidative stress, which are relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35237756"
        },
        "metabolism_34": {
            "question": "Does piracetam improve mitochondrial function in cells exposed to beta-amyloid, which is implicated in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20218980"
        },
        "metabolism_35": {
            "question": "Does curcumin enhance mitochondrial fusion activity and reduce fission machinery in Alzheimer's disease-like neurons?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27521081"
        },
        "metabolism_36": {
            "question": "Does copper deficiency during inflammation affect the expression of proteins involved in iron metabolism, potentially linking to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28118841"
        },
        "metabolism_37": {
            "question": "Does diazoxide pretreatment prevent oxidative stress in cholinergic neurons related to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24771316"
        },
        "metabolism_38": {
            "question": "Does the tumor stroma of metastasis-prone breast cancer patients show transcriptional similarities to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20442453"
        },
        "metabolism_39": {
            "question": "Does increased cerebral glucose metabolism correlate with worse verbal memory performance in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38102439"
        },
        "metabolism_40": {
            "question": "Does the dysregulation of iron metabolism in Parkinson's disease (PD) occur in a similar manner in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid33799121"
        },
        "metabolism_41": {
            "question": "Does Orexin-A exacerbate Alzheimer's disease by inducing mitochondrial impairment?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31927055"
        },
        "metabolism_42": {
            "question": "Does the inhibition of the mitochondrial Na+/Ca2+ exchanger (NCLX) contribute to neurodegeneration in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31918031"
        },
        "metabolism_43": {
            "question": "Does IMM-H004 protect neuronal mitochondrial function in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23523945"
        },
        "metabolism_44": {
            "question": "Does Salvianolic acid B protect against mitochondrial dysfunction in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29551684"
        },
        "metabolism_45": {
            "question": "Does UDCA improve mitochondrial function in fibroblasts from patients with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30171839"
        },
        "metabolism_46": {
            "question": "Does the pattern of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33490360"
        },
        "metabolism_47": {
            "question": "Does Zuo Gui Wan (ZGW) improve cognitive function in Alzheimer's disease (AD) animal models by inhibiting mitochondrial fission and activating AMPK/PGC-1alpha-regulated mitochondrial bioenergetics?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39884486"
        },
        "metabolism_48": {
            "question": "Does sialic acid metabolism play a role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid33867926"
        },
        "metabolism_49": {
            "question": "Does mannose consumption exacerbate Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39807036"
        },
        "metabolism_50": {
            "question": "Does maternal choline supplementation reduce brain homocysteine levels and improve cognitive deficits in Alzheimer's disease across multiple generations?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30622336"
        },
        "metabolism_51": {
            "question": "Does Codonopsis pilosula Polysaccharides alleviate energy dysmetabolism in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34102973"
        },
        "metabolism_52": {
            "question": "Does mitochondrial dysfunction in the proximal axon initial segment contribute to TAU missorting observed in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35119496"
        },
        "metabolism_53": {
            "question": "Is there a significant difference in homocysteine metabolism between Alzheimer's disease patients and vascular dementia patients as shown by the methionine loading test?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid20209467"
        },
        "metabolism_54": {
            "question": "Does amarogentin exhibit potential benefits for Alzheimer's disease by reducing reactive oxygen species (ROS) and improving the survival rate of PC12 cells under oxidative stress?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid32831994"
        },
        "metabolism_55": {
            "question": "Does the loss of SLC38A10 lead to lower cholesterol levels, which could have implications in neurodegenerative diseases like Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35450293"
        },
        "metabolism_56": {
            "question": "Does the regulation of lipid metabolism involving G-quadruplex structure in ACBP genes have any reported connection to Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid35748856"
        },
        "metabolism_57": {
            "question": "Does the lavender aqueous extract treatment affect metabolic pathways related to amino acids in Alzheimer's disease models?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29849984"
        },
        "metabolism_58": {
            "question": "How does urolithin A mitigate high glucose-induced amyloidogenesis in Alzheimer's disease?",
            "options": "A. By increasing mitochondrial ROS accumulation; B. By reducing TGM2-dependent ER-mitochondria contacts; C. By enhancing APP and BACE1 expression; D. By promoting Tau dephosphorylation",
            "correct_option": "B",
            "pmid": "pmid32704090"
        },
        "metabolism_59": {
            "question": "Which short-chain fatty acid (SCFA) metabolite of Akkermansia muciniphila is implicated in protecting against Alzheimer's disease by maintaining mitochondrial homeostasis?",
            "options": "A. Acetic acid; B. Propionic acid; C. Butyric acid; D. Valeric acid",
            "correct_option": "B",
            "pmid": "pmid39833898"
        },
        "metabolism_60": {
            "question": "How might hydrogen sulfide (H2S) affect mitochondrial dynamics in neuroblastoma cells, and what implication does this have for Alzheimer's disease?",
            "options": "A. H2S decreases mitochondrial fission via Drp1/ERK1/2 pathway; potentially benefiting Alzheimers disease.; B. H2S increases mitochondrial fission; worsening Alzheimers disease symptoms.; C. H2S has no effect on mitochondrial dynamics in neuroblastoma cells.; D. H2S promotes mitochondrial fusion; unrelated to Alzheimers disease.",
            "correct_option": "A",
            "pmid": "pmid28560384"
        },
        "metabolism_61": {
            "question": "Which metabolic pathway is activated in FH-deficient renal cell carcinoma cells when exposed to asparagine, potentially linking to delirium-related metabolic dysregulation?",
            "options": "A. Hexosamine biosynthetic pathway (HBP); B. Glycolytic pathway; C. Fumarate hydratase pathway; D. Mitochondrial electron transport chain",
            "correct_option": "A",
            "pmid": "pmid32774853"
        },
        "metabolism_62": {
            "question": "In Alzheimer's disease, which metabolic process in astrocytes is implicated in both detoxifying Abeta-derived ammonia and causing memory impairment?",
            "options": "A. Glycolysis; B. Urea cycle; C. Lipid metabolism; D. Ketogenesis",
            "correct_option": "B",
            "pmid": "pmid35738259"
        },
        "metabolism_63": {
            "question": "Which amino acid combination derived from garlic and buna-shimeji is associated with suppression of CCl4-induced hepatic injury, potentially relevant to neurodegenerative conditions like Alzheimer's disease?",
            "options": "A. S-allyl-l-cysteine sulfoxide (ACSO) and ornithine; B. Arginine and cysteine; C. Glutamine and serine; D. Histidine and tyrosine",
            "correct_option": "A",
            "pmid": "pmid34199038"
        },
        "metabolism_64": {
            "question": "Which miRNAs were found to be elevated in Alzheimer's disease brain tissues and might modulate arginine metabolism?",
            "options": "A. miRNA-9 and miRNA-128a; B. miRNA-16 and miRNA-21; C. miRNA-124 and miRNA-132; D. miRNA-29 and miRNA-34",
            "correct_option": "A",
            "pmid": "pmid26971935"
        },
        "metabolism_65": {
            "question": "Which of the following is associated with LacCer-induced oxidative stress and has been implicated in the pathogenesis of Alzheimer's disease?",
            "options": "A. Mitochondrial dysfunction; B. Platelet-derived growth factor (PDGF); C. Vascular endothelial growth factor (VEGF); D. Tumor necrosis factor-alpha (TNF-alpha)",
            "correct_option": "A",
            "pmid": "pmid33673027"
        },
        "metabolism_66": {
            "question": "How does mycolactone affect mitochondrial distribution in DRG neurons, and what is its relevance to Alzheimer's disease?",
            "options": "A. Mycolactone causes mitochondrial clustering; which is a known feature of Alzheimers disease.; B. Mycolactone has no effect on mitochondrial distribution but is relevant to Alzheimers disease.; C. Mycolactone increases mitochondrial density in neurites; which is protective against Alzheimers disease.; D. Mycolactone reduces mitochondrial density in cell bodies; which is unrelated to Alzheimers disease.",
            "correct_option": "A",
            "pmid": "pmid27325560"
        },
        "metabolism_67": {
            "question": "How does the anti-oxidative effect of ATB-344 relate to delirium?",
            "options": "A. It enhances cognitive function in delirium.; B. It prevents oxidative damage to the gastric mucosa; which is unrelated to delirium.; C. It reduces inflammation; a known factor in delirium.; D. It increases the production of hydrogen sulfide; which directly treats delirium.",
            "correct_option": "B",
            "pmid": "pmid37627540"
        },
        "metabolism_68": {
            "question": "In Alzheimer's disease, the expression of CD38 in senescent microglia is influenced by which of the following factors?",
            "options": "A. ATP levels; B. Mitochondrial ROS; C. Abeta1-40; D. NAD+ / NADH ratio",
            "correct_option": "C",
            "pmid": "pmid35241173"
        },
        "metabolism_69": {
            "question": "How does hydroxy-alpha-sanshool (HAS) affect glycogen synthesis in liver cells, which is relevant to understanding metabolic processes in Alzheimer's disease?",
            "options": "A. HAS reduces glycogen synthesis by inhibiting the PI3K/Akt pathway.; B. HAS increases glycogen synthesis by activating the PI3K/Akt/GSK-3β/GS pathway.; C. HAS decreases glycogen synthesis by suppressing GSK-3β phosphorylation.; D. HAS has no effect on glycogen synthesis in liver cells.",
            "correct_option": "B",
            "pmid": "pmid36582530"
        },
        "metabolism_70": {
            "question": "How might resveratrol's activation of the Keap-1/Nrf2 pathway in obese-asthmatic rats relate to Alzheimer's disease?",
            "options": "A. It could reduce oxidative stress; potentially mitigating Alzheimers pathology.; B. It might increase oxidative stress; worsening Alzheimers symptoms.; C. It could directly target amyloid-beta plaques in the brain.; D. It might enhance insulin resistance; contributing to Alzheimers progression.",
            "correct_option": "A",
            "pmid": "pmid30542383"
        },
        "metabolism_71": {
            "question": "Which of the following was shown to have antineuroinflammatory effects against Alzheimer's disease by upregulating GPR41 and suppressing the ERK/JNK/NF-kB pathway?",
            "options": "A. Acetate (Ace); B. Amyloid-beta (Aβ); C. Interleukin 1β (IL-1β); D. CD11b",
            "correct_option": "A",
            "pmid": "pmid32583667"
        },
        "metabolism_72": {
            "question": "Sodium butyrate (NaB) is known to inhibit which enzyme to reduce neuroinflammation in Alzheimer's disease?",
            "options": "A. Amyloid-beta (Abeta) plaques; B. Histone deacetylase (HDAC); C. Pro-inflammatory cytokines; D. Beta-amyloid (Abeta)",
            "correct_option": "B",
            "pmid": "pmid33785315"
        },
        "metabolism_73": {
            "question": "Which of the following NAD(+)-dependent enzymes has been shown to strongly affect the pathological changes of Alzheimer's disease (AD)?",
            "options": "A. PARP-1; B. SIRT1; C. SIRT2; D. Both B and C",
            "correct_option": "D",
            "pmid": "pmid22204321"
        },
        "metabolism_74": {
            "question": "How does WGX50 mitigate doxorubicin-induced cardiotoxicity, which shares similarities with the mitochondrial dysfunction observed in Alzheimer's disease?",
            "options": "A. By increasing mitochondrial ROS levels; B. By enhancing ferroptosis in cardiomyocytes; C. By reducing mitochondrial ROS and inhibiting ferroptosis; D. By promoting lipid ROS accumulation",
            "correct_option": "C",
            "pmid": "pmid37978379"
        },
        "metabolism_75": {
            "question": "Which polyphenolic compounds isolated from Corallodiscus flabellata B. L. Burtt are reported to ameliorate amyloid beta-protein induced Alzheimer's disease neuronal injury?",
            "options": "A. SDC-1-8 and hydroxytyrosol (HT); B. Mitofusin 1 and mdivi-1; C. Amyloid beta-protein 25-35 (Abeta25-35) and dynamin-related protein 1; D. 3;4-Dihydroxyphenylethanol-8-O-4-O-trans-caffeoyl-beta-D-apiofuranosyl-(1 3)-beta-D-glucopyranosyl (1 6)1-beta-D-glucopyranoside and hydroxytyrosol",
            "correct_option": "A",
            "pmid": "pmid36535434"
        },
        "metabolism_76": {
            "question": "How does the interaction between VDAC1 and Abeta contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. It enhances mitochondrial pore opening; improving ATP production.; B. It reduces phosphorylated tau levels; stabilizing neuronal function.; C. It promotes mitochondrial dysfunction; leading to impaired energy supply.; D. It decreases Abeta levels; preventing amyloid plaque formation.",
            "correct_option": "C",
            "pmid": "pmid22926141"
        },
        "metabolism_77": {
            "question": "How does OCIAD1 contribute to neurodegeneration in Alzheimer's disease?",
            "options": "A. By promoting synaptic plasticity; B. By impairing mitochondrial function; C. By enhancing neuroprotection; D. By reducing amyloid-beta production",
            "correct_option": "B",
            "pmid": "pmid31931285"
        },
        "metabolism_78": {
            "question": "Which metabolic cluster in tear fluid is associated with the progression of proliferative diabetic retinopathy (PDR), a condition that shares systemic attributes with Alzheimer's disease?",
            "options": "A. Acylcarnitines; B. Amino acid & related compounds; C. Ceramides; D. Bile acids",
            "correct_option": "C",
            "pmid": "pmid36845280"
        },
        "metabolism_79": {
            "question": "Which molecule is identified as a critical regulator of death-associated protein kinase 1 (DAPK1) in Alzheimer's disease?",
            "options": "A. Tau protein; B. Melatonin; C. Ubiquitin; D. Pin1",
            "correct_option": "B",
            "pmid": "pmid32358852"
        },
        "metabolism_80": {
            "question": "Which metabolic pathways were restored by Bushen Tiansui Formula (BSTSF) in the treatment of Alzheimer's disease in rats?",
            "options": "A. Sphingolipid metabolism and glycerophospholipid metabolism; B. Linoleic acid metabolism and amino acid metabolism; C. Glutamine and glutamate metabolism; D. All of the above",
            "correct_option": "D",
            "pmid": "pmid32655770"
        },
        "metabolism_81": {
            "question": "How does mild hypothermia affect isoflurane-induced cytotoxicity and DNA damage, potentially relevant to neurodegenerative conditions like Alzheimer's disease?",
            "options": "A. Increases cytotoxicity and DNA damage; B. Reduces cytotoxicity and DNA damage; C. No effect on cytotoxicity or DNA damage; D. Only reduces cytotoxicity; not DNA damage",
            "correct_option": "B",
            "pmid": "pmid28228717"
        },
        "metabolism_82": {
            "question": "Which selenium compound was found to preferentially increase the expression and activity of thioredoxin reductase, thereby reducing tau phosphorylation in Alzheimer's disease models?",
            "options": "A. Sodium selenate (SeNa); B. Selenomethionine (SeM); C. Se-methylselenocysteine (SMC); D. Glutathione peroxidase 1 (GPx1)",
            "correct_option": "C",
            "pmid": "pmid36978950"
        },
        "metabolism_83": {
            "question": "How does Exendin-4 (Ex-4) influence mitochondrial function in neurons under palmitic acid-induced oxidative stress, which is relevant to Alzheimer's disease pathophysiology?",
            "options": "A. Ex-4 impairs mitochondrial function and increases ROS production.; B. Ex-4 improves mitochondrial function and reduces ROS production.; C. Ex-4 has no effect on mitochondrial function or ROS levels.; D. Ex-4 enhances lipotoxicity and worsens mitochondrial dysfunction.",
            "correct_option": "B",
            "pmid": "pmid33435277"
        },
        "metabolism_84": {
            "question": "Which mitochondrial dysfunction is associated with NF-kappaB signaling and may contribute to Alzheimer's disease?",
            "options": "A. Increased ATP production; B. Decreased ATP production; C. Reduced ROS production; D. Enhanced calcium-induced mPTP opening",
            "correct_option": "B",
            "pmid": "pmid28317877"
        },
        "metabolism_85": {
            "question": "Which of the following is associated with increased GPR84 expression in macrophages and may contribute to the pathophysiology of Alzheimer's disease?",
            "options": "A. Hyperglycemia; B. Hypercholesterolemia; C. Oxidized LDL; D. All of the above",
            "correct_option": "D",
            "pmid": "pmid29973940"
        },
        "metabolism_86": {
            "question": "How does avasimibe modulate cholesterol metabolism to enhance the efficacy of the Kras vaccine, potentially offering insights into treatments for Alzheimer's disease?",
            "options": "A. By inhibiting ACAT1; avasimibe reduces cholesterol levels in T cells; enhancing their ability to target tumors.; B. Avasimibe increases cholesterol synthesis in cancer cells; making them more susceptible to the vaccine.; C. Avasimibe enhances cholesterol metabolism in regulatory T cells; reducing their suppressive activity.; D. Avasimibe modulates cholesterol metabolism in glial cells; improving cognitive outcomes.",
            "correct_option": "A",
            "pmid": "pmid31680003"
        },
        "metabolism_87": {
            "question": "How might decreased PSA expression in the liver be related to Alzheimer's disease progression?",
            "options": "A. Increased triglyceride accumulation in the liver; B. Impaired antioxidant response in the liver; C. Enhanced fatty acid beta-oxidation; D. Reduced NRF2 ubiquitination",
            "correct_option": "B",
            "pmid": "pmid34048566"
        },
        "metabolism_88": {
            "question": "Which natural compound found in olive oil has been shown to protect against 7-ketocholesterol-induced mitochondrial and peroxisomal dysfunction in microglial cells, which may be relevant to neurodegenerative diseases like Alzheimer's disease?",
            "options": "A. Alpha-tocopherol; B. Gamma-tocopherol; C. Oleic acid; D. Trolox",
            "correct_option": "A",
            "pmid": "pmid27897980"
        },
        "metabolism_89": {
            "question": "Methazolamide (MTZ) prevents mitochondrial dysfunction in Alzheimer's disease by inhibiting the release of which molecule from mitochondria?",
            "options": "A. Amyloid beta (Abeta); B. Cytochrome c (CytC); C. Caspase 9; D. Caspase 3",
            "correct_option": "B",
            "pmid": "pmid26581638"
        },
        "metabolism_90": {
            "question": "What effect did the extracts of Salvia triloba and Piper nigrum have on oxidative stress in Alzheimer's disease-induced rats?",
            "options": "A. Increased oxidative stress; B. Decreased oxidative stress; C. No change in oxidative stress; D. Aggravated neurodegeneration",
            "correct_option": "B",
            "pmid": "pmid22957416"
        },
        "metabolism_91": {
            "question": "Which metabolic pathway regulated by Jingfang Granules is associated with brain protection in Alzheimer's disease?",
            "options": "A. Metabolism of taurine and hypotaurine; B. Biosynthesis of valine; leucine; and isoleucine; C. Lipid metabolism; D. Carbohydrate metabolism",
            "correct_option": "A",
            "pmid": "pmid38809507"
        },
        "metabolism_92": {
            "question": "Which enzyme's inhibition partially mediates Abeta25-35-induced cytotoxicity in Alzheimer's disease?",
            "options": "A. Glucosylceramide synthase (GCS); B. Sphingomyelin synthase; C. Ceramide synthase; D. Ceramide phosphatase",
            "correct_option": "A",
            "pmid": "pmid34602551"
        },
        "metabolism_93": {
            "question": "How does spermine oxidase overexpression affect the brain in a way that could be relevant to Alzheimer's disease?",
            "options": "A. It increases oxidative stress; which is implicated in Alzheimers disease.; B. It decreases polyamine levels; enhancing neuroprotection.; C. It improves cognitive function by enhancing synaptic plasticity.; D. It reduces oxidative stress; mitigating Alzheimers disease progression.",
            "correct_option": "A",
            "pmid": "pmid23840306"
        },
        "metabolism_94": {
            "question": "Which enzyme has been suggested to link sulfur amino acids with lipid metabolism and may also play a role in Alzheimer's disease?",
            "options": "A. SCD-1; B. HMG-CoA reductase; C. Lipoprotein lipase; D. Acetyl-CoA carboxylase",
            "correct_option": "A",
            "pmid": "pmid26046927"
        },
        "metabolism_95": {
            "question": "Which factor is associated with improved muscle strength in older individuals with inadequate protein intake, potentially relevant to conditions like Alzheimer's disease or delirium?",
            "options": "A. High sugar intake; B. Branched-chain amino acids and eicosapentaenoic acid; C. Low protein diet; D. Sedentary lifestyle",
            "correct_option": "B",
            "pmid": "pmid37457975"
        },
        "metabolism_96": {
            "question": "Which of the following pesticides was found to not cause mitochondrial fragmentation or functional damage, nor inhibit the activity of the proteasome, thus potentially reducing the risk of Parkinsonism and possibly Alzheimer's disease?",
            "options": "A. Paraquat; B. Rotenone; C. Trichlorphon; D. Fenpyroximate",
            "correct_option": "C",
            "pmid": "pmid29168786"
        },
        "metabolism_97": {
            "question": "How does SERCA activation by CDN1163 potentially influence metabolic processes relevant to Alzheimer's disease?",
            "options": "A. Decreases glucose uptake in myotubes; B. Enhances fatty acid beta-oxidation; C. Reduces AMPK phosphorylation; D. Increases de novo lipogenesis",
            "correct_option": "B",
            "pmid": "pmid34909682"
        },
        "metabolism_98": {
            "question": "Which mung bean component is shown to regulate heat stress and may have implications for neurodegenerative diseases like Alzheimer's due to its antioxidant properties?",
            "options": "A. Mung bean proteins; B. Mung bean polysaccharides; C. Mung bean polyphenols; D. Mung bean oils",
            "correct_option": "C",
            "pmid": "pmid36890864"
        },
        "metabolism_99": {
            "question": "In Alzheimer's disease, how does hexokinase 2 (HK2) deficiency in microglial cells affect ATP generation and beta-amyloid clearance?",
            "options": "A. HK2 deficiency decreases ATP generation and reduces beta-amyloid clearance.; B. HK2 deficiency increases ATP generation through lipid metabolism and enhances beta-amyloid clearance.; C. HK2 deficiency has no significant effect on ATP generation or beta-amyloid clearance.; D. HK2 deficiency decreases lipid metabolism but increases ATP generation.",
            "correct_option": "B",
            "pmid": "pmid36203054"
        },
        "metabolism_100": {
            "question": "In rapidly progressive Alzheimer's disease (rpAD), compared to typical Alzheimer's disease (tAD), which of the following is true regarding mitochondrial dynamics?",
            "options": "A. rpAD shows a less pronounced decline in mitochondrial dynamics regulators.; B. rpAD shows a more pronounced decline in mitochondrial dynamics regulators.; C. Both rpAD and tAD show no significant changes in mitochondrial dynamics regulators.; D. Only rpAD exhibits an increase in mitochondrial dynamics regulators.",
            "correct_option": "B",
            "pmid": "pmid39584307"
        },
        "metabolism_101": {
            "question": "Which metabolic pathway affected by the You-Gui Pill (YGP) in treating Kidney-Yang Deficiency Syndrome (KYDS) is also implicated in Alzheimer's disease?",
            "options": "A. Glycine; serine; and threonine metabolism; B. Butanoate metabolism; C. TCA cycle; D. Dicarboxylate metabolism",
            "correct_option": "B",
            "pmid": "pmid31357410"
        },
        "metabolism_102": {
            "question": "Which COX-2 inhibitor was found to potentially affect kynurenic acid (KYNA) production, a biomarker implicated in Alzheimer's disease and delirium?",
            "options": "A. Celecoxib; B. Niflumic acid; C. Parecoxib; D. Ibuprofen",
            "correct_option": "B",
            "pmid": "pmid30178287"
        },
        "metabolism_103": {
            "question": "Willin/FRMD6 downregulation is associated with which feature of Alzheimer's disease pathogenesis?",
            "options": "A. Increased synaptic plasticity; B. Mitochondrial dysfunction and fragmentation; C. Reduced ERK1/2 signaling; D. Enhanced neuronal energy production",
            "correct_option": "B",
            "pmid": "pmid36231104"
        },
        "metabolism_104": {
            "question": "Which mitochondrial haplogroup cluster is associated with an increased risk of age-related macular degeneration (AMD) and may also influence the bioenergetic processes implicated in Alzheimer's disease?",
            "options": "A. JTU; B. J; C. U; D. H",
            "correct_option": "A",
            "pmid": "pmid23302509"
        },
        "metabolism_105": {
            "question": "Which metabolic change in Alzheimer's disease obscures the typical phenotype of type 2 diabetes?",
            "options": "A. Alzheimers disease subjects displayed a metabolic profile similar to cognitively normal elderly individuals with type 2 diabetes.; B. PLS-DA modeling resulted in poor classification accuracy for type 2 diabetes in Alzheimers disease subjects.; C. T2D discrimination was improved in Alzheimers disease subjects compared to cognitively healthy individuals.; D. The abundance of glucose and fatty acids was lower in Alzheimers disease subjects with T2D.",
            "correct_option": "B",
            "pmid": "pmid29351484"
        },
        "metabolism_106": {
            "question": "In Alzheimer disease, what is the relationship between argininosuccinate synthetase (ASS) and inducible nitric oxide synthase (iNOS) expression in neurons and glia?",
            "options": "A. ASS and iNOS expression are both increased in neurons and glia.; B. ASS expression is increased in neurons but not in glia.; C. iNOS expression is increased in neurons but not in glia.; D. ASS and iNOS expression are both decreased in neurons and glia.",
            "correct_option": "A",
            "pmid": "pmid11556547"
        },
        "metabolism_107": {
            "question": "Which early onset neurodegenerative disorder was found to have lower levels of kynurenine pathway metabolites in specific brain regions compared to Alzheimer's disease?",
            "options": "A. ALS; B. FTD; C. EOAD; D. delirium",
            "correct_option": "A",
            "pmid": "pmid37111372"
        },
        "metabolism_108": {
            "question": "Which factor was found to upregulate glutaminyl cyclase (QC) expression in neuronal cells, contributing to Alzheimer's disease pathogenesis?",
            "options": "A. Beta amyloid (Abeta) peptides; B. Unfolded protein response; C. Perturbed intracellular Ca(2+) homeostasis; D. C-fos and c-jun transcription factors",
            "correct_option": "C",
            "pmid": "pmid22970285"
        },
        "metabolism_109": {
            "question": "Which metabolite associated with a high-fiber diet was found to have the strongest binding affinity for SPEG, a gene linked to Alzheimer's disease?",
            "options": "A. Acetamidobenzoic acid; B. Glutamine; C. Insulin; D. Leptin",
            "correct_option": "A",
            "pmid": "pmid36733447"
        },
        "metabolism_110": {
            "question": "How might the biphasic effect of Carthamus Tinctorius extract on oxidative stress influence Alzheimer's disease treatment?",
            "options": "A. The extract could enhance mitochondrial function in Alzheimers patients.; B. The extract may have dual roles in modulating oxidative stress in Alzheimers disease.; C. The extract could serve as a novel biomarker for Alzheimers progression.; D. The extract may act as a pro-oxidant to reduce amyloid-beta plaques.",
            "correct_option": "B",
            "pmid": "pmid32013224"
        },
        "metabolism_111": {
            "question": "What metabolic process is primarily affected by Shengmai-San (SMS) intervention in Alzheimer's disease?",
            "options": "A. Protein Glycation; B. Carbohydrate Metabolism; C. Lipid Peroxidation; D. Nucleic Acid Synthesis",
            "correct_option": "C",
            "pmid": "pmid28379235"
        },
        "metabolism_112": {
            "question": "In Alzheimer's disease, where is increased HNE-histidine Michael adduct detected in the hippocampus?",
            "options": "A. Primarily in the dentate gyrus and CA1 sector.; B. Primarily in the subiculum and entorhinal cortex.; C. Significantly higher in the CA2, CA3, and CA4 sectors, specifically in the perikarya of pyramidal cells.; D. Distributed evenly throughout all hippocampal regions.",
            "correct_option": "C",
            "pmid": "pmid19729853"
        },
        "metabolism_113": {
            "question": "In Alzheimer-type dementia, which brain region shows decreased alpha-glucosidase activity?",
            "options": "A. Occipital lobe; B. Frontal lobe; C. Temporal cortex; D. Cerebellum",
            "correct_option": "C",
            "pmid": "pmid2935594"
        },
        "metabolism_114": {
            "question": "What metabolic changes are associated with postoperative delirium in patients undergoing surgery for oral carcinoma?",
            "options": "A. Elevated levels of hemoglobin, sodium, and total protein.; B. Significant increases in red blood cell count and alkaline phosphatase.; C. Significant reductions in hemoglobin, hematocrit, and sodium levels.; D. No significant changes in metabolic markers were observed.",
            "correct_option": "C",
            "pmid": "pmid19237264"
        },
        "metabolism_115": {
            "question": "What metabolic disruptions are linked to delirium in cases of massive amygdalin overdose?",
            "options": "A. Hyperglycemia, ketoacidosis, and hyperkalemia.; B. Hyponatremia, cerebral edema, and respiratory alkalosis.; C. Cyanide-induced histotoxic hypoxia, lactic acidosis, and metabolic acidosis.; D. Hypercalcemia, hypophosphatemia, and respiratory acidosis.",
            "correct_option": "C",
            "pmid": "pmid31322009"
        },
        "metabolism_116": {
            "question": "What metabolic disruptions are linked to delirium in liver transplant patients receiving cyclosporine?",
            "options": "A. Hypermagnesemia (high magnesium levels) and hypercholesterolemia (high cholesterol levels).; B. Low therapeutic serum levels of cyclosporine combined with hyperkalemia (high potassium levels).; C. High therapeutic, rapidly rising, or toxic serum levels of cyclosporine, hypomagnesemia (low magnesium levels), and hypocholesterolemia (low cholesterol levels).; D. Oral administration of cyclosporine combined with hyperglycemia (high blood sugar).",
            "correct_option": "C",
            "pmid": "pmid2003144"
        },
        "metabolism_117": {
            "question": "What metabolic disruptions are linked to delirium in geriatric general medical patients?",
            "options": "A. Hypernatremia, hypokalemia, decreased blood ammonia, leukopenia, and hematuria.; B. Hyponatremia, hyperkalemia, decreased blood ammonia, leukocytosis, and proteinuria.; C. Hypernatremia, potassium disturbances, raised blood ammonia, leukopenia, and hematuria.; D. Hyponatremia, potassium disturbances, raised blood ammonia, leukocytosis, and proteinuria.",
            "correct_option": "D",
            "pmid": "pmid21206582"
        },
        "metabolism_118": {
            "question": "What metabolic factors are associated with postoperative delirium in older patients undergoing cholecystectomy?",
            "options": "A. Elevated body mass index (BMI), hyperalbuminemia, and normal electrolyte levels.; B. Lower body mass index (BMI), hyperalbuminemia, and electrolyte balance.; C. Elevated body mass index (BMI), hypoalbuminemia, and electrolyte imbalance.; D. Lower body mass index (BMI), hypoalbuminemia, and electrolyte imbalance.",
            "correct_option": "D",
            "pmid": "pmid37336783"
        },
        "metabolism_119": {
            "question": "What metabolic or nutritional factor is most strongly associated with delirium development in CICU patients?",
            "options": "A. Elevated blood glucose; B. Low serum albumin level; C. Hypokalemia; D. Vitamin D deficiency",
            "correct_option": "B",
            "pmid": "pmid36937934"
        },
        "metabolism_120": {
            "question": "What mitochondrial dysfunctions are associated with delirium in an animal model of contrast-induced nephropathy?",
            "options": "A. Increased activities of mitochondrial respiratory chain complexes II and V in the hippocampus, elevated complex III activity in the occipital lobe, and increased creatine kinase activity in the cerebellum.; B. Decreased activities of mitochondrial respiratory chain complexes I and IV in the cerebral cortex, inhibited complex I activity in the prefrontal cortex, and reduced creatine kinase activity in the cerebral cortex.; C. Increased activities of mitochondrial respiratory chain complexes III and IV in the prefrontal cortex, inhibited complex II activity in the cerebral cortex, and increased creatine kinase activity in the hippocampus.; D. Decreased activities of mitochondrial respiratory chain complexes II and III in the cerebellum, elevated complex V activity in the prefrontal cortex, and unchanged creatine kinase activity in the cerebral cortex.",
            "correct_option": "B",
            "pmid": "pmid21437673"
        },
        "metabolism_121": {
            "question": "What is the association between antidiabetic medications and delirium development?",
            "options": "A. Metformin use is strongly linked to a decreased risk of delirium.; B. The use of sulfonylurea and insulin may be associated with an increased risk of delirium development.; C. All antidiabetic medications have been shown to prevent delirium in elderly patients.; D. Thiazolidinediones (TZDs) are the primary antidiabetic drugs associated with delirium.",
            "correct_option": "B",
            "pmid": "pmid38135802"
        }
    },
    "genetic": {
        "genetic_0": {
            "question": "How is PCT expression altered in ICU delirium?",
            "options": "A: PCT levels are significantly decreased in delirium patients compared to non-delirium patients.; B: PCT levels show no significant difference between delirium and non-delirium patients.; C: PCT levels are significantly increased in delirium patients compared to non-delirium patients.; D: PCT levels are only elevated in delirium patients with co-existing NSE elevations.",
            "correct_option": "C",
            "pmid": "pmid30045794"
        },
        "genetic_1": {
            "question": "What mechanism is primarily targeted by URMC-099 to prevent hippocampal vascular and synaptic injury in a model of delirium superimposed on dementia?",
            "options": "A. Inhibition of tau protein aggregation.; B. Activation of cholinergic signaling pathways.; C. Enhancement of amyloid-beta clearance from the hippocampus.; D. Suppression of inflammatory endothelial activation and microglial-mediated synaptic loss.",
            "correct_option": "D",
            "pmid": "pmid35535564"
        },
        "genetic_2": {
            "question": "How does IL6ST expression vary across disease stages in Delirium?",
            "options": "A: IL6ST methylation remains constant throughout the course of delirium.; B: There is a decrease in IL6ST methylation among patients who develop delirium.; C: There is an increase in IL6ST methylation among patients who never develop delirium.; D: One trajectory for IL6ST methylation showed low initial methylation increasing over time; and another showed high initial methylation decreasing over time.",
            "correct_option": "D",
            "pmid": "pmid36045041"
        },
        "genetic_3": {
            "question": "Which of the following is NOT supported by the identification of a significant CpG site near LDLRAD4 in patients with delirium?",
            "options": "A. Epigenetic regulation may influence immune response pathways.; B. Cholinergic synaptic mechanisms could be epigenetically affected in delirium.; C. DNA methylation patterns may serve as biomarkers for delirium.; D. LDLRAD4 protein mutations are a known genetic cause of delirium.",
            "correct_option": "D",
            "pmid": "pmid32590150"
        },
        "genetic_5": {
            "question": "What is the function of IL-1RA in delirium-related biological processes?",
            "options": "A: IL-1RA promotes delirium severity.; B: IL-1RA has no effect on delirium.; C: Low levels of IL-1RA are significantly associated with delirium.; D: IL-1RA only affects delirium when combined with APOE genotype.",
            "correct_option": "C",
            "pmid": "pmid19269948"
        },
        "genetic_6": {
            "question": "How does MCP-1 contribute to the development of delirium?",
            "options": "A: MCP-1 reduces inflammation; thus preventing delirium.; B: A statistically significant raise in MCP-1 is associated with delirium in the postoperative phase.; C: MCP-1 levels are consistently lower in patients with delirium.; D: MCP-1 plays no role in the development of delirium.",
            "correct_option": "B",
            "pmid": "pmid25943983"
        },
        "genetic_7": {
            "question": "How does FG contribute to the development of delirium?",
            "options": "A: The study supports the causal effects of FG on delirium risk.; B: The study found a strong genetic causal association between FG and delirium.; C: The study did not support the causal effects of FG on delirium risk.; D: The study showed that FG is a significant outlier in the MR analysis of delirium.",
            "correct_option": "C",
            "pmid": "pmid36896238"
        },
        "genetic_8": {
            "question": "How does CD4+ T cell contribute to the development of Delirium?",
            "options": "A: CD4+ T cell count is not a factor in the development of delirium.; B: Higher CD4+ T cell count is associated with shorter cardiopulmonary bypass time.; C: CD4+ T cell count is an independent predictor of delirium.; D: Lower CD4+ T cell count is an independent predictor of delirium.",
            "correct_option": "C",
            "pmid": "pmid36118695"
        },
        "genetic_10": {
            "question": "Is IL-12 involved in the pathogenesis of post-stroke delirium?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid29669581"
        },
        "genetic_11": {
            "question": "What is the role of CYP3A5 in coma and delirium?",
            "options": "A: CYP3A5 genetic polymorphisms were associated with delirium occurrence.; B: CYP3A5 genetic polymorphisms were associated with midazolam plasma levels.; C: CYP3A5 genetic polymorphisms were evaluated in patients with coma and/or delirium.; D: CYP3A5 genetic polymorphisms directly influence the inflammatory status in delirium.",
            "correct_option": "C",
            "pmid": "pmid23385102"
        },
        "genetic_12": {
            "question": "Can gamma-aminobutyric acid (GABA) contribute to delirium?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid20131213"
        },
        "genetic_13": {
            "question": "What is the role of Monocyte Chemoattractant Protein-1 (MCP-1) in delirium after cardiac surgery?",
            "options": "A: It decreases inflammation and reduces the risk of delirium.; B: Elevated preoperative levels are independently associated with postoperative delirium.; C: It is associated with delirium only when hsCRP levels are also elevated.; D: It is primarily associated with delirium in patients with pre-existing major depressive disorder.",
            "correct_option": "B",
            "pmid": "pmid33918634"
        },
        "genetic_14": {
            "question": "Is Gal-3BP involved in the pathogenesis of post-stroke delirium?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid33901789"
        },
        "genetic_15": {
            "question": "Can plasminogen activator inhibitor-1 serve as a biomarker for diagnosis or prognosis in delirium?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid27088157"
        },
        "genetic_16": {
            "question": "How does the GC receptor (GR) contribute to the development of delirium?",
            "options": "A: It directly causes cognitive impairment; leading to delirium.; B: Altered GC signaling via the GR may be involved in the pathogenesis and development of delirium.; C: It increases functional capacity; thus reducing the risk of delirium.; D: It protects against the effects of increased cortisol levels in elderly patients.",
            "correct_option": "B",
            "pmid": "pmid21438141"
        },
        "genetic_17": {
            "question": "How is blood superoxide dismutase (SOD) level altered in delirium superimposed on dementia?",
            "options": "A: Blood SOD levels >=129 U/mL is an independent risk factor.; B: Blood SOD levels <129 U/mL is not related to delirium.; C: Blood SOD levels <129 U/mL is an independent risk factor.; D: Blood SOD levels are not related to delirium in patients with senile dementia during hospitalization.",
            "correct_option": "C",
            "pmid": "pmid37812498"
        },
        "genetic_18": {
            "question": "Does KAT7 signaling epigenetically influence DYRK1A expression to improve insulin resistance in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38617985"
        },
        "genetic_19": {
            "question": "Does the IL6R gene variant (rs2228145, Asp358Ala) influence cognitive performance and Alzheimer disease biomarkers?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36810164"
        },
        "genetic_20": {
            "question": "In Alzheimer’s disease, dysregulation of noncoding RNAs contributes to neurodegeneration. Which of the following best describes the role of the long noncoding RNA GAS5 in the pathogenesis of Alzheimer’s disease?",
            "options": "A. GAS5 increases amyloid-beta production by enhancing APP gene transcription.; B. GAS5 acts as a sponge for miR-23b-3p, leading to increased PTEN and GSK-3β expression, which promotes tau hyperphosphorylation and neuronal apoptosis.; C. GAS5 binds directly to tau protein to prevent its aggregation in neurons.; D. GAS5 enhances Akt signaling through suppression of PTEN, leading to reduced GSK-3β activity.",
            "correct_option": "B",
            "pmid": "pmid39105371"
        },
        "genetic_21": {
            "question": "Which allele of the rs149474436 SNP in the PICK1 gene was found to be protective against Alzheimer's disease?",
            "options": "A. The T allele; B. The C allele; C. The G allele; D. The A allele",
            "correct_option": "A",
            "pmid": "pmid30687223"
        },
        "genetic_22": {
            "question": "Does the accumulation of amyloid-beta 1-42 (Abeta42) affect the epigenetic regulation of the Igf2/H19 gene cluster in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36739453"
        },
        "genetic_23": {
            "question": "Does the codon 311 (Cys --> Ser) polymorphism of the paraoxonase-2 gene interact with the apoE4 allele in the development of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid11803456"
        },
        "genetic_24": {
            "question": "Does lncRNA XIST play a role in Alzheimer's disease by inducing Abeta accumulation and neuroinflammation through epigenetic repression of NEP?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35098860"
        },
        "genetic_26": {
            "question": "Are promoter polymorphisms in the BACE1 gene associated with sporadic Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19441127"
        },
        "genetic_27": {
            "question": "Which genetic polymorphism in the HLA-DQB1 promoter region is associated with changes in transcription factor binding that may influence Alzheimer's disease risk?",
            "options": "A. G-71C (rs71542466); B. T-80C (rs9274529); C. Both A and B; D. Neither A nor B",
            "correct_option": "C",
            "pmid": "pmid37201029"
        },
        "genetic_28": {
            "question": "Does the -1314C allele of the ADAM9 gene promoter have a protective effect against Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid19237226"
        },
        "genetic_29": {
            "question": "Which mutation in the PSEN1 gene is associated with both familial Lewy body disease and variant Alzheimer's disease?",
            "options": "A. PS1 H163R; B. PS1 E280A; C. PS1 deltaE9; D. PS1 deltaT440",
            "correct_option": "D",
            "pmid": "pmid18045903"
        },
        "genetic_30": {
            "question": "Which gene's up-regulation is associated with the protective effects of omega-3 PUFAs against Alzheimer's disease?",
            "options": "A. APP; B. PS1; C. MAG; D. Fat-1",
            "correct_option": "C",
            "pmid": "pmid39453315"
        },
        "genetic_31": {
            "question": "What is the primary mechanism by which β-asarone exerts neuroprotective effects in an Alzheimer’s disease cellular model?",
            "options": "A. By increasing amyloid-beta production to strengthen cellular signalingl.; B. By inhibiting Nrf2 and promoting oxidative stress.; C. By enhancing mitochondrial membrane damage and apoptosis.; D. By activating the PI3K/Akt/Nrf2 signaling pathway to reduce oxidative stress and apoptosis.",
            "correct_option": "D",
            "pmid": "pmid34040526"
        },
        "genetic_32": {
            "question": "Does the missense variant rs117916664 in the ACAA1 gene contribute to early-onset Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34465723"
        },
        "genetic_33": {
            "question": "Which RYR3 gene variants are associated with the age at onset of Alzheimer's disease, hypertension, and diabetes?",
            "options": "A. rs2033610; rs2596164; rs2278317; B. rs4780174; rs7498093; C. rs2033610; rs4780174; D. rs2278317; rs7498093",
            "correct_option": "B",
            "pmid": "pmid29590321"
        },
        "genetic_34": {
            "question": "Does the MAPT-A152T mutation enhance neuronal excitability through the tau-Fyn-NMDAR pathway in excitatory neurons, contributing to Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39811068"
        },
        "genetic_35": {
            "question": "Which allele is associated with a higher risk of late-onset Alzheimer's disease (LOAD) when combined with the ALDH2(*)2 polymorphism?",
            "options": "A. APOE-epsilon2; B. APOE-epsilon3; C. APOE-epsilon4; D. APOE-epsilon5",
            "correct_option": "C",
            "pmid": "pmid15126281"
        },
        "genetic_37": {
            "question": "Does CRMP-2 expression influenced by the PI3K-mTOR-S6K pathway play a role in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28966575"
        },
        "genetic_38": {
            "question": "Does a mutation in the DAOA gene modify the age of onset in PSEN1 E280A Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26949549"
        },
        "genetic_39": {
            "question": "Does the inhibition of BET proteins reduce the expression of genes involved in the pathomechanism of Alzheimer's disease in microglia?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid36613460"
        },
        "genetic_40": {
            "question": "Which of the following is associated with an increased risk of developing Alzheimer's disease due to altered MS4A6A gene expression?",
            "options": "A. Lower expression of full-length V1-MS4A6A; B. Higher expression of V4-MS4A6A transcripts; C. Presence of the protective minor allele; D. Decreased expression of MS4A6A in brain tissue",
            "correct_option": "B",
            "pmid": "pmid24064185"
        },
        "genetic_41": {
            "question": "Does the N405S mutation in the PS1 gene lead to widespread cortical amyloid deposition in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid10644793"
        },
        "genetic_42": {
            "question": "Does the -499A>G polymorphism of the MAPK8IP1 gene increase the risk of Alzheimer's disease in individuals with the CC genotype of the LRP gene?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid12740599"
        },
        "genetic_43": {
            "question": "Does the P117R mutation in presenilin 1 affect cell cycle regulation and contribute to Alzheimer's disease progression?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22810102"
        },
        "genetic_44": {
            "question": "How does the dysregulation of NRIP1 expression in Down syndrome potentially relate to Alzheimer's disease?",
            "options": "A. NRIP1 overexpression leads to mitochondrial dysfunction; which is a known factor in Alzheimers disease.; B. NRIP1 underexpression increases the decay rate of NRIP1 mRNA; contributing to Alzheimers pathology.; C. NRIP1 downregulation enhances m6A modification; protecting against Alzheimers disease.; D. NRIP1 upregulation reduces METTL3 activity; directly causing Alzheimers disease.",
            "correct_option": "A",
            "pmid": "pmid33869171"
        },
        "genetic_46": {
            "question": "Which of the following best describes the association of the rs6922617 variant in the TREM gene cluster with Alzheimer's disease neuropathology?",
            "options": "A. It is linked to increased tau accumulation and accelerated cognitive decline.; B. It is associated with reduced amyloid burden and preserved glucose metabolism.; C. It directly impairs synaptic transmission leading to early memory deficits.; D. It is associated with elevated amyloid burden and reduced glucose metabolism, but not with increased tau accumulation.",
            "correct_option": "D",
            "pmid": "pmid39051708"
        },
        "genetic_47": {
            "question": "Is DSCR1 (Adapt78) gene expression associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid11483593"
        },
        "genetic_48": {
            "question": "Does downregulation of miR-29c correlate with increased BACE1 expression in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid25973041"
        },
        "genetic_49": {
            "question": "Does the upregulation of DR6 expression correlate with neuronal death in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid23559013"
        },
        "genetic_50": {
            "question": "Does loss of ataxin-1 increase BACE1 expression and contribute to Alzheimer's disease pathogenesis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31442405"
        },
        "genetic_51": {
            "question": "Which polymorphisms in the LXR-beta gene were associated with an increased risk of Alzheimer's disease when combined with the HO-1 (-413) TT genotype?",
            "options": "A. rs2695121 (intron 2) and rs1052533 (intron 5); B. rs1052533 (intron 5) and rs1405655 (intron 7); C. rs2695121 (intron 2); rs1052533 (intron 5); and rs1405655 (intron 7); D. Only rs2695121 (intron 2)",
            "correct_option": "C",
            "pmid": "pmid18597895"
        },
        "genetic_52": {
            "question": "Which allele in the CYP46A1 gene increases the risk of developing Alzheimer's disease when associated with the APOEpsilon3 allele?",
            "options": "A. APOEpsilon4 allele; B. CYP46A1-T allele; C. CYP46A1-C allele; D. APOEpsilon2 allele",
            "correct_option": "B",
            "pmid": "pmid16340204"
        },
        "genetic_53": {
            "question": "Does the downregulation of BARHL1 in Alzheimer's disease potentially affect cognitive functions through the ESR1 pathway?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28956815"
        },
        "genetic_54": {
            "question": "Does the presenilin 1 mutation (PS1M146L) linked to Alzheimer's disease affect filamin expression and distribution?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid20847418"
        },
        "genetic_55": {
            "question": "Does the C677T variant in MTHFR modulate associations between plasma ApoE levels and Alzheimer's disease biomarkers?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27380243"
        },
        "genetic_56": {
            "question": "Does the presence of the H63D variant in males with the E4 allele significantly lower the risk of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid18525129"
        },
        "genetic_57": {
            "question": "Is the SNP-rs6922617 in the TREM gene cluster associated with a higher global amyloid-ligands PET burden in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39051708"
        },
        "genetic_58": {
            "question": "In Alzheimer's disease (AD) human skin fibroblasts, which mutation is associated with highly aggressive AD and persistent BKB2R signaling?",
            "options": "A. PS-1 M146L; B. PS-2 mutation; C. Trisomy 21; D. Gamma-secretase inhibitor Compound E",
            "correct_option": "A",
            "pmid": "pmid19247475"
        },
        "genetic_59": {
            "question": "Is there an association between SIRT1 gene polymorphisms and Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37892107"
        },
        "genetic_60": {
            "question": "Which single-nucleotide polymorphism (SNP) of the MAPT gene was found to be associated with a lower risk of sporadic Alzheimer's disease (SAD) in a meta-analysis?",
            "options": "A. rs1467967A/G; B. rs3785883G/A; C. rs242557G/A; D. rs7521G/A",
            "correct_option": "C",
            "pmid": "pmid29098924"
        },
        "genetic_61": {
            "question": "Which gene variant interacts with APOE and increases the risk for Alzheimer's disease?",
            "options": "A. FTO TT-genotype; B. FTO AA-genotype; C. APOE epsilon3; D. APOE epsilon2",
            "correct_option": "B",
            "pmid": "pmid21098976"
        },
        "genetic_62": {
            "question": "Does the IDE gene variant (c.782G > A, p.R261Q) contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid39539495"
        },
        "genetic_63": {
            "question": "Which mutant allele is associated with Alzheimer's disease and affects Wnt/beta-catenin signaling by increasing TCF/beta-catenin/CBP-mediated transcription?",
            "options": "A. PS-1(L286V); B. APP; C. Notch; D. CREB",
            "correct_option": "A",
            "pmid": "pmid16093313"
        },
        "genetic_64": {
            "question": "Which allele of the COMT gene was found to be an independent risk factor for Alzheimer's disease in men without the APOE epsilon4 allele?",
            "options": "A. Val/Val; B. Val/Met; C. Met/Met; D. Met allele",
            "correct_option": "D",
            "pmid": "pmid24575113"
        },
        "genetic_65": {
            "question": "Which long noncoding RNA was shown to play a role in Alzheimer's disease progression by regulating the miR-361-3p/ZNF217 axis?",
            "options": "A. SNHG1; B. miR-361-3p; C. ZNF217; D. Abeta",
            "correct_option": "A",
            "pmid": "pmid32741808"
        },
        "genetic_66": {
            "question": "Does the SERPINA5 genetic variant p.E228Q contribute to clinical differences in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37327267"
        },
        "genetic_67": {
            "question": "Is decreased expression of the APOA1-APOC3-APOA4 gene cluster associated with the risk of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26491253"
        },
        "genetic_68": {
            "question": "Does the presence of a stop-loss variant in the RGS7 gene correlate with a specific subtype of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid37047347"
        },
        "genetic_69": {
            "question": "NF-kappaB-induced upregulation of miR-146a-5p was found to promote oxidative stress and pyroptosis in Alzheimer's disease by targeting which gene?",
            "options": "A. TIGAR; B. IL-1beta; C. Caspase-1; D. NLRP3",
            "correct_option": "A",
            "pmid": "pmid33935653"
        },
        "genetic_70": {
            "question": "Which of the following genetic variants was associated with a reduced risk of Alzheimer's disease relative to primary age-related tauopathy (PART)?",
            "options": "A. APOE ε4; B. APOE ε2; C. rs6656401 in CR1; D. All of the above",
            "correct_option": "D",
            "pmid": "pmid30128317"
        },
        "genetic_71": {
            "question": "Are variants in CYP17 and CYP19 cytochrome P450 genes associated with the onset of Alzheimer's disease in women with Down syndrome?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid22057025"
        },
        "genetic_73": {
            "question": "Is the IFITM3 gene associated with less vulnerability to cognitive decline and Alzheimer's disease biomarkers?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid35769874"
        },
        "genetic_74": {
            "question": "Which gene variant was found to have a protective effect against the progression to mild cognitive impairment or Alzheimer's disease (MCI/LOAD)?",
            "options": "A. APOE-e4; B. CLU-rs11136000-G; C. PICALM-rs3851179-G; D. MS4A6A-rs610932-C",
            "correct_option": "C",
            "pmid": "pmid25189118"
        },
        "genetic_75": {
            "question": "Does transferrin play a role in the regulation of APH-1alpha/beta and Presenilin 1 expression, which contributes to the pathogenesis of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30383537"
        },
        "genetic_76": {
            "question": "Does the T835M mutation in the UNC5C gene increase the risk of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid27068745"
        },
        "genetic_77": {
            "question": "Does PS1 mutation interfere with PS2-mediated activation of pathways relevant to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid16014629"
        },
        "genetic_78": {
            "question": "Does the PSEN1 His214Asn mutation contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38203287"
        },
        "genetic_79": {
            "question": "Which genetic polymorphism of ABCA1 is associated with an increased risk of late-onset Alzheimer's disease in females?",
            "options": "A. R219K (rs2230806); B. G-17C (rs2740483); C. APOE ε4; D. UBQLN1",
            "correct_option": "A",
            "pmid": "pmid16725228"
        },
        "genetic_80": {
            "question": "lncRNA NKILA exacerbates Alzheimer's disease progression by regulating which transcription-mediated process?",
            "options": "A. FOXA1-mediated transcription of TNFAIP1; B. FOXA1-mediated transcription of SOD; C. FOXA1-mediated transcription of MDA; D. FOXA1-mediated transcription of GSH-Px",
            "correct_option": "A",
            "pmid": "pmid37217807"
        },
        "genetic_81": {
            "question": "Which allele of the SIRT2 gene rs2015 locus is associated with a reduced risk of developing Alzheimer's disease?",
            "options": "A. A allele; B. C allele; C. G allele; D. T allele",
            "correct_option": "A",
            "pmid": "pmid32124252"
        },
        "genetic_82": {
            "question": "Does lower expression of Ndfip1 contribute to Alzheimer's disease pathogenesis by reducing DMT1 degradation and increasing iron influx in the brain?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29937728"
        },
        "genetic_83": {
            "question": "Which variant of the CHI3L1 gene is associated with slower progression of Alzheimer's disease?",
            "options": "A. A variant increasing CSF YKL-40 expression; B. A variant decreasing CSF YKL-40 expression; C. A variant with no effect on CSF YKL-40 expression; D. A variant increasing astrocyte activation",
            "correct_option": "B",
            "pmid": "pmid33328329"
        },
        "genetic_84": {
            "question": "Does inhibition of PARP1 enhance the expression of genes related to Alzheimer's disease in PC12 cells?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid28698968"
        },
        "genetic_85": {
            "question": "Does the UBTF E210K mutation contribute to the pathogenesis of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid29300972"
        },
        "genetic_86": {
            "question": "Are genes encoding the NALCN channelosome associated with susceptibility to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid24904279"
        },
        "genetic_87": {
            "question": "Which allele of the ACT gene is associated with an increased risk of Alzheimer's disease?",
            "options": "A. Codon -17*A allele; B. Codon 241*A allele; C. Codon 250*T allele; D. Codon 324*G allele",
            "correct_option": "A",
            "pmid": "pmid11941486"
        },
        "genetic_88": {
            "question": "Does the SNP rs76904798 of the LRRK2 gene reduce the risk of Alzheimer's disease in northern Han Chinese individuals?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26738859"
        },
        "genetic_89": {
            "question": "Does downregulation of OPTN contribute to neuroinflammation in Alzheimer's disease through AIM2 inflammasome and RIPK1 pathways?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid34861878"
        },
        "genetic_90": {
            "question": "Does the CP2/LBP-1c/LSF transcription factor enhance the transcription of the GARS-AIRS-GART gene in Down syndrome-related Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid17902044"
        },
        "genetic_91": {
            "question": "Is there evidence linking rumination, mediated by MTHFD1L gene variants, todelirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid26926881"
        },
        "genetic_92": {
            "question": "Are variants in the COX6B1, SURF1, and COX10 genes associated with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid30054583"
        },
        "genetic_94": {
            "question": "Is there an association between AOC1 gene variants and delirium in adult women with fibromyalgia?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37359379"
        },
        "genetic_95": {
            "question": "Does the 3'-UTR +1073 C/T polymorphism of the OLR1 gene associate with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid12807963"
        },
        "genetic_96": {
            "question": "Does the CYP19A1 gene polymorphism rs10046 increase the risk of Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31278540"
        },
        "genetic_97": {
            "question": "Are certain allele combinations involving IL6r and C9 genes associated with amyloid burden in Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid26626881"
        },
        "genetic_98": {
            "question": "Does the AGTPBP1 gene mutation in CONDCA lead to Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid34572343"
        },
        "genetic_99": {
            "question": "Which of the following best describes the gene expression levels of CHRM1 and CHRM4 in DLB compared to Alzheimer's disease?",
            "options": "A. CHRM1 is higher and CHRM4 is lower in DLB than in AD.; B. CHRM1 is lower and CHRM4 is higher in DLB than in AD.; C. Both CHRM1 and CHRM4 are higher in DLB than in A; D. Both CHRM1 and CHRM4 are lower in DLB than in AD.",
            "correct_option": "A",
            "pmid": "pmid34806612"
        },
        "genetic_100": {
            "question": "Does the Y831C mutation in the POLG gene have a statistically significant association with Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid37189790"
        },
        "genetic_101": {
            "question": "Does up-regulation of lncRNA WT1-AS alleviate neuronal damage in Alzheimer's disease by modulating the miR-186-5p/CCND2 axis?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid38372094"
        },
        "genetic_102": {
            "question": "Does miRNA-431 prevent synapse loss in an Alzheimer's disease neuronal model by targeting Kremen1?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid29643768"
        },
        "genetic_103": {
            "question": "Which mutation in the APP gene is associated with protection against Alzheimer's disease by promoting beta'-site cleavage?",
            "options": "A. Swedish mutation (K670N/M671L); B. Leuven mutation (E682K); C. A673V mutation; D. A673T mutation",
            "correct_option": "D",
            "pmid": "pmid27687728"
        },
        "genetic_104": {
            "question": "Is the DDAH2 (-449 G/C) gene polymorphism associated with Alzheimer's disease or delirium?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid33433489"
        },
        "genetic_105": {
            "question": "Does the SLC6A4 gene variant rs7224199 show an association with Alzheimer's disease?",
            "options": "A. Yes; B. No",
            "correct_option": "A",
            "pmid": "pmid31595439"
        },
        "genetic_106": {
            "question": "Which variant of the RELN gene has been associated with resilience against presenilin-linked autosomal-dominant Alzheimer's disease (ADAD)?",
            "options": "A. H3447R; B. A1234B; C. C5678D; D. E9876F",
            "correct_option": "A",
            "pmid": "pmid38754634"
        },
        "genetic_107": {
            "question": "Does the presence of EIF2B5 gene mutations associate with delirium in females with ovarioleukodystrophy?",
            "options": "A. Yes; B. No",
            "correct_option": "B",
            "pmid": "pmid35785335"
        },
        "genetic_108": {
            "question": "Which of the following best describes a key finding regarding Alzheimer’s disease-related molecular changes in SH-SY5Y cells exposed to methylglyoxal (MGO)?",
            "options": "A. MGO significantly decreased SH-SY5Y cell viability at all tested concentrations.; B. MGO downregulated both miR-125b and miR-107 expression.; C. MGO exposure did not affect oxidative stress-related gene expression.; D. MGO upregulated miR-125b and oxidative stress pathway genes while downregulating miR-107.",
            "correct_option": "D",
            "pmid": "pmid39206401"
        },
        "genetic_109": {
            "question": "What is the association between the -116C/G polymorphism of XBP1 and Alzheimer's disease?",
            "options": "A. No significant association; B. Increased susceptibility for AD; C. Decreased risk of AD; D. Protective effect against AD",
            "correct_option": "B",
            "pmid": "pmid23421912"
        },
        "genetic_110": {
            "question": "Which ABCA1 polymorphism was found to significantly increase the risk of Alzheimer's disease when homozygous in APOE epsilon4 carriers?",
            "options": "A. R219K; B. I883M; C. C-14T; D. C-477T",
            "correct_option": "C",
            "pmid": "pmid17510946"
        },
        "genetic_111": {
            "question": "How does the p.N370S GBA variant affect Alzheimer's disease risk?",
            "options": "A. It increases the risk of Alzheimers disease by 10 times.; B. It decreases lysosomal enzyme activity; potentially contributing to Alzheimers pathology.; C. It has no effect on Alzheimers disease risk.; D. It improves cognitive outcomes in Alzheimers disease.",
            "correct_option": "B",
            "pmid": "pmid36901867"
        },
        "genetic_112": {
            "question": "How do mutations in presenilin 1 (PS1) linked to Alzheimer's disease affect the balance between NF-kappaB and CHOP in neurons?",
            "options": "A. They decrease NF-kappaB activation and increase CHOP expression; B. They increase NF-kappaB activation and decrease CHOP expression; C. They have no effect on the balance between NF-kappaB and CHOP; D. They increase both NF-kappaB activation and CHOP expression",
            "correct_option": "B",
            "pmid": "pmid17927985"
        },
        "genetic_113": {
            "question": "Which APOE isoform was found to exacerbate TDP-43 related toxicity in the absence of Alzheimer pathology?",
            "options": "A. APOE2; B. APOE3; C. APOE4; D. Apoe-KO",
            "correct_option": "A",
            "pmid": "pmid36546684"
        },
        "genetic_114": {
            "question": "TMCC2 is associated with Alzheimer's disease (AD) via its interaction with which protein central to AD pathogenesis?",
            "options": "A. Amyloid protein precursor (APP); B. Tau protein; C. Beta-amyloid (Abeta); D. Methoxy-X04",
            "correct_option": "A",
            "pmid": "pmid39084860"
        },
        "genetic_115": {
            "question": "Which polymorphism of CHAT is associated with an increased risk of Alzheimer's disease in whites?",
            "options": "A. Rs1880676; B. Rs2177369; C. Rs3810950; D. Rs868750",
            "correct_option": "B",
            "pmid": "pmid27272392"
        },
        "genetic_116": {
            "question": "Which gene associated with attention function in adult ADHD has also been linked to Alzheimer's disease?",
            "options": "A. SORCS2; B. NUAK1; C. FGF20; D. DLG2",
            "correct_option": "A",
            "pmid": "pmid26174813"
        },
        "genetic_117": {
            "question": "Which gene is identified as a risk-modifying gene in Alzheimer's disease (AD) and is co-regulated with APOE in glial cells?",
            "options": "A. PGRN; B. FCGR3A; C. CTSH; D. APOE",
            "correct_option": "D",
            "pmid": "pmid38699303"
        },
        "genetic_118": {
            "question": "Which gene variant is associated with susceptibility to Thalidomide Embryopathy (TE) and may influence the CRL4-Cereblon complex's function, potentially relevant to delirium susceptibility?",
            "options": "A. CRBN; B. CUL4A; C. IKZF1; D. IKZF3",
            "correct_option": "B",
            "pmid": "pmid31964914"
        },
        "genetic_119": {
            "question": "Which molecule's activation is necessary for SREBP1 activation and lipogenesis in lipid-droplet-accumulating microglia in Alzheimer's disease?",
            "options": "A. TRPV1; B. PKM2; C. SREBP1; D. Capsaicin",
            "correct_option": "B",
            "pmid": "pmid39809738"
        },
        "genetic_120": {
            "question": "How does the expression of Apolipoprotein D (apoD) compare in Alzheimer's disease (AD) versus Frontotemporal Dementia (FTD)?",
            "options": "A. apoD is downregulated in both AD and FTD.; B. apoD is upregulated in AD but not affected in FTD.; C. apoD is upregulated in both AD and FT; D. apoD is downregulated in AD but upregulated in FTD.",
            "correct_option": "B",
            "pmid": "pmid30467822"
        },
        "genetic_121": {
            "question": "Which of the following is a key metabolic gene downregulated in Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)?",
            "options": "A. ATP1A1; B. BDNF; C. APP; D. APOE",
            "correct_option": "A",
            "pmid": "pmid32461378"
        },
        "genetic_122": {
            "question": "Which of the following SNPs in the ABCA7 gene was found to be significantly associated with an increased risk of Alzheimer's disease (AD) in the meta-analysis?",
            "options": "A. rs3764650; B. rs3752246; C. rs4147929; D. rs3752232",
            "correct_option": "A",
            "pmid": "pmid39484364"
        },
        "genetic_124": {
            "question": "Which statement best describes the role of alanine-to-threonine (A-to-T) substitutions related to Alzheimer’s disease?",
            "options": "A. A-to-T substitutions reduce beta-sheet formation and inhibit amyloid fibril development.; B. These substitutions increase protein solubility and protect against neurodegeneration.; C. The A539T substitution in BChE-K shows no relevance to amyloid-related pathology.; D. A-to-T substitutions, such as A539T in BChE-K, favor beta-sheet formation and may promote amyloid fibril aggregation.",
            "correct_option": "D",
            "pmid": "pmid20060816"
        },
        "genetic_125": {
            "question": "Which haplotype of the ACAT1 gene is associated with a protective effect against the development of Alzheimer's disease?",
            "options": "A. CGCA; B. CGGA; C. ACAT; D. APOE",
            "correct_option": "A",
            "pmid": "pmid33057949"
        },
        "genetic_126": {
            "question": "In Alzheimer's disease, overexpression of SRF and MYOCD in cerebral vascular smooth muscle cells leads to which outcome?",
            "options": "A. Increased Abeta clearance; B. Reduced Abeta clearance; C. Enhanced mitochondrial function; D. Improved cognitive outcomes",
            "correct_option": "B",
            "pmid": "pmid19098903"
        },
        "genetic_127": {
            "question": "Which miRNA is implicated in alleviating fibrosis and inflammatory responses in tendon cells by targeting NFAT5, a process that may have implications for conditions like Alzheimer's disease?",
            "options": "A. miR-192-5p; B. miR-193-5p; C. miR-200-5p; D. miR-212-5p",
            "correct_option": "A",
            "pmid": "pmid35836925"
        },
        "genetic_128": {
            "question": "Which ABC transporter variant was significantly associated with Alzheimer's disease risk after logistic regression analysis?",
            "options": "A. ABCA7 rs3752246; B. ABCB1 rs2032582; C. ABCC2 rs3740066; D. ABCG2 rs717620",
            "correct_option": "C",
            "pmid": "pmid23556446"
        },
        "genetic_129": {
            "question": "Which allele of the TNF-alpha gene was found to increase the risk of Alzheimer's disease, especially in individuals with the apolipoprotein E epsilon4 allele?",
            "options": "A. C allele; B. T allele; C. HLA-DR allele; D. APOE epsilon3 allele",
            "correct_option": "B",
            "pmid": "pmid11273064"
        },
        "genetic_130": {
            "question": "Which gene's expression is increased during the acute phase (7-30 days) after brain ischemia in the CA3 area of the hippocampus, potentially contributing to Alzheimer's disease progression?",
            "options": "A. LRP1; B. RAGE; C. Amyloid-beta precursor protein (APP); D. Tau protein",
            "correct_option": "B",
            "pmid": "pmid38067191"
        },
        "genetic_131": {
            "question": "Which of the following best describes the role of the APH1B T27I variant in Alzheimer's disease?",
            "options": "A. It significantly increases the risk of developing Alzheimers disease.; B. It is associated with a decrease in gamma-secretase activity.; C. It shows no discernable impact on gamma-secretase processing of substrates.; D. It causes mutations in the genes encoding nicastrin (NCT) or PEN-2.",
            "correct_option": "C",
            "pmid": "pmid31995180"
        },
        "genetic_132": {
            "question": "Which genetic risk factors for Alzheimer's disease were associated with larger EEA1 puncta volume in fibroblasts?",
            "options": "A. ABCA1; COX7C; and MYO15A; B. APOE; BACE1; and PSEN1; C. MAPT; GRN; and C9ORF72; D. SNCA; LRRK2; and GBA",
            "correct_option": "A",
            "pmid": "pmid36788216"
        },
        "genetic_133": {
            "question": "In studies examining the effects of statins on Alzheimer’s disease (AD)-related gene expression, which of the following was observed after simvastatin treatment in both astrocytes and neuroblastoma cells?",
            "options": "A. Significant reduction in ABCA1 gene expression; B. Increased expression of apolipoprotein E; C. Decreased expression of amyloid precursor protein; D. No change in expression of tau protein.",
            "correct_option": "A",
            "pmid": "pmid19461118"
        },
        "genetic_134": {
            "question": "Which TFAM SNP was associated with an increased risk of Alzheimer disease in females?",
            "options": "A. rs1937 G/G; B. rs2306604 A/G; C. Both A and B; D. Neither A nor B",
            "correct_option": "A",
            "pmid": "pmid15464268"
        },
        "genetic_135": {
            "question": "Which variant of TREM2 increases the risk of Alzheimer's disease?",
            "options": "A. Wild-type sTREM2; B. R47H variant; C. sTREM2 with increased Abeta binding; D. sTREM2 that inhibits Abeta aggregation",
            "correct_option": "B",
            "pmid": "pmid33823153"
        },
        "genetic_136": {
            "question": "How does the overexpression of SAA1 affect Alzheimer's disease progression?",
            "options": "A. It reduces amyloid aggregation.; B. It exacerbates glial activation and memory decline.; C. It decreases neuronal inflammation.; D. It improves cognitive function.",
            "correct_option": "B",
            "pmid": "pmid31407125"
        },
        "genetic_137": {
            "question": "Which transcription factor's regulated gene set was downregulated in the hippocampus after MDMA treatment, potentially contributing to chronic impairments similar to those seen in Alzheimer's disease?",
            "options": "A. Oct1; B. Vitamin D Receptor (VDR); C. FoxO1; D. Sp3",
            "correct_option": "B",
            "pmid": "pmid30559663"
        },
        "genetic_138": {
            "question": "Which TREM1 variant was associated with amyloid-beta deposition in Alzheimer's disease?",
            "options": "A. rs2234246A; B. rs2234246B; C. rs2234246C; D. rs2234246D",
            "correct_option": "A",
            "pmid": "pmid31721052"
        },
        "genetic_139": {
            "question": "Which PPAR-gamma haplotype was found to have a protective effect against Alzheimer's disease in APOE epsilon4 allele noncarriers?",
            "options": "A. TCCA haplotype; B. CCCT haplotype; C. GGGT haplotype; D. AAAT haplotype",
            "correct_option": "A",
            "pmid": "pmid19660836"
        },
        "genetic_140": {
            "question": "What is the therapeutic potential of targeting DAT1 in Alzheimer's disease?",
            "options": "A: Enhancing dopamine reuptake to improve memory retrieval.; B: Reducing inflammation in the brain.; C: Increasing amyloid-beta clearance from the brain.; D: Promoting neurogenesis in the hippocampus.",
            "correct_option": "A",
            "pmid": "pmid29423319"
        },
        "genetic_141": {
            "question": "How does SGPT expression vary across disease stages in delirium tremens?",
            "options": "A: SGPT levels increase with the severity of DT.; B: SGPT levels decrease between admission and recovery in grade 2 patients.; C: SGPT levels remain constant across all stages of DT.; D: SGPT levels are higher in grade 3 patients due to liver damage.",
            "correct_option": "B",
            "pmid": "pmid7211434"
        },
        "genetic_142": {
            "question": "How does P-selectin contribute to delirium-related CNS damage?",
            "options": "A: By promoting adhesion of leukocytes to endothelial cells.; B: By increasing the production of pNF-H.; C: By inhibiting BBB disruption.; D: By reducing neuroinflammation.",
            "correct_option": "A",
            "pmid": "pmid31574089"
        },
        "genetic_143": {
            "question": "What is the role of TFEB in Alzheimer's disease?",
            "options": "A: Enhances lysosomal function and autophagy; B: Reduces beta-amyloid accumulation; C: Promotes the transport of APP to the lysosome; D: Prevents the cleavage of APP into CTFbeta",
            "correct_option": "A",
            "pmid": "pmid31164812"
        },
        "genetic_144": {
            "question": "How is RCAN1 expression altered in Alzheimer's disease?",
            "options": "A: RCAN1 is significantly elevated in both WBCs and brain tissue of AD patients.; B: RCAN1 is significantly elevated in AD brain tissue but not in WBCs.; C: RCAN1 is downregulated in both WBCs and brain tissue of AD patients.; D: RCAN1 levels remain unchanged in both WBCs and brain tissue of AD patients.",
            "correct_option": "B",
            "pmid": "pmid31263630"
        },
        "genetic_145": {
            "question": "What is the therapeutic potential of targeting ACE2 in Alzheimer's disease?",
            "options": "A: Targeting ACE2 could worsen cognitive impairment.; B: Targeting ACE2 could enhance neuroprotection and slow disease progression.; C: Targeting ACE2 has no therapeutic potential in Alzheimers disease.; D: Targeting ACE2 would increase the risk of neurodegeneration.",
            "correct_option": "B",
            "pmid": "pmid33197881"
        },
        "genetic_146": {
            "question": "How is NPTX2 expression altered in delirium?",
            "options": "A: NPTX2 levels are significantly lower in patients with delirium.; B: NPTX2 levels are significantly higher in patients with delirium.; C: NPTX2 levels remain unchanged across different stages of delirium.; D: NPTX2 levels fluctuate unpredictably in delirium patients.",
            "correct_option": "A",
            "pmid": "pmid38741580"
        },
        "genetic_147": {
            "question": "What is the role of rSO2 at T4 in delirium?",
            "options": "A: It is associated with an increased risk of delirium.; B: It is used to diagnose delirium.; C: It is a treatment for delirium.; D: It is unrelated to delirium.",
            "correct_option": "A",
            "pmid": "pmid36405895"
        },
        "genetic_148": {
            "question": "What is the role of EGFL7 in Alzheimer's disease?",
            "options": "A: It is involved in the regulation of synaptic signaling.; B: It is associated with increased angiogenesis in the brain.; C: It contributes to immune activation in AD.; D: It promotes the differentiation of oligodendrocytes.",
            "correct_option": "B",
            "pmid": "pmid32989152"
        },
        "genetic_149": {
            "question": "What is the role of E4BP4 in delirium?",
            "options": "A: E4BP4 promotes microglial activation by activating the ERK1/2 signaling pathway.; B: E4BP4 inhibits ERK1/2 signaling by trans-repressing Mapk1/3.; C: E4BP4 increases long-term potentiation in the hippocampus.; D: E4BP4 enhances circadian rhythm disturbances in delirium.",
            "correct_option": "B",
            "pmid": "pmid35713240"
        },
        "genetic_150": {
            "question": "What is the role of SOAT-1 in delirium?",
            "options": "A: It provides augmented protection against stress; reducing the risk of delirium.; B: It has no significant role in the appearance of delirium after bypass heart surgery.; C: It is associated with a higher frequency of delirium post-surgery.; D: It contributes to cognitive decline; which is a precursor to delirium.",
            "correct_option": "B",
            "pmid": "pmid17593314"
        },
        "genetic_151": {
            "question": "How is NLR expression altered in delirium?",
            "options": "A: NLR levels increase significantly during the onset of delirium.; B: NLR levels decrease during the onset of delirium.; C: NLR levels remain unchanged compared to baseline.; D: NLR levels are higher in non-delirium patients.",
            "correct_option": "A",
            "pmid": "pmid34912245"
        },
        "genetic_152": {
            "question": "What is the role of LPS in Alzheimer's disease?",
            "options": "A: LPS is involved in the degradation of myelin basic protein (MBP).; B: LPS decreases cytokine production mediated by NFkB.; C: LPS promotes amyloid-beta (Abeta) degradation.; D: LPS reduces blood-brain barrier permeability.",
            "correct_option": "A",
            "pmid": "pmid29520228"
        },
        "genetic_153": {
            "question": "What is the role of GAD65 in delirium?",
            "options": "A: It is a neural autoantibody associated with delirium.; B: It is a neurotransmitter involved in synaptic plasticity.; C: It is a receptor that binds alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.; D: It is an enzyme that converts leucine to isoleucine.",
            "correct_option": "A",
            "pmid": "pmid34757245"
        },
        "genetic_154": {
            "question": "How does DIO2 contribute to the development of Alzheimer's disease?",
            "options": "A: By potentially influencing cognitive performance through thyroid hormone metabolism.; B: By promoting the deposition of amyloid-beta plaques.; C: By increasing neuroinflammation.; D: By impairing synaptic plasticity.",
            "correct_option": "A",
            "pmid": "pmid35629879"
        },
        "genetic_155": {
            "question": "What is the role of FABP3 in delirium?",
            "options": "A: It is released following brain injury and correlates with neurodegenerative biomarkers.; B: It is a cytoplasmic neuronal protein unrelated to delirium.; C: It acts as a therapeutic target for delirium.; D: It is downregulated in delirium patients compared to controls.",
            "correct_option": "A",
            "pmid": "pmid32804136"
        },
        "genetic_156": {
            "question": "What is the therapeutic potential of targeting SLC6A3 in Alzheimer's disease?",
            "options": "A: Modulating SLC6A3 activity could alleviate symptoms through condensate-based risk action.; B: Targeting SLC6A3 could help reduce alcohol use disorder-related symptoms.; C: SLC6A3 modulation might improve attention-deficit/hyperactivity disorder in Alzheimers patients.; D: SLC6A3 targeting is a well-established treatment for movement disorders.",
            "correct_option": "A",
            "pmid": "pmid34650206"
        },
        "genetic_157": {
            "question": "What is the role of CCL2 in delirium?",
            "options": "A: It decreases neuroinflammation.; B: It is associated with the development of delirium and may play a role in its pathophysiology.; C: It improves blood-brain barrier integrity.; D: It reduces leukocyte extravasation into brain parenchyma.",
            "correct_option": "B",
            "pmid": "pmid35815182"
        },
        "genetic_158": {
            "question": "How does plasma GFAP correlate with CSF GFAP in delirium?",
            "options": "A: Plasma GFAP correlates significantly with CSF GFAP.; B: Plasma GFAP shows no correlation with CSF GFAP.; C: Plasma GFAP is inversely correlated with CSF GFAP.; D: Plasma GFAP and CSF GFAP are unrelated in delirium.",
            "correct_option": "A",
            "pmid": "pmid38161287"
        },
        "genetic_159": {
            "question": "What is the role of HIF-1 in delirium?",
            "options": "A: HIF-1 promotes neuronal apoptosis in delirium.; B: HIF-1 has a neuroprotective role by regulating multiple pathways such as glucose metabolism and angiogenesis.; C: HIF-1 increases the risk of postoperative complications in elderly patients.; D: HIF-1 inhibits cerebral desaturation during general anesthesia.",
            "correct_option": "B",
            "pmid": "pmid37773821"
        },
        "genetic_160": {
            "question": "What is the role of CRP in TBI-related delirium?",
            "options": "A: CRP levels are associated with the risk of emotional symptoms in TBI patients.; B: CRP levels are inversely related to self-efficacy in TBI patients.; C: CRP levels are unaffected by delirium in TBI patients.; D: CRP levels are solely responsible for the development of delirium in TBI patients.",
            "correct_option": "A",
            "pmid": "pmid39554848"
        },
        "genetic_161": {
            "question": "What is the role of tyrosine hydroxylase (TH) in delirium?",
            "options": "A: TH activity is increased during severe abstinence disorders.; B: TH activity is decreased during delirium.; C: TH activity remains unchanged across all disease stages.; D: TH activity is normalized after discontinuation of delirium.",
            "correct_option": "A",
            "pmid": "pmid1971467"
        },
        "genetic_162": {
            "question": "What is the therapeutic potential of targeting JUN in Alzheimer's disease?",
            "options": "A: JUN modulation can alleviate neuroinflammation and improve cognitive outcomes.; B: Targeting JUN can lead to increased neurodegeneration in Alzheimers disease.; C: JUN is a potential target for modulating tumor necrosis factor signaling.; D: JUN targeting can reduce the expression of interleukin 17 in Alzheimers disease.",
            "correct_option": "A",
            "pmid": "pmid35992596"
        },
        "genetic_163": {
            "question": "How is AQP4 expression altered in Alzheimer's disease?",
            "options": "A: It is downregulated in the hippocampus and cortex.; B: It is upregulated in perivascular regions during infection.; C: It remains unchanged across different disease stages.; D: It is downregulated in response to amyloid-beta accumulation.",
            "correct_option": "B",
            "pmid": "pmid37013549"
        },
        "genetic_164": {
            "question": "What is the therapeutic potential of targeting PMAT in Alzheimer's disease?",
            "options": "A: Modulating PMAT could reduce the sensitivity to amisulpride in AD patients.; B: Targeting PMAT could increase the brain uptake of haloperidol.; C: PMAT targeting could improve BBB function in AD.; D: PMAT modulation could enhance the clearance of amyloid-beta from the brain.",
            "correct_option": "A",
            "pmid": "pmid31842924"
        },
        "genetic_165": {
            "question": "Which of the following statements best reflects the genetic or molecular contribution to the development of delirium in patients with acute pancreatitis, as indicated by recent evidence?",
            "options": "A. Serum RIP3 levels decrease with increasing disease severity and are not associated with delirium.; B. Elevated serum levels of RIP3, a necroptosis-related kinase, are independently associated with greater disease severity and increased risk of in-hospital delirium.; C. The relationship between RIP3 expression and delirium is only significant in elderly patients with low BMI.; D. RIP3 functions primarily as an anti-inflammatory cytokine and is unrelated to cell death or delirium mechanisms.",
            "correct_option": "B",
            "pmid": "pmid39569322"
        },
        "genetic_166": {
            "question": "Is PS1 a potential therapeutic target for Alzheimer's disease?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid28741167"
        },
        "genetic_167": {
            "question": "What is the therapeutic potential of targeting IL6R in delirium?",
            "options": "A: Targeting IL6R is a promising approach for treating delirium.; B: Targeting IL6R has shown significant therapeutic benefits in animal research.; C: Targeting IL6R could alleviate symptoms of delirium in elderly patients.; D: There is no evidence supporting the therapeutic potential of targeting IL6R in delirium.",
            "correct_option": "D",
            "pmid": "pmid21851175"
        },
        "genetic_168": {
            "question": "What is the role of PARP1 in Alzheimer's Disease?",
            "options": "A: It decreases histone serine-ADP-ribosylation.; B: It mediates DNA repair processes.; C: It increases tyrosine levels in the serum.; D: It promotes neurodegeneration.",
            "correct_option": "B",
            "pmid": "pmid35688816"
        },
        "genetic_169": {
            "question": "What is the therapeutic potential of targeting NF-kappaB in delirium?",
            "options": "A: Enhancing its activity could reduce neuroinflammation.; B: Inhibiting its translocation could alleviate delirium symptoms.; C: Increasing its expression could improve cognitive outcomes.; D: Activating it could enhance the anti-inflammatory effect of DEX.",
            "correct_option": "B",
            "pmid": "pmid36077505"
        },
        "genetic_170": {
            "question": "How does HTR1A contribute to the development of delirium?",
            "options": "A: It is a key receptor involved in modulating neuroinflammation.; B: It directly causes the release of scopolamine in the brain.; C: Its antagonism leads to increased monoamine concentrations.; D: It enhances cognitive functions and prevents delirium.",
            "correct_option": "A",
            "pmid": "pmid27760517"
        },
        "genetic_171": {
            "question": "What is the role of myeloperoxidase-DNA in delirium?",
            "options": "A: It is a marker of neuronal damage in delirium.; B: It indicates neuroinflammation and neutrophil extracellular traps.; C: It serves as a therapeutic target for delirium.; D: It is a biomarker for cognitive decline in delirium.",
            "correct_option": "B",
            "pmid": "pmid39737468"
        },
        "genetic_172": {
            "question": "How is HLA-DR expression altered in delirium?",
            "options": "A: It is significantly higher in delirium patients compared to controls.; B: It is not detectable in delirium patients.; C: It decreases with the progression of the disease.; D: It is only elevated in the white matter.",
            "correct_option": "A",
            "pmid": "pmid21978081"
        },
        "genetic_173": {
            "question": "What is the role of NG2 in Alzheimer's disease?",
            "options": "A: NG2 is involved in maintaining blood-brain barrier integrity.; B: NG2 is responsible for clearing amyloid-beta plaques.; C: NG2 promotes neurogenesis in Alzheimers disease.; D: NG2 increases synaptic plasticity in affected neurons.",
            "correct_option": "A",
            "pmid": "pmid29453790"
        },
        "genetic_174": {
            "question": "What is the role of CXCL2 in Alzheimer's disease?",
            "options": "A: It promotes neuroprotection by reducing neuroinflammation.; B: It exacerbates neuronal loss and cognitive decline.; C: It enhances cognitive performance by improving synaptic plasticity.; D: It decreases anxiety-like behavior by modulating neurotransmitter systems.",
            "correct_option": "B",
            "pmid": "pmid39605963"
        },
        "genetic_175": {
            "question": "What is the spatial expression pattern of NPY in the brain regions affected by Alzheimers disease?",
            "options": "A: NPY is highly expressed in the basal ganglia.; B: NPY is reduced in the frontal and occipital regions.; C: NPY is increased in the cortical regions.; D: NPY is expressed in cerebrovascular regions.",
            "correct_option": "A",
            "pmid": "pmid36670121"
        },
        "genetic_176": {
            "question": "What is a notable difference between genetic findings in non–alcohol withdrawal delirium and alcohol withdrawal delirium?",
            "options": "A. Most genetic findings in non–alcohol withdrawal delirium involve APOE, while dopamine-related genes are more often linked to alcohol withdrawal delirium; B. Genetic associations in non–alcohol withdrawal delirium are reported more frequently than those in alcohol withdrawal delirium; C. DRD3 is consistently linked to alcohol withdrawal delirium across all available data; D. APOE is consistently protective against the onset of non–alcohol withdrawal delirium.",
            "correct_option": "A",
            "pmid": "pmid19219710"
        },
        "genetic_177": {
            "question": "What is the therapeutic potential of targeting RUNX3 in Alzheimer's disease?",
            "options": "A: It could restore immune cell function; potentially slowing disease progression.; B: It might reduce neuroinflammation by targeting microglial activation.; C: It could increase amyloid-beta deposition in the brain.; D: It might enhance beta-amyloid clearance from the brain.",
            "correct_option": "A",
            "pmid": "pmid35282112"
        },
        "genetic_178": {
            "question": "What is the therapeutic potential of targeting MAOA in Alzheimer's disease?",
            "options": "A: It can increase the effectiveness of immune checkpoint inhibitors.; B: It can alleviate symptoms by modulating neurotransmitter levels.; C: It can reduce the production of amyloid-beta plaques.; D: It can enhance memory formation and retrieval.",
            "correct_option": "A",
            "pmid": "pmid38349393"
        },
        "genetic_179": {
            "question": "How is RNF146 expression altered in delirium?",
            "options": "A: It is upregulated after anesthesia and surgery.; B: It remains constant throughout the disease stages.; C: It is downregulated in the hippocampus.; D: It is only expressed during the early stages of delirium.",
            "correct_option": "A",
            "pmid": "pmid37883680"
        },
        "genetic_180": {
            "question": "Is DAT differentially expressed in single-cell transcriptomic profiles of agitated cocaine delirium?",
            "options": "A: Yes; B: No",
            "correct_option": "A",
            "pmid": "pmid10581411"
        },
        "genetic_181": {
            "question": "What is the therapeutic potential of targeting HSV1 in Alzheimer's Disease?",
            "options": "A: It can completely cure Alzheimers Disease in all patients.; B: It can reduce the risk of disease progression in APOE-epsilon4 carriers.; C: It has no potential as HSV1 is not implicated in Alzheimers Disease.; D: It increases the risk of neurodegeneration.",
            "correct_option": "B",
            "pmid": "pmid34205498"
        },
        "genetic_182": {
            "question": "How is DRD1 expression altered in Alzheimer's disease?",
            "options": "A: It is upregulated in affected brain regions.; B: It is downregulated in the superior temporal gyrus.; C: It remains unchanged compared to controls.; D: It varies unpredictably across disease stages.",
            "correct_option": "B",
            "pmid": "pmid27336024"
        },
        "genetic_183": {
            "question": "What is the role of OAS1 in Alzheimer's disease?",
            "options": "A: It acts as a genetic link between Alzheimers disease and COVID-19.; B: It regulates the production of beta-amyloid plaques.; C: It is involved in the inflammatory response to neurodegeneration.; D: It promotes the clearance of tau proteins.",
            "correct_option": "A",
            "pmid": "pmid38259635"
        },
        "genetic_184": {
            "question": "What is the role of IL1RL1 in Alzheimer's disease?",
            "options": "A: It increases soluble ST2 levels and worsens AD pathology.; B: It decreases soluble ST2 levels and reduces AD risk in APOE-epsilon4 carriers.; C: It enhances amyloid-beta clearance and microglial activation.; D: It modulates interleukin-33 signaling in AD pathogenesis.",
            "correct_option": "B",
            "pmid": "pmid37117777"
        },
        "genetic_185": {
            "question": "Which of the following molecular features was specifically highlighted as a potential therapeutic target based on genetic and protein-level analysis of plasma exosomes in patients with postoperative delirium?",
            "options": "A. APOE4 polymorphism and its modulation of tau phosphorylation; B. SLC6A3 gene expression in relation to dopamine signaling; C. COMT gene variation affecting prefrontal dopamine levels; D. Upregulation of MMP9, supported by molecular docking of small molecules such as mirin and orantinib.",
            "correct_option": "D",
            "pmid": "pmid39604493"
        },
        "genetic_186": {
            "question": "How does ACE2 expression vary across disease stages in Alzheimer's disease?",
            "options": "A: ACE2 expression decreases as Alzheimers disease progresses.; B: ACE2 expression is highest in the early stages of Alzheimers disease.; C: ACE2 expression is not significantly altered across disease stages.; D: ACE2 expression is consistently low across all stages of Alzheimers disease.",
            "correct_option": "B",
            "pmid": "pmid36291338"
        },
        "genetic_187": {
            "question": "How is PD-1 expression altered in Alzheimer's Disease?",
            "options": "A: PD-1 expression is significantly increased in all T cell subsets.; B: PD-1 expression is similar between AD patients and healthy volunteers.; C: PD-1 expression is decreased in CD8+ T cells specifically.; D: PD-1 expression is downregulated in CD4+ T cells.",
            "correct_option": "B",
            "pmid": "pmid36180897"
        },
        "genetic_188": {
            "question": "What is the role of NQO2 in Alzheimer's disease?",
            "options": "A: It is involved in quinone metabolism and may contribute to oxidative stress.; B: It acts as a detoxifying enzyme for antitumor drugs.; C: It regulates alcoholism and nervous system drug toxicity.; D: It is associated with cognitive decline and neurodegeneration.",
            "correct_option": "D",
            "pmid": "pmid38254976"
        },
        "genetic_190": {
            "question": "What is the role of ACE2R in delirium?",
            "options": "A: Acts as an entry point for SARS-CoV-2; potentially affecting neuronal and glial cells.; B: Regulates blood pressure exclusively.; C: Serves as a primary marker for Alzheimers disease.; D: Promotes synaptic plasticity in the brainstem.",
            "correct_option": "A",
            "pmid": "pmid37172190"
        },
        "genetic_191": {
            "question": "What is the therapeutic potential of targeting GRIN2B in Alzheimer's disease?",
            "options": "A: Enhancing synaptic plasticity and cognitive function.; B: Reducing inflammation in brain tissues.; C: Increasing insulin sensitivity in neurons.; D: Preventing amyloid-beta plaques formation.",
            "correct_option": "A",
            "pmid": "pmid30475886"
        },
        "genetic_192": {
            "question": "Which genotypes are associated with decreased odds of incident delirium in elderly post-surgical patients?",
            "options": "A. KLOTHO and SIRT1; B. KIBRA, MTNR1B, and KLOTHO; C. FKBP5, KLOTHO, and SIRT1; D. KIBRA, MTNR1B, and FKBP5",
            "correct_option": "D",
            "pmid": "pmid35017578"
        },
        "genetic_193": {
            "question": "Does cardiac surgery trigger NLRP3 inflammasome activation?",
            "options": "A. Yes; B. No; C. Possibly, but only in young mice; D. The context does not mention NLRP3 inflammasome activation",
            "correct_option": "A",
            "pmid": "pmid37968531"
        },
        "genetic_194": {
            "question": "What was the finding regarding the association between IGF-1 levels and delirium in this study?",
            "options": "A. IGF-1 levels were found to significantly increase the risk of delirium.; B. IGF-1 levels were associated with a reduced duration of normal mental state.; C. This study found no association between IGF-1 and delirium.; D. Elevated IGF-1 levels were protective against delirium.",
            "correct_option": "C",
            "pmid": "pmid21294938"
        },
        "genetic_195": {
            "question": "What was the adjusted odds ratio (OR) for delirium in sigma4 carriers compared to non-sigma4 carriers, accounting for age, cognitive, and functional impairment?",
            "options": "A. 1.1 (95% CI: 0.9-2.7); B. 2.6 (95% CI: 1.1-2.7); C. 1.7 (95% CI: 0.9-2.6); D. 1.7 (95% confidence interval [CI]: 1.1-2.6)",
            "correct_option": "D",
            "pmid": "pmid19910874"
        },
        "genetic_197": {
            "question": "Was cathepsin-B identified as a biomarker in the study?",
            "options": "A. No, it was not identified.; B. Yes, it was identified.; C. It was only identified in the validation set.; D. It was identified as a signature of exposure to CPB.",
            "correct_option": "B",
            "pmid": "pmid36567636"
        },
        "genetic_198": {
            "question": "What temperature was the mean core body temperature recorded in excited delirium deaths?",
            "options": "A. 37.0 degrees C; B. 39.2 degrees C; C. 42.1 degrees C; D. 40.7 degrees C",
            "correct_option": "D",
            "pmid": "pmid19541436"
        },
        "genetic_199": {
            "question": "What was the median cerebrospinal fluid apolipoprotein E level in LOAD outpatients?",
            "options": "A. 9.55 mug/mL [5.65-15.05]; B. 12.00 mug/mL [8.00-16.00]; C. 22.00 mug/mL [18.00-26.00]; D. 16.86 mug/mL [14.82-20.88]",
            "correct_option": "D",
            "pmid": "pmid28868067"
        },
        "genetic_200": {
            "question": "At what locations does PLK1 phosphorylate Drosha?",
            "options": "A. S301 and S303; B. S299 and S301; C. S300 and/or S302; D. S303 and/or S305",
            "correct_option": "C",
            "pmid": "pmid37762595"
        },
        "genetic_201": {
            "question": "Does the upregulation of miR-204-5p lead to the death of dopaminergic cells by targeting DYRK1A-mediated apoptotic signaling?",
            "options": "A. Yes; B. No; C. Only in mouse models; D. Only in vitro",
            "correct_option": "A",
            "pmid": "pmid31572127"
        },
        "genetic_202": {
            "question": "In Neuro2a cells, how does miR-137 affect Abeta-induced neurotoxicity?",
            "options": "A. miR-137 enhances Abeta-induced neurotoxicity through activation of the NF-kappaB pathway by targeting TNFAIP1.; B. miR-137 attenuates Abeta-induced neurotoxicity through inactivation of the NF-kappaB pathway by targeting TNFAIP1.; C. miR-137 has no effect on Abeta-induced neurotoxicity.; D. miR-137 directly activates TNFAIP1, leading to increased neurotoxicity.",
            "correct_option": "B",
            "pmid": "pmid28655611"
        },
        "genetic_203": {
            "question": "Which genotypes of the rs2421943 polymorphism increase the risk of Alzheimer's disease?",
            "options": "A. CC and AA; B. AG and GG; C. TT and CG; D. Only AA",
            "correct_option": "B",
            "pmid": "pmid35236268"
        },
        "genetic_204": {
            "question": "According to this study, is ESR1 a promising target of the Yizhiqingxin formula against Alzheimer's disease and major depression disorder comorbidities?",
            "options": "A. Yes; B. No; C. Maybe; D. Possibly",
            "correct_option": "A",
            "pmid": "pmid35548356"
        },
        "genetic_205": {
            "question": "What amino acid change is caused by the T to C single nucleotide polymorphism (SNP) in the CPE gene at bp980?",
            "options": "A. Alanine to Threonine (A to T); B. Glycine to Serine (G to S); C. Proline to Leucine (P to L); D. Tryptophan to Arginine (W to R)",
            "correct_option": "D",
            "pmid": "pmid28114332"
        },
        "genetic_206": {
            "question": "In C9orf72 mutation carriers, does the rs7550295 variant in the CLSTN1 gene delay the age of disease onset?",
            "options": "A. Yes, by 8 years; B. No, it anticipates the onset; C. Yes, by 17 years; D. No, it has no effect on disease onset",
            "correct_option": "C",
            "pmid": "pmid39000564"
        },
        "genetic_207": {
            "question": "How does the UAF1 deubiquitinase complex affect NLRP3 and pro-IL-1beta expression?",
            "options": "A. It enhances NLRP3 and pro-IL-1beta expression by targeting NLRP3 and p65.; B. It decreases NLRP3 and pro-IL-1beta expression by promoting ubiquitination.; C. It has no effect on NLRP3 or pro-IL-1beta expression.; D. It reduces NLRP3 expression while increasing pro-IL-1beta expression.",
            "correct_option": "A",
            "pmid": "pmid33247121"
        },
        "genetic_208": {
            "question": "Which genetic variant was found to act as a protective factor against late-onset Alzheimer's disease (LOAD)?",
            "options": "A. rs3764650 ABCA7; B. rs6656401 CR1; C. rs610932 MS4A6A; D. rs3865444 CD33",
            "correct_option": "D",
            "pmid": "pmid28477215"
        },
        "genetic_209": {
            "question": "Which of the following AKT1 alleles are considered protective factors for microscopic polyangiitis (MPA)?",
            "options": "A, rs2494752 A, rs5811155 delT; B. rs2498786 G, rs2494752 G, rs5811155 insT; C. rs2498786 T, rs2494752 C, rs5811155 delA; D. rs2498786 C, rs2494752 T, rs5811155 G",
            "correct_option": "B",
            "pmid": "pmid37029297"
        },
        "genetic_210": {
            "question": "Does the ACE insertion/deletion polymorphism affect the onset age of Alzheimer's disease?",
            "options": "A. Yes, regardless of APOE-epsilon4 carrier status.; B. No, it was not associated with age at dementia onset, regardless of APOE-epsilon4 carrier status.; C. Yes, but only in APOE-epsilon4 non-carriers.; D. Yes, but only in APOE-epsilon4 carriers.",
            "correct_option": "B",
            "pmid": "pmid34034613"
        },
        "genetic_211": {
            "question": "Which genetic variants in ERBB4 are associated with a reduced risk of chronic HBV infection?",
            "options": "A. rs1234567 A>G and rs9876543 C>T; B. rs6147151 Ins/Del and rs1836725 T>C; C. rs7147150 Ins/Del and rs1836724 T>T; D. rs6147150 Ins/Del and rs1836724 T>C",
            "correct_option": "D",
            "pmid": "pmid26701850"
        },
        "genetic_212": {
            "question": "What molecules are significantly affected by the deregulation of LRSAM1?",
            "options": "A. TP53, BRCA1, ATM, and CHEK2; B. KRAS, MYC, PIK3CA, and BRAF; C. CTNNB1, APC, AXIN1, and GSK3B; D. TSG101, UBE2N, VPS28, EGFR, and MDM2",
            "correct_option": "D",
            "pmid": "pmid30726272"
        },
        "genetic_213": {
            "question": "What effect does the CFH gene variant rs800292 have on CSF tau and Abeta levels?",
            "options": "A. Decreases both CSF tau and Abeta levels.; B. Decreases CSF tau levels and increases Abeta levels.; C. Increases both CSF tau and Abeta levels.; D. No effect on CSF tau and Abeta levels.",
            "correct_option": "C",
            "pmid": "pmid26243271"
        },
        "genetic_214": {
            "question": "Which gene's regulation by BIN1 is implicated in the inflammatory response during Alzheimer's disease pathogenesis?",
            "options": "A. Ifitm3; B. CX3CR1; C. PU.1; D. IRF1",
            "correct_option": "A",
            "pmid": "pmid35526014"
        },
        "genetic_215": {
            "question": "Which of the following genes are identified as Alzheimer's disease-related immune hub genes?",
            "options": "A. TLR4; B. IL-6; C. TNF-alpha; D. PIK3R1",
            "correct_option": "D",
            "pmid": "pmid32925027"
        },
        "genetic_216": {
            "question": "Which BDNF SNPs were significantly associated with measures of cognitive decline?",
            "options": "A. rs908867, rs11030094, rs6265; B. rs1157659, rs11030094, rs11030108; C. rs12273363, rs11030094, rs925946; D. rs1050187, rs2203877, rs11030104",
            "correct_option": "B",
            "pmid": "pmid24086677"
        },
        "genetic_217": {
            "question": "Which single nucleotide polymorphism (SNP) in the ATP7B gene showed a significant association with Alzheimer's disease under a recessive model?",
            "options": "A. rs1801243; B. rs1801244; C. rs1801249; D. rs1801250",
            "correct_option": "C",
            "pmid": "pmid23830383"
        },
        "genetic_218": {
            "question": "Which allele of the NEP gene locus rs701109 may be a potential risk factor for Alzheimer's disease in Tibetan males?",
            "options": "A. Allele A; B. Allele G; C. Allele T; D. Allele C",
            "correct_option": "D",
            "pmid": "pmid33314757"
        },
        "genetic_219": {
            "question": "Which gene variant was identified in a sub-cohort of VCI patients?",
            "options": "A. HTRA1; B. TREX1; C. COL4A1; D. MTHFR",
            "correct_option": "C",
            "pmid": "pmid35307828"
        },
        "genetic_220": {
            "question": "Does the 647C variant of the ENT1 (SLC29A1) gene have an association with alcohol withdrawal seizures?",
            "options": "A. No, it is only associated with alcohol dependence.; B. No, it has no association with alcohol-related conditions.; C. Yes, at a nominally significant level.; D. Yes, at a highly significant level.",
            "correct_option": "C",
            "pmid": "pmid21283641"
        },
        "genetic_221": {
            "question": "Which molecule, increased in Alzheimer's disease, negatively regulates synaptotagmin 1 (SYT1) through the ROS-JNK-p53 pathway?",
            "options": "A. miR-34c; B. ROS; C. p53; D. JNK",
            "correct_option": "A",
            "pmid": "pmid32092796"
        },
        "genetic_222": {
            "question": "Which gene was identified as an interactor of Drosophila VAPB in the genetic screen?",
            "options": "A. alsin2; B. Tsc1; C. S6K; D. Rapamycin",
            "correct_option": "A",
            "pmid": "pmid25361581"
        },
        "genetic_223": {
            "question": "Which genotype of the CHI3L1 rs4950928 C>G polymorphism is associated with a reduced risk of Alzheimer's disease?",
            "options": "A. CC; B. CG+GG; C. CT; D. TT",
            "correct_option": "B",
            "pmid": "pmid30223258"
        },
        "genetic_224": {
            "question": "Which gene encodes the alpha7 nicotinic acetylcholine receptor and has been implicated in various psychiatric and behavioral disorders, including schizophrenia?",
            "options": "A. DRD2; B. CHRNA7; C. GRIN2A; D. NRXN1",
            "correct_option": "B",
            "pmid": "pmid28045139"
        },
        "genetic_225": {
            "question": "What was discovered from tumor samples using in silico analysis?",
            "options": "A. Large deletions of the mitochondrial genome.; B. Recurrent tumor-associated somatic variants.; C. Three predicted pathogenic variants.; D. Correlation between clinical features and mtDNA variants.",
            "correct_option": "C",
            "pmid": "pmid36793390"
        },
        "genetic_226": {
            "question": "Which miRNA was identified as a potentially good candidate for treating both Alzheimer's disease and breast cancer?",
            "options": "A. miR-124-3p; B. miR-146a; C. miR-6785; D. miR-107",
            "correct_option": "D",
            "pmid": "pmid37487248"
        },
        "genetic_227": {
            "question": "Which genetic factor, when found with elevated blood MCP-1 levels, is associated with an increased risk of Alzheimer's disease?",
            "options": "A. HLA-DRB1 rs9271192-AA; B. APOE epsilon2; C. HLA-DRB1 rs9271192-AC/CC; D. APOE epsilon4",
            "correct_option": "C",
            "pmid": "pmid36396603"
        },
        "genetic_228": {
            "question": "Which of the following mechanisms may potentially link NPTX2 dysregulation to neurological conditions such as delirium?",
            "options": "A. NPTX2 demethylation enhances synaptic pruning via the mTORC1 pathway.; B. NPTX2 overexpression directly increases dopamine receptor D3 activity.; C. NPTX2 promotes blood-brain barrier permeability by downregulating ICAM1.; D. NPTX2 hypermethylation may suppress p53 signaling, affecting neuronal apoptosis and plas.",
            "correct_option": "D",
            "pmid": "pmid33896384"
        },
        "genetic_229": {
            "question": "Which of the following genes showed a positive correlation with gamma delta T cell expression?",
            "options": "A. CXCL10; B. CXCL13; C. S100A2; D. CXCL11",
            "correct_option": "C",
            "pmid": "pmid35432485"
        },
        "genetic_230": {
            "question": "Which gene associated with Alzheimer's disease is upregulated by a constitutively active IRF3 in microglia?",
            "options": "A. Apolipoprotein-e; B. Z-DNA binding protein-1 (ZBP1); C. TLR4; D. Interferon Regulatory Factor 3 (IRF3)",
            "correct_option": "A",
            "pmid": "pmid39215356"
        },
        "genetic_231": {
            "question": "What optimal cutoff value of DAO levels distinguishes Alzheimer's disease patients from healthy controls with high sensitivity and specificity?",
            "options": "A. 25.50; B. 42.25; C. 30.10; D. 38.75",
            "correct_option": "C",
            "pmid": "pmid29093468"
        },
        "genetic_232": {
            "question": "Which of the following best describes the relationship between MMP9 and delirium based on current experimental findings?",
            "options": "A. MMP9 gene polymorphisms were identified as a risk factor for postoperative delirium.; B. MMP9 overexpression in neurons was linked to delirium through a genetic knockout model.; C. Inherited MMP9 mutations were shown to affect blood-brain barrier function in delirium.; D. No direct genetic association was established; the study focused on protein-level MMP9 activity in postoperative neuroinflammation.",
            "correct_option": "D",
            "pmid": "pmid38796964"
        },
        "genetic_234": {
            "question": "Which of the following best describes the relationship between CCKAR gene polymorphisms and delirium tremens?",
            "options": "A. The -85CC genotype has been confirmed as a causal variant for delirium tremens.; B. Multiple CCKAR promoter polymorphisms are consistently linked to all alcohol withdrawal symptoms.; C. A strong genetic predisposition to delirium tremens is attributed to variations at the -388 locus.; D. No direct genetic association has been established; only a statistical link with hallucination in delirium tremens was observed.",
            "correct_option": "D",
            "pmid": "pmid12198366"
        },
        "genetic_235": {
            "question": "What is the effect of miR-6775 on the CHRNA7 gene?",
            "options": "A. It increases the expression of CHRNA7.; B. It has no effect on the expression of CHRNA7.; C. It indirectly increases the expression of CHRNA7.; D. It silences the transcription of CHRNA7.",
            "correct_option": "D",
            "pmid": "pmid26347869"
        },
        "genetic_236": {
            "question": "Which genotypes of the miR-148 rs4719839 single nucleotide polymorphism (SNP) were more prone to VAP?",
            "options": "A. CC/CG genotypes; B. AA/AG genotypes; C. GG/GC genotypes; D. AC genotype",
            "correct_option": "B",
            "pmid": "pmid32940422"
        },
        "genetic_237": {
            "question": "Which gene polymorphism was studied in relation to delirium tremens in alcoholics?",
            "options": "A. GRK2; B. GRIK3; C. DRD4; D. SLC6A4",
            "correct_option": "B",
            "pmid": "pmid16314883"
        },
        "genetic_238": {
            "question": "According to the study, how are growth hormone (GH) levels associated with delirium?",
            "options": "A. GH levels are not associated with delirium.; B. Low levels of GH are associated with delirium.; C. GH levels remain stable regardless of delirium status.; D. High levels of GH are associated with delirium.",
            "correct_option": "D",
            "pmid": "pmid33014722"
        },
        "genetic_239": {
            "question": "How does APOE epsilon4 status influence the relationship between CRP and delirium incidence?",
            "options": "A. APOE epsilon4 carriers show a stronger association between high CRP and delirium incidence.; B. Non-epsilon4 carriers show a stronger association between high CRP and delirium incidence.; C. APOE epsilon4 status eliminates the association between CRP and delirium incidence.; D. APOE epsilon4 status has no influence on the CRP-delirium incidence relationship.",
            "correct_option": "A",
            "pmid": "pmid31761478"
        },
        "genetic_240": {
            "question": "What biomarkers were found to have significant associations with ICU delirium in the pooled analysis?",
            "options": "A. Pathologic tau and neurodegeneration biomarkers; B. Amyloid beta-peptide 1-40, interleukin (IL)-1 receptor antagonist, and IL-6; C. Amyloid beta-peptide 1-42 and IL-8; D. Only amyloid beta-peptide 1-40",
            "correct_option": "B",
            "pmid": "pmid34195769"
        },
        "genetic_241": {
            "question": "According to the study, what difference was observed in IGF-I levels between delirious and non-delirious groups?",
            "options": "A. IGF-I levels were significantly higher in the delirious group.; B. IGF-I levels were significantly lower in the delirious group.; C. IGF-I levels showed a strong positive correlation with delirium severity.; D. IGF-I levels did not show a significant difference between the two groups.",
            "correct_option": "D",
            "pmid": "pmid26846868"
        },
        "genetic_242": {
            "question": "In both mice and humans after surgery, how did YKL-40 levels change in plasma versus cerebrospinal fluid (CSF)?",
            "options": "A. Plasma YKL-40 decreased, and CSF YKL-40 increased.; B. Plasma YKL-40 did not change, but CSF YKL-40 increased.; C. Plasma YKL-40 and CSF YKL-40 both increased.; D. Plasma YKL-40 increased, and CSF YKL-40 decreased.",
            "correct_option": "D",
            "pmid": "pmid36457825"
        },
        "genetic_243": {
            "question": "According to the text, what does sustained dopamine D2 receptor (D2R) signaling in the hippocampal formation induce?",
            "options": "A. Hypoxia; B. Oxidative stress; C. Apoptosis; D. Inflammatory responses",
            "correct_option": "C",
            "pmid": "pmid24852225"
        },
        "genetic_244": {
            "question": "According to the study, what function does the SLC7A11 subunit perform?",
            "options": "A. It modulates glutamate N-methyl-D-aspartate receptor activity.; B. It mediates glutamate release.; C. It inhibits the production of pLG72 protein.; D. It regulates white blood cell count in AD patients.",
            "correct_option": "B",
            "pmid": "pmid35986919"
        },
        "genetic_245": {
            "question": "What factor is associated with greater delirium severity at baseline in individuals with dementia?",
            "options": "A. Lower Clinical Dementia Rating Scale; B. Absence of APOE epsilon4 allele; C. Higher Clinical Dementia Rating Scale; D. High occupational complexity",
            "correct_option": "C",
            "pmid": "pmid27122004"
        },
        "genetic_246": {
            "question": "What correlation do PER2 and HO1 expression levels have with delirium?",
            "options": "A. Low expression levels increase the odds of delirium occurrence.; B. There is no correlation between expression levels and delirium occurrence.; C. High expression levels decreased the odds of delirium occurrence.; D. High expression levels increased the odds of delirium occurrence.",
            "correct_option": "D",
            "pmid": "pmid34321570"
        },
        "genetic_247": {
            "question": "What effect does downregulation of RXRA have on delirium in mice with COPD?",
            "options": "A. It promotes the development of delirium by increasing endoplasmic reticulum stress.; B. It has no effect on the delirium state.; C. It reduces the delirium state by decreasing endoplasmic reticulum stress and cell apoptosis.; D. It reduces the delirium state by increasing PLA2G2A expression.",
            "correct_option": "C",
            "pmid": "pmid38372090"
        },
        "genetic_248": {
            "question": "In individuals who died from cocaine-related causes, how does heat shock protein 70 (HSP70) expression in the brain compare to control subjects?",
            "options": "A. HSP70 expression is significantly lower.; B. HSP70 expression is unchanged.; C. HSP70 expression is significantly increased.; D. HSP70 expression fluctuates wildly.",
            "correct_option": "C",
            "pmid": "pmid22803793"
        },
        "genetic_249": {
            "question": "What effect does CCR5 deficiency have on neurons?",
            "options": "A. It increases neuronal resilience to oxidative stress.; B. It has no effect on neurons.; C. It protects neurons from cell death.; D. It decreases neuronal resilience to oxidative stress.",
            "correct_option": "D",
            "pmid": "pmid37489764"
        },
        "genetic_251": {
            "question": "What role does D-amino acid oxidase (DAO) play in the context of N-methyl-D-aspartate receptor (NMDAR) function?",
            "options": "A. DAO enhances NMDAR function by synthesizing D-amino acids.; B. DAO regulates NMDAR function by degrading NMDAR-related D-amino acids.; C. DAO inhibits NMDAR function by directly binding to the receptor.; D. DAO has no direct impact on NMDAR function.",
            "correct_option": "B",
            "pmid": "pmid35430632"
        },
        "genetic_252": {
            "question": "Were polymorphisms in the COMT gene associated with delirium?",
            "options": "A. Yes, certain polymorphisms significantly increased the risk of delirium.; B. Yes, specific polymorphisms offered protection against delirium.; C. No, polymorphisms in the COMT gene were not associated with the development of delirium.; D. The study only examined the association between COMT gene expression and delirium, not polymorphisms.",
            "correct_option": "C",
            "pmid": "pmid21613790"
        },
        "genetic_253": {
            "question": "Which genetic factors interacting decreases the likelihood of delirium tremens in alcoholics?",
            "options": "A. DRD2 rs6276 A allele and SLC6A4 SS genotype; B. DRD2 rs6276 G allele and SLC6A4 LL genotype; C. SLC6A4 promoter polymorphism (5-HTTLPR) independently; D. DRD2 exon 8 single nucleotide polymorphism rs6276 independently",
            "correct_option": "B",
            "pmid": "pmid20002020"
        },
        "genetic_254": {
            "question": "What is the effect of disrupting the VCAM1-ApoE interaction on microglial Abeta chemotaxis?",
            "options": "A. It increases microglial clearance of Abeta.; B. It enhances microglial Abeta chemotaxis.; C. It abolishes microglial Abeta chemotaxis.; D. It has no impact on microglial Abeta chemotaxis.",
            "correct_option": "C",
            "pmid": "pmid37735240"
        },
        "genetic_255": {
            "question": "What happens to D2 concentration in cerebrospinal fluid during recovery from delirium tremens?",
            "options": "A. It remains unchanged.; B. It decreases to half its normal value.; C. It increases to double its normal value.; D. It disappears completely.",
            "correct_option": "C",
            "pmid": "pmid6160732"
        },
        "genetic_256": {
            "question": "What is the function of the DRD4 receptor?",
            "options": "A. It is primarily involved in regulating sodium ion channels in neurons.; B. It influences the postsynaptic action of dopamine and is implicated in many neurological processes.; C. It directly controls the reuptake of serotonin from the synaptic cleft.; D. It plays a crucial role in the synthesis of acetylcholine.",
            "correct_option": "B",
            "pmid": "pmid21873960"
        },
        "genetic_257": {
            "question": "What role might galectin-3 play in delirium among postpartum ICU women?",
            "options": "A. It may be a protective factor against inflammation.; B. It might serve as a biomarker for predicting delirium, due to its involvement in the inflammatory process underlying delirium-related brain injury.; C. It is likely a consequence of the medications administered in the ICU.; D. It is only relevant in cases involving pre-existing neurological conditions.",
            "correct_option": "B",
            "pmid": "pmid28828226"
        },
        "genetic_258": {
            "question": "Considering the role of dipeptidyl peptidase 4 (DPP4) in central nervous system (CNS) disorders, which of the following statements best reflects its clinical relevance to delirium or delirium-related conditions? ",
            "options": "A. Although DPP4 is expressed in the brain, current DPP4 inhibitors do not cross the intact blood-brain barrier and likely exert their beneficial effects on delirium-related conditions through peripheral mechanisms.; B. The primary mechanism by which DPP4 inhibitors affect CNS disorders like delirium is through direct modulation of brain neurotransmission.; C. DPP4 inhibitors are known to aggravate neuroinflammation and should be avoided in patients at risk of delirium.; D. DPP4 plays no role in neuropsychiatric or neurodegenerative disorders and is only relevant for metabolic diseases like diabetes.",
            "correct_option": "A",
            "pmid": "pmid35771831"
        }
    }
}